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S u m m a ry
Proteinuria is the hallmark of impaired glomerular permselectivity and is associated 
with a poor prognosis in renal disease. It is widely acknowledged that a fall in urine 
protein excretion may indicate an improvement in renal function or retardation of 
disease progression. The finding that diets rich in polyunsaturated fatty acids 
(PUFA), reduced urine albumin excretion in two healthy strains of rat (Lewis and 
DA) with differing susceptibilities to glomerular disease, was therefore deemed 
worthy of further investigation.
Each successive study in this thesis is an attempt to unravel the mechanism behind 
the apparent anti-proteinuric actions of PUFA diets. However, establishing a 
relationship between PUFA diets and albumin excretion is complicated by not only 
the many and varied functions of PUFAs which include eicosanoid biosynthesis, cell 
membrane structure and function and lipid metabolism but also the various factors 
which control the filtration of albumin such as glomerular capillary wall structure and 
charge, glomerular haemodynamics and the physico-chemical characteristics of the 
filtered molecule.
As precursors of prostaglandins and thromboxane, polyunsaturated fatty acids can 
regulate glomerular blood flow and pressure and modulate the activity of the renin- 
angiotensin system but ultimately, the observed fall in albumin excretion rate in 
Lewis and DA rats could neither be attributed to changes in glomerular or circulating 
levels of prostaglandins, thromboxane or renin levels in the PUFA diet groups. That 
PUFA diets might effect changes in the intrinsic permeability properties of the 
glomerular capillary wall in such a way as to reduce the filtration of albumin was 
explored by assessing the magnitude of the negative charge on the glomerular 
capillary wall (glomerular polyanion). Lewis rat glomeruli sequestered significantly 
less of a radiolabelled cationic protein probe than DA rat glomeruli and this was 
taken as confirmation of a diminished glomerular polyanion in Lewis rats relative to 
DA rats but overall, PUFA diets had little effect on glomerular capillary wall charge.
The binding of fatty acids to serum albumin can alter the electrical charge of the 
albumin molecule and it was shown that the isoelectric point of Lewis rat serum 
albumin was reduced in all the experimental PUFA diet groups compared to that from 
rats fed a standard laboratory diet. Structural modification of the serum albumin 
molecule, induced by the binding of unsaturated fatty acids, may have further 
increased its anionic charge and thereby reduced its filtration across the glomerular 
capillary wall.
The PUFA diet-induced fall in albumin excretion rate in healthy Lewis and DA rats 
prompted a study to investigate the capacity of evening primrose oil diet to prevent an 
anticipated rise in albumin excretion rate in diabetic Lewis rats. Although it reduced 
both total protein and albumin excretion in Lewis rats during the non-diabetic phase 
of the study, evening primrose oil diet did not prevent a rise in albumin excretion rate 
in diabetic Lewis rats.
It is unlikely that the anti-proteinuric effects of PUFA diets in healthy Lewis and DA 
rats were mediated by either changes in glomerular prostanoid or renin levels or the 
intensity of the glomerular polyanion and is more likely to be related to a change in 
the isoelectric point (pi) of the albumin molecule as a result of binding fatty acids. 
The failure to demonstrate a fall in albumin excretion rate in diabetic Lewis rats fed 
evening primrose oil diet could be due to competition between glucose and fatty acid 
molecules for binding sites on the albumin molecule.
S e c t i o n  1 
INTRO DUCTIO N
PROGRESSION o f  GLOMERULAR DISEASE S e c t io n  1.1
1.1.1 B a c k g ro u n d  a n d  a im s
It is still unclear why some individuals develop the more serious or progressive forms 
of renal disease than others with identical symptoms (Hood et al, 1981, MacTier et al,
1986). Differences in susceptibility to nephropathies such as IgA, membranous or 
diabetic nephropathy might best be explained by the inheritance of a particular 
glomerular characteristic such as a weakened glomerular polyanion or impaired 
mesangial clearance function, in association with a particular tissue type (Rees et al, 
1984, Klouda et al, 1979, Kashiwabara et al, 1982, Weening et al, 1986) or defective 
sulphation enzyme activity which results in a diminished negative charge on the GCW 
(Deckert et al, 1989). These properties of the glomerulus may determine how it 
responds to a change in blood flow or pressure or eliminates macromolecules or 
immune complexes and the subsequent course of disease development (O'Donnell et 
al, 1985, Remuzzi et al, 1988, Bertani e ta l , 1989).
Lewis and DA are two healthy strains of rat with different inherited glomerular 
properties which make them useful models in which to study differences in disease 
progression (Boulton-Jones et al, 1986). The Lewis rat strain is more susceptible to 
Heymann nephritis, an animal model of membranous nephropathy to which the DA rat 
strain is resistant and when diabetes is induced by STZ in Lewis rats, they develop 
more pronounced proteinuria and extensive mesangial expansion than DA rats (Payton 
and Boulton-Jones, 1989). Compared to DA rats, Lewis rats also have a weaker 
glomerular polyanion, exhibit reduced rates of mesangial uptake of circulating 
macromolecules and higher levels of proteinuria following administration of the 
polycation hexadimethrine (Chandrachud and Boulton-Jones, 1988). Inherited 
variations in glomerular properties was the most plausible explanation for the 
differences in susceptibility to diabetic nephropathy between Lewis and DA rats 
(Payton and Boulton-Jones, 1989).
The work carried out in this thesis attempts to develop the concept of inherited 
differences in glomerular properties and disease susceptibility in relation to the 
feeding of polyunsaturated fatty acids (PUFA) diets to Lewis and DA rats with 
particular reference to an apparent lowering of urine albumin excretion. PUFAs are 
recognised as precursors of prostaglandins, thromboxane and leukotrienes, structural 
and functional components of cell membranes and lipid-lowering agents linked to a 
reduced incidence of cardiovascular risk (see section 1.3) and their effects have been 
studied in various experimental and human renal diseases (see section 1.4).
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1.1.2 F a c to rs  a s s o c ia te d  with g lo m e ru la r  d i s e a s e  p ro g re s s io n
Renal disease progresses in association with systemic and glomerular hypertension 
and renal hypertrophy, mesangial overloading and glomerulosclerosis and 
derangements of coagulation, lipid metabolism and the immune and inflammatory 
responses. Proteinuria has long been recognised as the clinical hallmark of glomerular 
injury, denoting an increased permeability of the glomerular capillary wall to plasma 
proteins that often mirrors the extent of disease severity (Bright, 1836, Hulme and 
Hardwicke, 1968, Brenner et al, 1978, Winetz et al, 1981a, Bertani et al, 1986a, 
Grond et al, 1986, Anderson et al, 1988, Rennke and Klein, 1989). However, as a 
reflection of large amounts of protein filtering both across the glomerular capillary 
wall and through the mesangium, proteinuria is now regarded as an important factor 
associated with the precipitation and persistance of glomerular injury (Klahr et al, 
1988, Eddy et al, 1989, Remuzzi and Bertani, 1990). Many studies have shown that 
proteinuria precedes the onset of glomerulosclerosis (Olsen et al, 1982, Weening et al, 
1983, Zatz et al, 1986, Anderson et al, 1986; 1989, Fogo et al, 1988) although nearly 
half of experimental adriamycin nephrosis (ADR) rats with extensive epithelial cell 
damage and proteinuria did not develop glomerulosclerosis (Bertani et al, 1986a) and 
there was little sign of glomerulosclerosis in rats with Heymann nephritis in which 
large quantities of protein filter across the glomerular capillary wall (Barabas et al, 
1985).
Further evidence of the pernicious nature of proteinuria is the slow incipient rise in 
urine albumin excretion (microalbuminuria) that predicts of the onset of renal disease 
in diabetes (Parving et al, 1982, Mogensen, 1987) and its association with increased 
mortality and morbidity in chronic heart disease, perhaps as indicative of more 
widespread vascular damage (Borch-Johnsen et al, 1985, Borch-Johnsen and Kreiner, 
1987, Deckert et al 1989, Jensen et al, 1989). Diabetic patients with 
microalbuminuria are not only at greatly increased risk of developing nephropathy but 
are also much more likely to suffer other vascular complications such as ischaemic 
heart disease (Jensen et al, 1987). Established cardiovascular risk factors such as 
elevated blood pressure and heightened plasma lipid and fibrinogen levels are 
common in diabetic patients with microalbuminuria (Jensen et al, 1988). A fall in 
albuminuria in diabetic patients as a result of antihypertensive treatments, glycaemic 
control or low protein diets is taken to indicate an improvement in disease activity (see 
section 2.5.1)
Several theories have been forwarded to explain the initiation and progression of 
glomerular disease but the most widely favoured is that glomerular injury is 
precipitated and perpetuated by changes in glomerular haemodynamics (Anderson et
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al, 1985a, Zatz and Brenner, 1986, Blantz et al, 1987, van Hooft et al, 1991). When a 
critical amount of functioning renal tissue is removed either surgically, as in 
experimental renal ablation or clinically, as a result of disease, there is a sustained, 
compensatory rise in blood flow and pressure (hyperperfusion and hyperfiltration) 
which sets up a cycle of destruction within the remaining healthy nephrons (Deen et 
al, 1974, Shimamura et al, 1975, Brenner et al, 1981; 1982; 1983, Hostetter et al 
1981; 1982, Provoost et aly 1991). Hyperperfusion not only damages the glomerular 
endothelium, weakening its natural thromboresistance and increasing the incidence of 
intraglomerular thrombosis and coagulopathies but also increases transglomerular 
protein flux (Purkerson et al, 1982; 1985, Olsen et al, 1984, Schiepatti et al, 1984, 
Zoja et aly 1990a, Lianos and Zanglis, 1990).
Hypertrophy is yet another consequence of glomerular hyperfunction and is the 
kidneys response to a heightened functional demand for reabsorption of an increased 
filtered solute load in which all the component parts of the nephron are enlarged to 
increase its reabsorptive and secretory capacity (Fine, 1986, Schweiger and Fine,
1990). Glomerular hypertrophy can cause epithelial cell to detach from the underlying 
GBM and is associated with heavy proteinuria and progressive glomerulosclerosis 
(Brenner et aly 1985, Fries et al, 1989, Yoshida et aly 1989, Miller et aly 1990). Many 
groups challenge the importance of haemodynamic factors in the initiation of 
glomerular injury (Bank et aly 1987, Fogo et alt 1988, Remuzzi et aly 1988, Scholey et 
ah 1989, Yoshida et al, 1989; 1989a).
The primary glomerular injury is often precipitated by immune mechanisms (Couser 
et aly 1985, Glassock et aly 1992). Immune complexes can cause the glomerular 
capillary wall to leak either through structural damage or complement-mediated 
release of cellular and humoral mediators (Cavallo et aly 1983, Groggel et aly 1985, 
Cybulsky et aly 1986, Salant et aly 1989, Stahl et aly 1990). Alternatively, agents such 
as cytokines (Bevilaqua et a l  1985, Tipping et al,  1991), growth factors (Bertani et aly 
1987, Shultz et aly 1988: McNamara et a ly 1989: Border et a l , 1989, Zoja et a ly 1990), 
hydrolytic enzymes (Bolton et aly 1987), proteases and reactive oxygen species 
released by native or infiltrating immune and inflammatory cells can alter GCW and 
damage the glomerular capillary wall and mesangium (Fantone et a l , 1982, Nathan, 
1987).
1.1.3 R e ta rd in g  th e  p ro g re s s io n  of g lo m e ru la r  d i s e a s e
Hypertension not only increases the risk of developing renal disease but also 
accelerates the rate of decline in renal function in nephrotic patients (National High 
Blood Pressure Education Program, 1991). Animal (Yoshida et aly  1989),
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epidemiological (Miller et al, 1991) and clinical (Payton et al, 1988) studies suggest 
that reducing systemic blood pressure to within normal limits, not only retards the rate 
of progression of renal disease but lowers the risk and incidence of cardiovascular 
disease in susceptible subjects (Neugarten et al, 1982, Blantz et al, 1987a, ter Wee and 
Donker, 1992). Although many anti-hypertensive therapies do slow the rate of disease 
progression (Neugarten et al, 1985, Meyer et al, 1987, Dworkin et al, 1989) some are 
less effective than others (Dworkin et al, 1987). This discrepancy is most likely to be 
related to the fact that a reduction in systemic hypertension is not always accompanied 
by a corresponding fall in glomerular blood pressure, the latter being a critical factor 
in reducing proteinuria and glomerulosclerosis. ACE inhibitors, which selectively 
reduce Pgc, afford superior protection from glomerular injury in both animal 
(Anderson et al, 1985; 1986; 1989, Meyer et al, 1985, Zatz et al, 1986, Brunner et al,
1987) and human (Heeg et al, 1987, Mann et al, 1987, Marre et al, 1988, Ruilope et 
al, 1989, Praga et al, 1991) glomerulopathies albeit the anti-proteinuric effects of ACE 
inhibitors in humans vary from significant (Marre et al, 1987, Taguma et al, 1985, 
Parving et al, 1988) to modest (Hommel et al, 1986a, Valvo et al, 1988) to non­
existent (Bjorck et al, 1986).
Dietary protein restriction has been shown to be as effective as antihypertensive 
therapy in lowering glomerular blood pressure (Pgc) in animal models particularly 
(Neugarten et al, 1983, Diamond et al, 1987, Woods, 1993). High protein diets 
increase GFR, protein excretion and histological damage in normal and nephrotic 
animals (Hostetter et al, 1986) and humans (Bosch et al, 1986, Ilhe et al, 1989) while 
protein restriction diets retard the progression of renal insufficiency (Brenner et al, 
1982, El Nahas et al, 1984, Wen et al, 1985, Remuzzi et al, 1985a, Nath, 1986a, 
Cohen D et al, 1987, Okuda et al, 1987, Wiseman et al, 1987, Evanoff et al, 1988, 
Castellino et al, 1989). Increased dietary protein is thought to impair glomerular 
function by inducing glomerular hypertension as a result of afferent arteriolar 
vasodilation; however, changes in protein intake are not always accompanied by shifts 
in Pgc (Ichikawa et al, 1980, Mauer et al, 1985, O'Donnell et al, 1990, Weigmann et 
al, 1990). The vasodilation has been linked to activation of the renin-angiotensin 
system (Rosenberg et al, 1987; 1990) or heightened prostaglandin (Levine et al, 1986, 
Stahl et al, 1987a, Krishna et al, 1988), hormone (Kontessis et al, 1990) or nitric 
oxide (King et al, 1991) activity. Protein loading may also induce hypertrophy by 
increasing the renal work load required to excrete urea (Ichikawa et al, 1980a). While 
both enalapril and low protein diets reduced protein excretion and early sclerotic 
lesions in experimental renal disease (Marinides et al, 1990) only enalapril markedly 
lowered proteinuria in patients with chronic glomerular injury - protein restriction did
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not (Don et al, 1991). Neither did protein restriction improve renal function nor size 
selectivity in patients with membranous nephropathy (Remuzzi et al, 1991).
Hyperlipidaemia is implicated in both the initation and progression of renal disease 
(Kasiske et al, 1990, Keane et al, 1990; 1991: Diamond, 1989, Kaysen et al, 1986; 
1991, Klahr and Harris, 1989). Accelerated rates of glomerulosclerosis were observed 
in rats fed cholesterol-rich diets (Diamond and Kamovsky, 1987a) while lipid 
lowering drugs such as clofibric acid and lovastatin improved renal function in obese 
Zucker rats and rats with reduced renal mass (Kasiske et al, 1985; 1988; 1988a), PAN 
rats (Harris et al, 1990) and nephrotic humans (Rabelink et al, 1990, Chan et al,
1992). Hyperlipidaemia is thought to be the result of diminished clearance and 
heightened synthesis of lipids and lipoproteins by the liver, the latter in reponse to a 
low serum oncotic pressure (Appell et al, 1985, Kaysen et al, 1987). Loss of 
liporegulatory proteins via the urine may also contribute to hyperlipidaemia (de 
Mendoza et al, 1976, Staprans et al, 1981).
The link between hyperlipidaemia and proteinuria has been attributed to both 
abnormal lipid deposition which can impair the permeability of the glomerular 
capillary wall (Iverius, 1972, Grone et al, 1989, Moorhead et al, 1991, Takemura et al,
1993) and glomerular hypertension due to raised plasma viscosity (Keane et al, 1991). 
Glomerulosclerosis and atherosclerosis have similar pathogenetic origins (Diamond 
and Kamovsky, 1988). An increased uptake of low density- and oxidised lipoproteins 
by the mesangium may stimulate mesangial proliferation and expansion (Coritsidis et 
al, 1991). However, the relative infrequency of renal disease in patients with common 
forms of hyperlipidaemia does suggest that lipids induce glomerular injury mainly in 
conjunction with other predisposing factors. The lipid-lowering activity of PUFA 
diets (Harris et al, 1983, Nestel et al, 1984; 1990, Barcelli et al, 1988, Mensink et al, 
1989) may contribute to improvements in blood viscosity, pressure and flow (Terano 
et al, 1983, Cartwright et al, 1985, Rogers et al, 1987) and lipid deposition within the 
glomerular and systemic vasculature (Phillipson et al, 1985, Boberg et al, 1986).
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THE GLOMERULUS - A  MOLECULAR SIEVE S e c t io n  1 .2
The kidney functions as a molecular sieve, filtering, reabsorbing and metabolising 
proteins while conserving serum albumin stores which are essential for maintaining 
up to 80% of the oncotic pressure of the blood. The glomerular capillary wall was 
defined as the major structural barrier to the filtration of proteins, after minute 
quantities of the glomerular ultrafiltrate were aspirated directly from Bowmans 
capsule or the proximal tubule and found to contain negligible amounts of protein 
(Walker et al, 1941). Solutes and low molecular mass proteins which do pass from 
the plasma into the glomerular ultrafiltrate are reabsorbed to varying degrees by 
endocytosis and degraded in the renal proximal tubules; normally, more than 90% of 
any albumin which is filtered is reabsorbed (Landewehr et al, 1977, Mogenesen and 
Soiling, 1977).
Proteinuria occurs when the filtered load of albumin or other proteins overwhelms the 
reabsorptive capacity of the tubules. The passage of an albumin molecule across the 
glomerular capillary wall is a function of
• the structure and electrostatic charge of the glomerular capillary wall
• blood flow and pressure within the glomerular capillary 
and
• the size, charge and shape of the filtered molecule
but the amount of protein which appears finally in the urine is dependent also upon its 
plasma concentration and the rates of both glomerular filtration and tubular 
reabsorption.
1.2.1 G lo m e ru la r  c a p il la ry  w all (GCW ) s tru c tu re
Each glomerulus is a network of anastamosing capillaries across which blood filters 
passively but under pressure, to form a virtually protein-free ultrafiltrate of the 
plasma (Pappenheimer, 1951). The glomerular capillary wall (GCW) allows solutes 
and low molecular weight macromolecules or proteins to pass through unimpeded 
while molecules the size of albumin (36 A) and larger are restricted to varying 
degrees.
From the lumen outwards, the GCW comprises three layers - (i) a vascular 
endothelium, (ii) an extracellular glomerular basement membrane (GBM) and (iii) a 
visceral epithelium. For a plasma protein such as albumin (36 A) to reach the 
glomerular ultrafiltrate, it must overcome all three layers.
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The glomerular endothelium, which is perforated with numerous pores of up to 100 A 
in diameter, is unlikely to offer much resistance to circulating macromolecules 
although a layer of anionic sialic acid residues on the endothelial cell surface, known 
as the glycocalyx, will repel anionic molecules like albumin to some degree (Blau 
and Haas, 1973).
The glomerular basement membrane (GBM) is a three-layered extracellular gel 
matrix comprising a central lamina densa sandwiched between the sub-endothelial 
lamina rara interna and sub-epithelial lamina rara externa. Strong, tensile 
perpendicular fibrils tether these two outer layers to the lamina densa (Batsford et al, 
1987, Caulfield et al, 1987). The GBM is approximately 300 nm wide in humans and 
150 nm in the rat or mouse (Takami et al, 1991). Extensively crosslinked by 
disulphide bonds, the GBM can be separated into a collagenous glycopeptide fraction 
containing hydroxylysine, hydroxyproline and glycine and a more polar proteoglycan 
fraction. The collagen backbone of the GBM complexes with (i) glycoproteins such 
as fibronectin, laminin (Ekblom et al, 1991), podocalyxin (Keijaschki et al, 1984) 
and the entactin-nidogen complex (Katz et al, 1991) and (ii) various large 
polyanionic proteoglycans (95% polysaccharide and 5% protein) which bind water 
and cations (Gallagher et al, 1986, Lelongt et al, 1987b). Glycosaminoglycans 
(GAG) are the variable disaccharide units of glucosamine and galactosamine, the 
sulphate and carboxylate groups of which give proteoglycans their negative charge 
(Lindahl and Hook, 1978, Kanwar et al, 1981). Heparan sulphate, chondroitin 
sulphate and keratan sulphate, hyaluronic acid and heparin are the principal GAGs of 
the glomerular polyanion and are abundant particularly in the lamina rara externa 
(Caulfield et al, 1976, Kanwar and Farquhar, 1979a; 1984, Timpl,1986). These 
anionic groups were first identified using cationic dyes or tracers such as ruthenium 
red (Kanwar and Farquhar, 1979), alcian blue (Caulfield et al, 1979), cationic ferritin 
(Danon et al 1972, Rennke et al, 1975) and polyethyleneimine (Schurer et al, 1978). 
Glomerular permeability to anionic ferritin (Kanwar et al, 1980) and albumin 
(Rosenzweig and Kanwar, 1982) was shown to rise following removal of heparan 
sulphate with heparinase. In contrast, chondroitinase and neuraminidase, enzymes 
which hydrolyse only sialic acid residues, did not have the same potency (Vernier et 
al, 1983). The GAG and sialic acid content of the GCW is altered or diminished in 
many glomerulopathies and experimental diabetes (Cohen and Surma, 1981, Brown 
DM et al, 1982, Parasarathy and Spiro, 1982, Wahl et al, 1982, Rohrbach et al, 1986, 
Groggel et al, 1988).
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The GBM becomes thickened in a variety of glomerulopathies but whether as a result 
of increased synthesis, or diminished degradation of GBM glycoproteins is not clear 
(Sternberg et al, 1983, Reddi et al, 1985, Cohen, 1987, Nimni and Harkness, 1988). 
Reduced collagenase and lysosomal enzyme activity is reflected by increased GBM 
glycan levels in established diabetic nephropathy (Monahan and Bose, 1983). In 
diabetes, endogenous GBM proteins with a slow turnover rate, are susceptible to non- 
enzymatic glycosylation (Cohen and Ku, 1984, Sternberg et al, 1985, Tarsio et al,
1985) and although early glycation products are relatively harmless and their 
production can be reduced by insulin, gradual accumulation of advanced glycation 
products is more persistent and destructive (Brownlee et al, 1988, Ellis and Good,
1991). Glycosylation can alter the structure and binding properties of GBM proteins 
and phospholipids (Brownlee et al, 1985, Abrahamson, 1986, Klein et al, 1986, 
Vishwananth et al, 1986, Silbiger et al, 1993) but to date, the evidence suggesting 
that non-enzymatic glycosylation of GCW components is responsible for increased 
glomerular permeability in diabetes is still rather weak (Copeland et al, 1987). GBM 
thickening normally starts during the incipient phase of diabetic nephropathy (and 
presents about two years after diagnosis) but does not correlate with declining renal 
function (Osterby, 1975, Falk et al, 1983, Mauer et al, 1984, Thompsen et al, 1984, 
Ellis et al, 1986, Tarsio et al, 1988).
The third and outermost layer of the glomerular capillary wall is the visceral 
epithelium with its characteristic interdigitating foot processes, known also as 
podocytes. The passage of a molecule through this layer is limited by thin filtration 
slit diaphragms (4A - 6A thick) which span the narrow filtration slits (20A - 30A 
wide) between the foot processes. Viewed face on, the slit diaphragm comprises an 
ordered zipper-like array of rectangular pores which have dimensions similar to those 
of an albumin molecule (40A x 140A) (Furukawa et al, 1991). Colloidal iron 
staining identified a substantial glycocalyx extending over the surface of the 
epithelial foot processes and into the filtration slits, terminating deep within the 
lamina rara externa (Caulfield, 1979). Glomerular epithelial cells also synthesise not 
only constituent glycoproteins and proteoglycans of the underlying GBM but secrete 
heparin or heparin-like substances which may inhibit mesangial cell proliferation and 
glomerular hypertrophy (Castellot et al, 1985). Glomerular epithelial cell damage, in 
particular, is associated with nephrotic range proteinuria in animal and human 
nephropathies (Grishman and Churg, 1975, Bertani et al, 1982, Weening and Rennke, 
1983, Rollason and Brewer, 1984, Messina et al, 1987, Fries et al, 1987). Being 
unable to replicate in response to a proliferative stimulus, podocytes become distorted 
and detached from the underlying GBM, giving rise to 'bald' patches along the 
glomerular capillary wall through which proteins can pass freely into Bowman's
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capsule (Kanwar and Rosenzweig, 1982, Fries et al, 1989). Glomerular epithelial 
cells may also function as antigen presenting cells in immune mediated glomerular 
injury (Mendrick et al, 1991).
A large proportion of the charge on the GCW (glomerular polyanion) is invested in 
the glomerular epithelium and depletion of this charge characterises a variety of 
glomerulopathies (Rohrbach et al, 1983, 1986, Chakrabarti et al, 1989, Templeton et 
al, 1989). The increased proteinuria resulting from epithelial cell damage caused by 
cationic protamine sulphate (Seiler et al, 1975) or hexadimethrine (Hunsicker et al,
1981) was reversed by the polyanion, heparin (Seiler et al, 1977).
Intravenous administration of electron dense tracer molecules has been used to locate 
the ultrastructural barriers within, and follow the progress of proteins or 
macromolecules through the glomerular capillary wall. Although in early studies, the 
significance of the isoelectric point of the tracer molecules used was not fully 
appreciated, the results of experiments shown in Table 1.2.1 show that larger 
molecules such as ferritin (61 A) localise more readily in the endothelium and lamina 
rara interna whereas smaller, cationic molecules penetrate more deeply into the 
lamina rara externa and epithelial slit diaphragms. These studies gave rise to the 
early hypotheses that both the size and electrical charge of a molecule are important 
in determining its passage across the glomerular capillary wall.
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T ab le  1.2.1 U ltrastructu ra l t r a c e r  m o le c u le s
Tracer Pi
Ferritin (native) 
(Farquhar et al, 1961)
4.5
Serum albumin 
(Ryan e ta l, 1978)
4.7
Catalase
(Venkatachalam et al, 1970)
5.7
Neutral dextrans 
(Caulfield et al, 1974)
7.4
Horseradish peroxidase 
(Graham & Karnovsky, 1966) 
(Venkatachalam eta l, 1970)
7.4
Ferritin (cationic) 
(Rennke etal, 1977)
>8.0
Lactoperoxidase 8.0
(Graham and Kellermeyer, 1968)
Myeloperoxidase 
(Graham & Karnovsky, 1966)
10.5
M olecular 
radius (A)
Location
61 endothelium and LRI
36 endothelium and LRI
52 GBM and slit diaphragm
Polydisperse GBM
30 Urinary space and GBM
61 GBM and slit diaphragm
38 Slit diaphragm
44 Slit diaphragm
1.2.2 T h e m e s a n g iu m
The mesangium, which is centred axially deep within the glomerulus, comprises 
mesangial cells embedded in an extracellular glycoprotein matrix (Kriz et al, 1990). 
Circulating macromolecules can enter the mesangium directly, via the glomerular 
endothelium and at various points, the mesangium reflects on to the glomerular 
basement membrane (see plate 1.1). There are two types of mesangial cell, the 
predominant one being smooth muscle-like with contractile properties while the 
remainder (-5% ) are phagocytic (Michael et al, 1980; 1984, Schlondorff, 1987, Badr 
et al, 1989, Ishino et al, 1991). Mesangial cells synthesise their own extracellular 
matrix and GBM components plus a variety of regulatory peptides, prostaglandins 
(Lovett et al> 1987a), growth (Yoshimura et al, 1991) and platelet activating (Abboud 
et al, 1987) factors and cytokines and indeed, receptors for many of these same 
mediators are expressed on the surface of mesangial cells (Foidart et al, 1980, Cosio 
et al, 1990, Ray et al, 1991).
Mesangial cells are fairly quiescent under normal conditions but they do proliferate in 
response to injury (Lovett et al, 1987, Kitamura et al, 1991). Mesangial 
hypercellularity and matrix expansion, which are the histological hallmarks of 
glomerulosclerosis, may occur in response to the action of growth factors and 
cytokines released by either native or infiltrating cells (Abbott et al, 1991, Shultz et 
al, 1988, Ross et al, 1986b, Schriener et al, 1984, Striker et al, 1985, Floege et al, 
1991, Shultz and Raij, 1991). Heparin, heparan sulphate and heparin-like molecules 
secreted by glomerular epithelial and endothelial cells can exert anti-proliferative 
effects on mesangial cells (Guyton, 1980, Castellot, 1984; 1985, Floege et al, 1993). 
Acting as a local reticuloendothelial system, the mesangium helps to maintain the 
patency of the GCW (Kanwar and Rosenzweig, 1982) but plasma proteins and 
circulating inflammatory cells percolating through, or their accumulation within the 
mesangium is yet another potent stimulus for glomerulosclerosis (Raij et al, 1984, 
Striker et al, 1984, Grond et al, 1985, Keane and Raij, 1985). The rate of mesangial 
clearance of molecular debris influences the rate of progression of 
glomerulosclerosis: sclerosis progressed more rapidly in PAN rats with diminished 
mesangial clearance rate compared to ADR rats in which mesangial function is 
unchanged (Grond et al, 1984). In diabetes, expansion of the mesangial matrix is 
evident usually after around five years of diabetes and is more extensive in those 
diabetics who develop nephropathy than those who do not: however, unlike GBM 
thickening, mesangial expansion does correlate with renal functional impairment by 
occluding capillaries and reducing capillary surface area (Mauer et al, 1984, Osterby 
et al, 1988).
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Plate 1.1 A glomerular lobule (adapted from 
Clinical Diabetes, Besser et a l )
The mesangium can also regulate glomerular filtration, independently of blood flow, 
by contracting and relaxing to alter the glomerular capillary surface area across which 
filtration takes place. The contractile effects of angiotensin II and arginine 
vasopressin (Ausellio et al, 1980, Foidart et al, 1980, Ardaillou et al, 1987), 
endothelin (Badr et al, 1989, Zoja et al, 1990) bradykinin and platelet activating 
factor (Schlondorff et al, 1984) or leukotrienes (Barnett et al, 1986) on the 
mesangium are attenuated by prostaglandins (Ardaillou et al, 1983; 1984, Yamamoto 
e ta l, 1991).
1.2.3 M e c h a n ic s  o f g lo m e ru la r  filtration
Although there is no histological evidence of any physical pores, the glomerular 
capillary wall was conceptualised originally as a "membrane" perforated by identical 
cylindrical pores of radius 50-55 A, each with a uniform distribution of intrinsic 
anionic charges. The most popular hypothesis is that the glomerular capillary wall is 
heteroporous, with up to 99% of its surface area invested with standard 55 A pores 
through which most of the ultrafiltrate flows: the remainder of the capillary wall 
comprises larger, non-restrictive pores with an effective radius in excess of 70A and 
is termed the shunt pathway (wQ) (Deen etal, 1980; 1981; 1985, Myers e ta l , 1982).
Physical properties of the GCW such as
• the ultrafiltration coefficient (Kf), which is a function of the permeability 
(hydraulic conductivity (k) and capillary surface area (s))
• effective pore radius (rQ) 
and
• density of fixed negative charges (Cm)
act in concert with the forces of plasma water flux (convection) and solute 
concentration (diffusion) to regulate the transglomerular passage of molecules 
(Bohrer e ta l, 1977).
The rate of filtration across a single nephron (SNGFR) is dependent upon
• renal plasma flow (RPF) or initial glomerular plasma flow rate (Qa)
• oncotic pressure in the afferent arteriole (7cJ
• hydrostatic pressure within the glomerular capillary (Pgc).
Glomerular blood flow and pressure are regulated by changes in afferent and efferent 
arteriolar resistance. The ultrafiltration pressure (P^), is the difference between the 
hydraulic (AP) and colloid osmotic pressure (Ap) across the glomerular capillary wall. 
The rate of filtration across a single nephron (SNGFR) is a product of P^ and Kf.
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1.2.4 The ren in -an g io ten sin  system  a n d  th e  g lom eru lus
The renin-angiotensin system (RAS) controls blood pressure and fluid and electrolyte 
balance. Renin is synthesised, stored in granules and released from cells in the 
afferent arteriole of the glomerulus but has no direct physiological function other than 
to convert its plasma substrate angiotensinogen, produced in the liver, to the non- 
pressor decapeptide angiotensin I (Al). Subsequently, A l is converted by angiotensin 
I converting enzyme (ACE) to the potent pressor, angiotensin II (All) - a step which 
is blocked by ACE inhibitors. Renin also promotes sodium reabsorption by 
stimulating aldosterone production (Laragh, 1981).
Angiotensin II has marked effects on glomerular function through its actions on both 
the afferent and efferent arterioles and the mesangium (Blantz et al, 1976, Ichikawa 
and Brenner, 1979, Blantz and Gabbai, 1987). The normal kidney responds to a fall 
in blood pressure through dilation of the afferent, and constriction of the efferent 
arteriole, which raises the hydrostatic pressure within the glomerulus (Pgc) and 
maintains filtration fraction (FF = GFR + RPF; Icikawa et al, 1983). Although it is 
widely held that A ll constricts the efferent arteriole preferentially, to preserve both 
GFR and filtration fraction when glomerular perfusion falls, filtration is likely to be 
compromised due to a fall in glomerular blood flow and pressure if A ll constricts the 
afferent arteriole.
Angiotensin II can also impair glomerular filtration through contractile and 
proliferative effects on the mesangium (Kaizu et al, 1985, Yoshida et al, 1989). AD 
stimulated mesangial uptake of large ferritin molecules (Raij et al, 1982) and IgG 
complexes (Singhal et al, 1990) in vitro while saralasin (an All receptor antagonist) 
blocked the increased mesangial uptake of IgG in PAN rats (Mauer et al, 1985). 
ACE inhibitors have been shown to curtail the progression of sclerosis (Grond et al 
1985, Bertani et al, 1986, Klahr et al, 1988). With its growth-promoting properties, 
A ll stimulates mesangial cell proliferation and hypertrophy (Fogo et al, 1990, 
Ardaillou et al, 1990, Ray et al, 1991, Wolf et al, 1991) and although A ll appears to 
have no mitogenic potential in vascular smooth muscle cells (Geisterfer et al, 1988) it 
may cause them to hypertrophy (Berk et al, 1989) and evidence that enalapril inhibits 
hyperplasia in nephrectomised rats implicates AH in the hypertrophic response to 
systemic hypertension (Wang et al, 1990, Wight et al, 1990).
1 2
1.2.5 N orm al g lo m eru la r perm selectiv ity
In practical terms, it is not easy to characterise the filtration of a molecule across the 
glomerular capillary wall. The sieving co-efficient (SC) can only be measured in 
animals because it requires micropuncture of Bowmans space or the first part of the 
proximal tubule to establish the concentrations of a solute in both the glomerular 
ultrafiltrate and blood. The fractional clearance (FC) of a molecule on a timed urine 
collection is more convenient measurement because it compares the clearance of a 
test molecule to that of the small polysaccharide inulin (MWt = 5200 kD; Mr = 14A) 
which passes freely across the GCW and is neither secreted nor reabsorbed by the 
proximal tubule. The clearance rate of inulin is an acceptable approximation to GFR. 
A FC value of 1 (or 100%) implies unrestricted filtration whereas a FC value close to 
zero suggests filtration is impeded. Implicit in the finding of a SC of 0.0001 and FC 
of 0.01 is that 99% of the filtered albumin is reabsorbed in the proximal tubule 
(Maack et al, 1992). The selectivity index (SI), which compares the clearance of a 
large, neutral molecule such as IgG (Mr = 55A; MWt = 155,000 kD; pi = 7.4-7.6) to 
that of a smaller, more anionic molecule like albumin (MWt = 69, 000 kD; Mr = 36A; 
pi = 4.7 - 4.9) can also be used to assess glomerular permselectivity. A high SI 
denotes impaired size selectivity (although a concommitant loss of charge selectivity 
cannot be overlooked) whereas a low SI implies that charge although size selectivity 
may also be impaired. A SI value equal to or below 0.2 characterises diabetic 
humans with varying degrees of microalbuminuria (Viberti and Keen, 1984). The 
isoamylase clearance ratio (ICR) is yet another, but perhaps more appropriate index 
of glomerular permselectivity because it compares the clearance of two differently 
charged isoforms of the same protein (Fox et al, 1993). The pancreatic isomer of 
amylase (Mr = 29A; MWt = 56, 000 kD; pi = 7) is more cationic than the anionic 
salivary isomer of amylase (pi = 5.9 - 6.4) of the same molecular weight (Wetzels et 
aly 1988). A low isoamylase clearance ratio (PAM /  SAM) is associated with depleted 
glomerular charge.
Graded neutral dextrans and polyvinylpyrrolidone have been used mainly in animal, 
but also in some human experiments to study the relationship between the size or 
dimensions of a molecule and its passage through the GCW (Caulfield and Farquhar, 
1979). Homogeneous in chemical structure, molecular configuration and charge, 
their molecular weight and size can be varied, and like inulin, they are neither 
secreted nor reabsorbed by the renal tubules. Early experiments characterising 
glomerular permselectivity showed that neutral dextrans with a molecular radius up 
to 20A passed virtually unhindered across the glomerular capillary wall (SC = 1 or 
FC =100%) but clearance tailed off sharply towards zero as their molecular radius 
increased from 20A to 42A (Chang et al 1975; 1975a; 1975b).
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For any given molecular size, the glomerular capillary wall restricts the passage of 
anionic molecules more strongly than neutral ones while facilitating the transport of 
cationic molecules. Interaction between molecules of differing electrostatic charge 
and the glomerular capillary wall was further investigated by comparing the clearance 
of neutral dextrans (Chang et al, 1975a), anionic (-) dextran sulphate (Bennett et al, 
1976) and cationic (+) diethylaminoethyl dextrans (Bohrer et al, 1978). Cationic 
dextrans, the same size as albumin, were filtered more readily (FC = 0.42) than 
anionic dextrans (FC = 0.01), the clearance of which was retarded relative to neutral 
dextrans (FC = 0.15) (Brenner et al, 1977), suggesting that the negative charge on the 
albumin molecule was responsible for the significant reduction in its clearance. 
Rennke et al (1978) compared the filtration rates of anionic, cationic and neutral 
forms of the smaller horseradish peroxidase protein (Mr = 30A).
The shape or conformation of a molecule is another important determinant of its 
filtration. A rigid globular protein like albumin is restricted more than dextran 
molecules which are relatively flexible (Rennke et al, 1979). To establish that the 
difference in filtration was not due to differences between proteins and 
polysaccharides, Bohrer et al (1979) compared the clearance of two polysaccharides 
and showed that coiled flexible dextrans were filtered more readily than rigid, cross- 
linked spherical ficoll molecules. The fractional clearance of a rigid ficoll molecule, 
the same size as albumin, was about half that of a dextran molecule of comparable 
radius while the clearance of neutral dextrans was increased seven-fold relative to 
native globular horseradish peroxidase (Mr = 28A; pi = 7.4). Both studies confirmed 
the conformational differences between proteins and non-proteins of similar 
dimensions and charge.
1.2.6 Im p a ire d  g lo m e ru la r  p e rm se le c tiv ity
Usually, high levels of protein in the urine is evidence that the normal permselective 
properties of the glomerular capillary wall are defective (Waller et al, 1989). 
Glomerular permeability to proteins is related to the size, number and electrostatic 
charge of the GCW pores which, in turn, are influenced by glomerular blood flow and 
pressure and the hydraulic conductivity of the glomerular capillary wall.
Although a loss of glomerular size selectivity might initially suggest increased pore 
diameter, the size of a GCW pore is also affected by its charge, intraglomerular blood 
pressure and mesangial expansion or GBM thickening. When glomerular pores 
become enlarged or stretched, by whatever means, their inherent charge may be 
diminished. Enlarged pores is the only plausible explanation for a simultaneous
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increase in the filtration of both large cationic and anionic molecules (Bertolatus and 
Hunsicker, 1985, Bertolatus e ta l, 1987, Groggel eta l, 1988).
On the other hand, a fundamental loss of charge selectivity has been cited as being 
responsible for the impaired permselectivity in many forms of experimental 
glomerular injury (Michael et al, 1970, Lelongt et al, 1987a, Bennett et al, 1976, 
Bohrer et al, 1977, Carrie and Myers, 1980) and MCN patients (Carrie et al, 1981, 
Bridges et al, 1982). However, diminished GCW charge can also weaken the 
electrostatic interactions which maintain pore structure and so impair size selectivity 
(Olsen et al, 1981, Weening and Rennke, 1983, Barnes et al, 1984, Bertolatus et al, 
1985, 1987). Raised blood pressure or plasma volume expansion too, can cause a 
generalised increase in pore diameter and increase the volume of ultrafiltrate passing 
through the shunt pathway or alternatively, aggravate pre-existing size selective 
defects within the GCW (Carrie et al, 1980, Shemesh et al, 1986, Alfino et al, 1988). 
The shunt pathway allows large and small molecules, irrespective of charge, to pass 
unimpeded into the glomerular filtrate and its utilisation may be heightened when 
blood pressure is raised (Bohrer et al, 1977, Alfino et al, 1988, Neugarten et al, 1985: 
1988, Yoshioka et al, 1986; 1987, Shemesh et al, 1986. It was presumed that anti­
hypertensive drugs or aortic ligation reduced proteinuria by limiting the contribution 
of the shunt pathway (Neugarten et al, 1985; 1988, Alfino et al, 1988). In relation to 
the pressor effects of dietary protein intake, a high protein diet altered glomerular 
haemodynamics in ADR rats but size selectivity was not affected directly (Remuzzi 
et al (1985) and neither did a low protein diet improve size selectivity in membranous 
nephropathy (Remuzzi eta l, 1991).
The hydraulic conductivity of the GCW is affected by GBM thickening, mesangial 
expansion or foot process fusion (Robson et al, 1974) all of which can alter effective 
pore size, density and charge (Chang et al, 1976, Bohrer et al, 1977a, Bridges et al, 
1982). The effective number or density of GCW pores is directly proportional to 
total pore surface area but indirectly proportional to pore length: thus GBM 
thickening reduces pore density by increasing effective pore length while mesangial 
expansion effectively reduces the number of functional pores.
Angiotensin II can heighten glomerular permeability to proteins by increasing 
filtration fraction as a result of a fall in glomerular plasma flow (Eisenbach et al, 
1975, Bohrer et al, 1977a, Carrie et al, 1980, Olivetti et al, 1984, Yoshioka et al, 
1986) although Loon et al (1989) proposed that angiotensin II actually lowers 
proteinuria by the same mechanism. Despite substantial experimental evidence of a 
link between angiotensin II and proteinuria in animals, the data for humans is less
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persuasive (Marinides et al, 1987, Scholey et al, 1987; 1989, Beukers et al 1988, 
Heeg et al, 1991, Gansevoort et al, 1993). The anti-proteinuric properties of ACE 
inhibitors are attributed to their ability to reduce glomerular hypertension specifically 
(Anderson et al, 1986, Zatz et al, 1986, Hommel et al, 1986, Parving et al, 1988) but 
may also be related to an ability to reduce the radius of the largest membrane pores 
and thus diminish flow through the shunt pathway (Yoshioka et al, 1987, Morelli et 
al, 1990, Heeg et al, 1987, Remuzzi et al, 1990, 1991a). Some reports have gone as 
far as to suggest that ACE inhibitors reduce only large pores in IgA nephropathy 
(Remuzzi et al, 1991) but both large and small pores in diabetic nephropathy (Morelli 
eta l, 1990)
In diabetes, the GCW is subject to a variety of biochemical changes (see section
1 .2 . 1 ) and changes in glomerular permselectivity may be governed by different 
determinants at different stages of nephropathy (Carrie et al, 1980, Michels et al,
1982). Although by no means definitive, early changes in permeability have been 
associated with glomerular hypertension and subsequent loss of size and charge 
selectivity (Viberti et al, 1984). In advanced diabetes, the decline in GFR is 
associated with loss of ultrafiltration capacity related to GBM thickening and 
mesangial expansion which affects pore characteristics and utilisation of the shunt 
pathway becomes more marked (Myers et al, 1982, Winetz et al, 1982, Friedman et 
al, 1983, Tomlanovich et al, 1987, Nakamura et al, 1988).
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POLYUNSATURATED FATTY ACIDS: POSSIBLE LINKS WITH PROTEINURIA S ection  1.3
Polyunsaturated fatty acids are not only a source of metabolic energy and inherent 
components of cell membrane phospholipids but certain essential polyunsaturated 
fatty acids (EFA: see below) can be oxygenated to generate prostaglandins and 
thromboxane (prostanoids) and leukotrienes, known collectively as eicosanoids. This 
section will be limited to the effects of prostaglandins and thromboxane on 
glomerular function in relation to vascular reactivity (blood pressure and 
coagulation), the renin-angiotensin system, mesangial function and to a lesser extent, 
more general aspects of cellular function including the immune and inflammatory 
responses, proliferation and hypertrophy.
1.3.1 E ssen tia l fa tty  a c id  m e ta b o lis m  a n d  p ro s ta n o id  b io sy n th e s is
The co- 6  and co-3 pathways of EFA metabolism are probably the most important 
Linoleic acid (LA: 18: 2co-6) is converted to arachidonic acid (AA: 20: 4co-6) along 
the co- 6  pathway and a-linolenic acid (ALA: 18:3co-3) is converted to 
eicosapentaenoic acid (EPA: 20:5co-3) down the parallel co-3 pathway (Figure 1.3.1). 
Fatty acids are classified according to the number and position of double bonds 
contained within the molecule: linoleic acid, for example, is denoted as C l 8 : 2 co- 6  
because it contains eighteen carbon atoms and two double bonds, the first of which is 
located six carbon atoms from the co end of the molecule. Although not all PUFAs 
are essential fatty acids (EFA), all EFAs are polyunsaturated and the double bonds 
must be in the cis conformation to confer prostanoid activity.
The three main series of prostanoids (mono-, di- and tri- enoic) with varying degrees 
of potency, are derived from "^linolenic acid (DGLA), arachidonic acid (AA) and 
eicosapentaenoic acid (EPA), respectively. Dienoic (or 2- series) prostanoids which 
include PGE2, PGI2, and TxA2  are regarded as being the most abundant and 
biologically active. However, prostanoid biosynthesis cannot occur without a supply 
of free unesterified AA which must be acquired either from (i) hydrolysis of 
membrane phospholipids through the actions of phospholipases or (ii) by dietary 
supplementation with essential fatty acid (EFA) which cannot be synthesised de novo 
by humans. Oils from the seeds of the evening primrose or safflower are rich in 
linoleic acid (LA) and GLA whereas leaves and grasses contain high levels of a- 
linolenic acid (ALA) and it is the high levels of a-linolenic acid in phytoplankton 
which makes oils from marine animals a rich source of eicosapentaenoic acid (EPA). 
The relative amounts of a particular prostanoid series generated, depends upon the 
variable rates of the reaction steps within the EFA pathways. The initial step in the
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Figure 1.3.1
co- 6  pathway, which is rate-limiting and catalysed by A- 6  desaturase, is the slow 
conversion of LA to ^linolenic acid (GLA: C l 8 : 3co-6) and because GLA is then 
elongated rapidly to dihomo y  linolenic acid (DGLA: C20: 3co-6), tissue levels of 
GLA are low under normal conditions: DGLA then undergoes another slow 
desaturation step to arachidonic acid (AA: C20: 4co-6). Depending upon the 
abundance or availability of GLA, DGLA is converted to either arachidonic acid and 
2- series prostanoids or 1- series prostanoid derivatives such as PGEj and 15 OH- 
DGLA.
The co-3 pathway utilises the same desaturase and elongase enzymes to convert a- 
linolenic acid to EPA and 3- series prostanoids, which have modified activity and
potency relative to the 2- series prostanoids (Marshall et al, 1983; see Figure 1.3.1).
Essential fatty acids surplus to requirements, may be reincorporated into cell 
membrane phospholipids.
1.3.2 C o n v e rs io n  o f EFA to  p ro s ta n o id s
Prostaglandins comprise a pentane ring with two acyl side chains containing a 
number of double bonds which determine the prostanoid series formed.
• 1- series prostanoids with one double bond are derived from DGLA
• 2- series prostanoids with two double bonds are derived from AA
• 3- series prostanoids with three double bonds are derived from EPA.
Prostaglandins are classified (A, B, C, D, E or F) according to the substituents on the 
pentane ring. Prostacyclin (PGI2) is not an authentic prostaglandin because of the 
presence of an oxygen bridge between carbon atoms 6  and 9 and likewise, 
thromboxane A 2  has an unstable bicyclic oxane-oxetane ring structure.
The first step in the conversion of arachidonic acid to a prostanoid is its oxygenation 
to the unstable prostaglandin endoperoxides, PGG2  and PGH2  by cyclooxygenase 
(Hamberg et al, 1975, Gryglewski et al, 1976) - a step which can be inhibited by 
indomethacin and other non-steroidal anti-inflammatory drugs (Vane, 1971, 
Carmichael and Shankel, 1985, Schlondorff, 1993). Specific enzymes then convert 
PGG2  to a variety of prostaglandins and thromboxanes (Figure 1.3.2).
The alternative lipoxygenase enzyme pathway can convert EFAs to pro-inflammatory 
and vasoconstrictory leukotrienes and DGLA has anti-inflammatory properties 
because its metabolites PGEj and 15 OH-DGLA inhibit lipoxygenase activity 
(Lagarde et al, 1987, Lewis et al, 1990). Not only is there competition between the 
oo- 6  and co-3 EFA pathways for the elongase and desaturase enzymes but EPA and
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AA compete for the cyclooxygenase and lipoxygenase enzymes (Culp et al, 1979). 
When EPA replaces AA as a substrate for cyclooxygenase, the trienoic prostanoids, 
PGI3  and TxA3  are generated and although PGI3  and PGI2  have equally potent 
vasodilatory properties and abilities to inhibit platelet aggregation, TxA 3  is a weaker 
vasoconstrictor and platelet aggregating agent than TxA 2  (Dyerberg and Bang, 1979, 
Fischer and Weber, 1983; 1984; 1985). Similarly, when EPA replaces A A as a 
substrate for the lipoxygenase enzyme, 5- series leukotrienes with attenuated 
inflammatory properties relative to 4- series leukotrienes derived from arachidonic 
acid, are formed and this explains the states of reduced vascular resistance, 
thrombogenicity and inflammation induced by fish oils (Culp et al, 1979, Jim et al, 
1982, Sraer et al, 1983, Lee et al, 1984, Terano et al, 1984; 1986, Leaf et al, 1988, 
Endres e ta l , 1989).
1.3.3 G e n e ra l  p ro s ta n o id  fu n c tio n
The kidney, along with the lungs and liver, is particularly active in relation to 
prostanoid biosynthesis, and activity increases progressively from the cortex through 
the medulla to the papilla. At various sites within the kidney, different prostanoids 
are synthesised to perform specific functions (Shryver et al, 1984, Eriksen et al, 1987, 
Bonventre and Nemenoff, 1991). For example, in humans, PGI2  is the principal 
prostanoid in the highly vascular renal cortex although in rats, PGE2  is the 
predominant prostanoid (Whorton et al, 1977). In the renal medulla, PGE2  is the 
main prostanoid in association with its role in the control of salt and water excretion 
and its modulatory effects on the actions of ADH (Grantham and Orloff, 1968, 
Muirhead et al, 1972, Larsson and Angaard, 1974, McGiff and Wong, 1979).
Native and infiltrating cell types contribute to the glomerular prostanoid profile 
(Folkert and Schlondorff, 1979, Hassid et al, 1979). Glomerular endothelial cells 
synthesise prostacyclin (Bunting et al, 1976, Moncada and Vane, 1979; 1979a) 
whereas epithelial and mesangial cells produce large amounts of PGE2  (Sraer et al, 
1979, 1982, Petrulis et al, 1981, Kreisberg et al, 1982). Platelets are the principal 
source of thromboxane (Hamberg et al, 1975, Needleman et al, 1976; 1979) but 
peripheral blood mononuclear cells (Goldstein et al, 1978) and macrophages (Brune 
et al, 1978) also produce significant quantities of prostanoids.
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1.3.4 P ro s ta n o id s  a n d  g lo m e ru la r  fu n c tio n
Perhaps the most significant distinction between prostaglandins and thromboxane is 
that prostaglandins are vasodilators and inhibit platelet aggregation whereas 
thromboxane is a vasoconstrictor and potent platelet aggregating agent. Prostacyclin 
produced by endothelial cells in vessel walls, opposes the effects of thromboxane A 2  
released by activated platelets following endothelial damage or immune injury and so 
the synthetic balance between these two prostanoids is important in maintaining 
normal thromboresistance and systemic and glomerular blood pressure and flow 
(Grylewski et al, 1976, Moncada and Vane, 1979, Perico et al, 1982, Chang et al, 
1984).
It is widely accepted that prostanoid activity is dormant in kidneys which are 
functioning normally but prostaglandin levels, in particular, often rise to maintain 
glomerular function when it is threatened: thromboxane, on the other hand, is perhaps 
more likely to be generated when the kidney is damaged (Finn and Arendshorst, 
1976, Baylis, 1980, Zipser et al, 1985, Benigni et al, 1986).
Prostaglandins maintain glomerular filtration when blood flow is reduced (see Table
1.3.1) and modulate the effects of vasoconstrictors such as angiotensin n, antidiuretic 
hormone (ADH) and epinephrine (Baylis and Brenner, 1978, Gerber et al, 1978, 
Ichikawa and Brenner, 1980a, Yarger et al, 1980, Myers et al, 1981, Patrono et al, 
1982, Podjamy et al, 1986). A close relationship between prostanoids and various 
components of the renin-angiotensin system was first recognised when McGiff et al 
(1970) observed that prostaglandin levels rose in response to constriction of the renal 
artery or an infusion of angiotensin II (Aiken and VAne, 1973, Oates et al, 1979, 
Schlondorff et al, 1980, Stahl et al, 1984a). Moreover, specific prostaglandins may 
control renin release from different parts of the glomerulus (Ito et al, 1989). 
Prostaglandins may also modulate blood pressure by altering both vascular reactivity 
and extracellular volume in association with their diuretic and natriuretic actions 
(Laragh, 1981: Axelrod, 1982, Dusing e ta l,  1983, Dunn andGroene, 1985).
The use of cyclooxygenase inhibitors (COI) has reinforced the importance of 
prostaglandins in maintaining renal function (Kimberly and Plotz, 1977, Dunn and 
Zabramski, 1980, Clive and Stoff, 1984, Brater et al, 1985, Carmichael et al, 1985, 
Patrono and Dunn, 1987, Schlondorff, 1993) and have been shown to abolish 
compensatory increases in GFR in STZ rats (Craven and De Rubertis, 1989) and 
impair renal function in patients with chronic glomerulonephritis (Ciabattoni et al, 
1984), lupus nephritis (Kimberly et al, 1978) and nephrotic syndrome (Arisz et al, 
1976).
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Nephrotoxic serum nephritis Lianos e ta l, 1983 
Kaizu eta l, 1985
Immune complex glomerulonephritis Rahman et al, 1987
Stahl e ta l, 1987
STZ diabetes Jensen et al, 1986
Obstructive nephropathy Yarger et al, 1980
Folkert and Schlondorff, 1981 
Yanagasawa et al, 1990
2-Kidney, 1-Clip hypertension Stahl eta l, 1984
Nephrotic syndrome Donker et al, 1978
Glomerulonephritis Donadio et al, 1984
Stork and Dunn, 1985
Table 1.3.1 C om pensato ry  in creases  in p rostanoid  synthesis in various 
g lom erulopath ies
Thromboxane appears to be more damaging than prostaglandins in terms of 
glomerular functional deterioration and impaired permselectivity (see Table 1.3.2). 
In relation to its ability to raise intraglomerular blood pressure (Pgc), reduce 
glomerular blood flow and stimulate renin production, thromboxane is a strong 
contender in the pathophysiology of hypertension (Purkerson et al, 1986, Baylis et 
al, 1987, Mistry et al, 1990). Glomerular thromboxane levels were shown to be 
raised in genetically hypertensive SHR (Shibouta et al, 1979) and Lyon rats 
(Geoffroy et al, 1989) although the hypertension which developed in Sabra rats after 
DOCA-salt treatment was attributed to a deficiency of prostacyclin rather than any 
increase in thromboxane production (Geoffroy et al, 1988). However, improvements 
in renal function in hypertensive Dahl-S rats (Yamashita et al, 1988) and 
normotensive Milan rats following thromboxane inhibition occurred independently of 
any change in blood pressure (Pugliese et al, 1986, Salvati et al, 1990). It has been 
suggested that thromboxane mediates the renovascular effects of angiotensin II 
(Shibouta et al, 1979, Geoffroy et al, 1989, Wilcox et al, 1990; 1991).
The hypercoagulable state of the nephrotic syndrome and other glomerulopathies is 
likely to be associated with raised thromboxane levels (Perico et al, 1982, Mortensen 
et al, 1983, Socini et al, 1985, Purkerson et al in 1985, Schlondorff et al, 1986, 
Morrison e ta l, 1986, Yoshida eta l, 1978, Patrignani eta l, 1982, Donadio eta l, 1988) 
although a deficiency in prostacyclin production cannot be discounted. The benefits 
of thromboxane synthesis inhibition in rats with reduced in renal mass were attributed 
to attenuated platelet activity, intraglomerular thrombosis and hypertension. 
However, comparisons between the effects of low dose aspirin, which suppresses 
only platelet TxA2  and a Tx-receptor antagonist, which blocks both platelet and 
vascular receptors for TxA2, and neither of which had any effect on blood pressure, 
led to the conclusion that platelet activation and thromboxane production made no 
substantial contribution to renal functional deterioration in patients with lupus 
nephritis (Pierucci et al, 1989) or type I diabetes (Allesandrini et al, 1988).
Many aspects of mesangial function are influenced by prostanoids (Mene et al, 1990). 
A fall in GFR, secondary to the contractile actions of angiotensin II (Kreisberg et al, 
1984, Schlondorff et al, 1985), thromboxane (Mene et al, 1986), leukotrienes 
(Simonson et al, 1986) or endothelin (Zoja et al, 1990) may be offset by 
prostaglandins and cyclooxygenase inhibitors have been shown to intensify the 
effects of mesangial contraction on glomerular filtration (Dworkin et al, 1983, 
Scharschmidt et al, 1986, Dunn and Scharschmidt, 1987). In addition, the growth- 
promoting and proliferative effects of prostanoids are implicated in mesangial 
expansion and glomerulosclerosis (Levine et al, 1977, Taylor and Polgar 1980,
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Ureteral obstruction Okegawa e ta l , 1983 
Stahl ef al, 1986
Renal ablation Purkerson e ta l , 1985 
Zoja et al, 1990a
Adriamycin nephrosis Remuzzi et al, 1985
Progressive kidney disease 
(Milan normotensive model)
Salvati et al, 1990
STZ diabetes Craven et al, 1992
Nephrotoxic serum nephritis Lianos et al, 1983
Immune complex glomerulonephritis Saito et al, 1984 
Rahman et al 1987 
Yamashita et al, 1988 
Stahl e ta l , 1990 
Thaiss et al, 1989
Unilateral glomerulonephritis Cook e ta l , 1986
Mercuric chloride (ICGN) Papanikalou, 1987
Anti-GBM nephritis Suzuki et al, 1987
Murine lupus Kelley eta l, 1986
Systemic lupus erythymatosis Patrono et al, 1985 
Pierucci et al, 1989
Haemolytic uraemic syndrome Tonshoff e ta l, 1990
Table 1.3.2 Raised th rom boxane  levels in experim ental a n d  hum an 
glom erulopath ies
Habenicht et al, 1985, Mene et al, 1990, Floege et al, 1990, Ardaillou et al, 1990) 
and may relate to changes in intracellular message transmission or an increased 
glomerular work load (Nath et al, 1986, Mene and Dunn, 1990). Indomethacin 
suppressed DNA synthesis and renal function in uninephrectomised rats (Logan et al,
1986). Thromboxane is also recognised as a strong chemoattractant (Saito et al, 
1984) and may act as a growth factor, stimulating mesangial cell proliferation and 
matrix expansion (Ishimtsu et al, 1988, Shultz et al, 1988, McNamara et al, 1989, 
Border et al, 1989, Yamamoto et al, 1991, Bruggeman et al, 1991). Both 
indomethacin and a thromboxane synthetase inhibitor preserved renal function in an 
experimental model of mesangial cell injury (Stahl et al, 1990).
Prostanoids are involved also in regulation of the immune response (Goodwin, 1980, 
Herbert, 1978, Eriksen et al, 1986, Couser et al, 1985) and have potent anti­
inflammatory properties (Zurier et al, 1977, Winkelstein and Kelley, 1981, Kunkel et 
al, 1986, Salmon and Higgs, 1987, Goodwin, 1991, Lefkowith et al, 1992).
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1.3.5 P ro s ta n o id s  a n d  a l te r e d  g lo m e ru la r  p e rm se le c tiv ity
The anti-proteinuric effects of cyclooxygenase inhibitors (COI) implicate 
prostaglandins, in particular, in the impaired permselectivity of many animal and 
human glomerulopathies (Kimberly et al, 1978a, Kirschenbaum and Serros, 1981, 
Plotz and Kimberly, 1981, Zatz et al, 1985, Benigni et al, 1986). Although the 
mechanism is unclear, it is most likely that COI reduce proteinuria by lowering 
prostaglandin levels (Arisz et al, 1976, Donker et al, 1983, Alavi et al, 1986, 
Vreisendorp et al, 1985, 1986). Indomethacin reduced proteinuria, without any 
further fall in glomerular function, in patients with heavy proteinuria (Tiggler et al, 
1979), experimental passive Heymann nephritis (Zoja et al, 1987) and autologous 
immune complex glomerulonephritis (Kirschenbaum et al, 1985). However, 
Kirschenbaum questioned whether the effects of indomethacin were related to 
prostaglandin inhibition after showing that aspirin did not lower proteinuria, despite 
inhibiting PGE2  to a similar degree. Alternatively, COI may lower proteinuria by 
suppressing the activity of the renin-angiotensin system (Eisenbach et al, 1975, 
Donker et al, 1978), a direct effect on the glomerular capillary wall (Sessa et al, 
1973, Suzuki et al, 1984), redirection of blood flow from outer to less permeable 
inner cortical nephrons (Chang et al, 1975) or stimulation of tubular reabsorption of 
proteins (Brater, 1979). Nevertheless, indomethacin did not reduce proteinuria in 
either the NSN rat model of anti-GBM nephritis (Kurokawa et al, 1982) or 
autologous immune complex nephropathy (Donker et al, 1983) which suggests that it 
may only be an effective anti-proteinuric agent in conjuction with an activated renin- 
angiotensin system (Arisz et al, 1976, Alavi et al, 1986).
Yet another possibility is that cyclooxygenase inhibitors reduce glomerular pore size 
directly. The reduced clearance of proteins and large (> 42A) neutral dextrans in 
NSN rats given indomethacin, correlated with a fall in both GFR and filtrate volume 
but glomerular hypertension was unchanged (Neugarten et al, 1989). Golbetz's group 
(1989) also concluded that the anti-proteinuric effects of indomethacin in NS patients 
was related to restoration of impaired glomerular permselectivity despite a 
concommitant reduction in GFR.
The substantial variability and many inconsistencies in the anti-proteinuric effects of 
cyclooxygenase inhibitors, suggests that prostaglandins do not play a major role in 
the pathogenesis of proteinuria. On the other hand, heightened thromboxane levels 
often correlate with rising proteinuria in animal and human glomerulopathies (see 
Table 1.3.3) but thromboxane is regarded as being more likely to induce proteinuria 
either in reponse to, or in conjunction with other mediators of glomerular injury. In 
immune-mediated glomerulopathies, the association between thromboxane and
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Streptozotocin diabetes 
Renal ablation
Spontaneous progressive renal disease
Adriamycin nephrosis 
Nephrotoxic serum nephritis
Heymann nephritis 
Insulin-dependent diabetes
Systemic lupus erythematosus
Collins et al, 1989 
Hora et al, 1990 
de Rubertis et al, 1992 
Craven et al, 1992
Purkerson et al, 1985
Yamashita et al, 1988 
Salvati 1990
Remuzzi et al, 1985
Lianos et al, 1983 
Takahashi et al, 1990
Cybulsky et al, 1986
Barnett et al, 1984 
Esmatjes et al, 1990
Pierucci et al, 1989
Table 1.3.3 Raised th rom boxane  levels co rre la te  with protein excre tion  in 
various g lom erulopath ies
proteinuria may be linked to complement-mediated generation of thromboxane, 
proteolytic enzymes or inflammatory agents which impair the permselectivity of the 
glomerular capillary wall (Camussi et al, 1984; 1986, Brown et al, 1987, Cybulsky et 
al, 1987, Lianos e ta l , 1990). Nevertheless, blocking thromboxane production neither 
prevented nor lowered proteinuria in rats with NSN (Lianos et al, 1983), immune 
complex glomerulonephritis (Rahman et al, 1987a) or experimental membranous 
nephropathy (PHN) although in the latter case, complement depletion did (Stahl et al,
1987). A broad spectrum platelet inhibitor (Zoja et al, 1990a) and triple action 
inhibitor of thromboxane and leukotriene synthesis and lipid peroxidation (Shibouta 
et al, 1991) were more effective than thromboxane inhibitors in terms of improving 
disease progression in non-immune-mediated glomerular disease.
1.3.6 PUFAs a s  m e m b r a n e  c o m p o n e n ts
Polyunsaturated fatty acids are structural and functional components of all cell 
membranes, having undergone transacylation to glycerolipids and conversion to 
various phospholipids which associate spontaneously to form the characteristic 
membrane lipid bilayer (Kummerow, 1988, Kinsella, 1990). The three major lipid 
components of eucaryotic cell membranes are phosphoglycerides (or 
glycerophospholipids), sphingolipids and cholesterol. Phosphatidylethanolamine, 
phosphatidylcholine, phosphatidylinositol and phosphatidylserine are the most 
abundant phospholipids, containing myristic (C14:0), palmitic (C16:0), palmitoleic 
(0 6 :1 ) , stearic (0 8 :0 ) , oleic (0 8 :1 ) , linoleic (0 8 :2 ) , linolenic (0 8 :3 )  and 
arachidonic (C20:4) acids: usually, a saturated and unsaturated fatty acid are bound to 
the first and second carbon atom of the glycerol molecule, respectively. 
Phosphatidylethanolamine, for example, has palmitic or oleic acid esterified to the 
first, but one of the longer chain polyunsaturated or essential fatty acids such as 
arachidonic acid to the second carbon atom.
A constant turnover of unsaturated fatty acids, in particular, within phospholipids 
maintains the membrane fluidity and flexibility of cell (Schacter et al, 1984, Stubbs 
and Smith, 1984, Cartwright et al, 1985). Membrane fluidity affects a host of cellular 
functions including:
• the lateral movement and rotational diffusion of integral membrane proteins 
(glycoproteins) and enzymes
• selective ion exchange across the cell membrane
• hormone receptors and intracellular signalling
• mobility and adhesion, secretion, endocytosis and phagocytosis, lymphocyte 
capping
Membrane fluidity is related to both the degree of fatty acid unsaturation and acyl 
chain length and replacement of a saturated, with an unsaturated fatty acid is likely to 
improve membrane fluidity. Saturated and trans unsaturated fatty acids are straight 
chain molecules but the presence of a cis double bond creates a bend in the 
hydrocarbon chain of the fatty acid which prevents crystallisation and maintains 
fluidity. Saturated acyl chains form highly ordered membranes with low fluidity 
(Kamada and Otsuji, 1983) and incorporation of cholesterol reduces membrane 
fluidity (Huang et al, 1986: Kinsella, 1990). Differences in melting points between 
saturated and unsaturated fatty acids effect transitions between the fluid and 
crystalline gel states of the membrane (Le Grimellec et al, 1992). The concept of 
membrane polarity is a function of differences in fluidity between the inner and outer
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leaflets of the lipid bilayer in relation to the proportions of saturated, or trans or cis 
unsaturated fatty acids with different melting points.
Changes in the PUFA content of the membrane may influence various aspects of 
cellular activity such as:
(i) the orientation and conformation of cation transport mechanisms such as the Na+- 
K+ ATPase, Ca**- ATPase or sodium-lithium countertransport system (Almeida et al, 
1984, Pagnan et al, 1989). Ion transport across the red blood cell membrane may be 
abnormal in hypertensive patients (Canessa et al, 1980, Carr et al, 1990, Dominiczak 
et al, 1991) and indeed, linoleic acid had favourable effects on blood pressure in 
normotensive volunteers in relation to changes transmembrane sodium flux (Heagarty 
eta l, 1986).
(ii) the expression and/or affinity of a variety of receptors including those for insulin 
or low density lipoproteins (Kinsella, 1990). Heightened membrane fluidity in Friend 
erythroleukaemia cells grown in medium supplemented with linoleic, as opposed to 
oleic acid, was associated with an increased number, and decreased affinity of insulin 
receptors (Ginsberg et al, 1981). Hormones and polypeptides bind to cell membrane 
receptors and transmit their signal through intracellular messengers such as cAMP 
and the protein kinase A pathway, phophatidylinositol 4,5-bisphosphate (PIP2), the 
protein kinase C pathway and the inositol 1, 4, 5 triphosphate (IP3) - calcium 
pathways or cGMP and activation of protein kinase G pathway, embedded in the cell 
membrane. A greater degree of membrane fatty acid unsaturation reduces the 
binding of various steroids and hormones and so a deficiency of UFAs may 
exaggerate the response to normal peripheral levels of a particular agonist.
(iii) the deformability and passage of erythrocytes through capillary beds (Terano et 
al, 1983, Popp-Snijders et al, 1986). co-3 fatty acids improved the impaired fluidity 
of erythrocyte membranes in diabetic patients (Kamada et al, 1986).
(iv) the response of platelets to ADP and thrombin, their subsequent aggregation and 
release of growth and mitogenic factors and their interactions with endothelial cells to 
promote coagulation and thrombosis (Dyerberg et al, 1979, Berlin et al, 1980, Seiss 
et al, 1980, Sanders et al, 1983, Fischer and Weber, 1983, Croft et al, 1984, von 
Schacky et al, 1985, Heemskerk et al, 1989).
(v) the locomotion and migration, phagocytosis and endocytosis by neutrophils 
(Ziboh et al, 1986, Prescott et al, 1984) and macrophages (Mahoney et al, 1977), the 
secretory functions of platelets and lymphocytes (Singh et al, 1988, Meydani et al, 
1991). The incorporation of co-3 fatty acids into the membrane of neutrophil and 
monocytes reduces the production of pro-inflammatory mediators such as 
leukotrienes and cytokines (Lee et al, 1984; 1985, Kremer et al, 1987, Endres et al,
1989).
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(vi) capping of antigens on the surface of lymphocytes (Kinsella, 1990).
(vii) the assembly and activity of membrane-bound complement with significant 
implications for glomerular epithelial cells and glomerular permselectivity (Cybulsky 
e t a l  1986; 1989; 1990: C larkes al, 1993).
1.3.7 L ip id-low ering  e ffe c ts  o f PUFAs
Disturbances in plasma lipid and lipoprotein metabolism contribute to excess risk of 
atherosclerosis and coronary heart disease (Jensen et al, 1987, Scanu, 1991). 
Cholesterol is transported in low density lipoproteins (LDL) and removed from cells 
by high density lipoproteins (HDL) which transport it to the liver for excretion in the 
bile. The cholesterol-lowering effects of co- 6  fatty acids have been reported widely 
(Huang et al, 1987, Kissebah and Schectman, 1988) and the effects of PUFA diets on 
plasma lipid levels is discussed in the following section (1.4).
An outline of lipid metabolism may be viewed in any biochemistry textbook. In 
relation to the diabetic study reported in section 2.5, it is interesting that the 
hypertriglyceridaemia which is characteristic of IDDM, occurs despite greatly 
diminished fatty acid synthesis, because a low insulin to glucagon ratio causes 
uncontrolled lipolysis in adipose tissue. Circulating fatty acid levels increase and 
there is acclerated production by the liver of ketone bodies which accumulate along 
with hydrogen ions resulting in ketoacidosis. Excess fatty acids which do not 
undergo oxidation or ketogenesis generate VLDL more rapidly than they can be 
cleared from the blood by lipoprotein lipase, the activity of which is also dependent 
upon the insulin to glucagon ratio. Diabetic rats have an increased requirement for 
EFA because they are more easily oxidised than saturated fatty acids (Horrobin,
1990).
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PUFA DIETS a n d  GLOMERULAR DISEASE S e c t io n  1 .4
Enthusiasm for the use of polyunsaturated fatty acid (PUFA) diets in the treatment of 
glomerular disease evolved in association with their success in ameliorating symptoms 
of cardiovascular disease (Kromhout et al, 1985, Leaf and Weber, 1988), systemic 
lupus erythematosus (Clark et al, 1989; 1993), diabetes (Horrobin, 1988; 1992) and 
rheumatoid arthritis (Belch, 1990, Kremer et al, 1987; 1990). The rationale behind the 
use of PUFA diets is to stimulate the production of favourable prostanoids like PGE! 
or suppress of the synthesis of eicosanoids with unfavourable effects such as 
thromboxane and leukotrienes (Scherhag et al, 1982, Lorenz et al, 1983, Croft et al, 
1984). Supplying co- 6  EFAs, in the form of an evening primrose or safflower oil diet, 
raises the levels of monoenoic relative to dienoic prostanoids whereas co-3 PUFA diets 
redirect eicosanoid synthesis in favour of 3 series prostanoids which are associated 
with a limited incidence of cardiovascular, atherosclerotic and inflammatory events 
(Saynor et al, 1984, Endres et al 1989, Laker and Alberti, 1991). Many of the 
complications associated with experimental and clinical diabetes have been attributed 
to diminished A- 6  and A-5 desaturase enzyme activity in the EFA pathways which 
generate prostanoids: such metabolic blockades may be bypassed by dietary provision 
of EFA prostanoid precursors.
Much of the literature suggests that PUFA diets not only delay the onset and lessen the 
degree of glomerular injury but may also prevent the progression of renal disease 
(Barcelli and Pollack, 1985) in relation to their favourable effects on
• blood pressure and hypertension (Norris et al, 1986, Knapp et al, 1989, Bonaa et
al, 1990)
• coagulation (Goodnight et al, 1981, Sanders et al, 1983, Knapp et al, 1986, von
Shacky et al, 1985, Haines et al, 1986, Rogers et al, 1987, Hansen et al, 1989)
• hyperlipidaemia (Singer et al, 1986)
• cell proliferation (Fox et al, 1988)
• the immune (Endres et al, 1989) and inflammatory response (Meydani et al, 1990)
• sclerosis (Weiner et al, 1986)
• hypertrophy (Logan et al, 1990, Wight et al, 1990, Mene et al, 1990) 
and
• proteinuria (see Tables 1.4.1 and 1.4.2)
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To a large extent, the success of PUFA diet treatment is rated on the basis of either 
lowered blood pressure, lipid levels or proteinuria, improved renal function, a more 
favourable prostanoid balance, heightened immunosuppression or attenuated 
glomerulosclerosis. This section reviews the capacity of PUFA diets to lower 
proteinuria and retard disease progression in non-immune (see Table 1.4.1) and 
immune-mediated (see Table 1.4.2) glomerular diseases and diabetic renal disease.
Non-immune mediated glomerulopathies: The beneficial effects of PUFA diets
appear to be dose-dependent with high linoleic acid (HLA) diets being more beneficial 
than low linoleic acid (LLA) diets (Barcelli et al, 1982, Hoffman et al, 1982, Izumi et 
al, 1986, Heifets et al, 1987) although Hirschberg et al (1984) reported that varying 
the concentrations of dietary essential fatty acids and triglycerides did not alter disease 
outcome either in rats with reduced renal mass or mice with experimental lupus. 
However, despite many favourable reports, the indiscriminate use of PUFA diets was 
questioned when Scharschmidt et al (1987) reported that fish oil diets might actually 
impair renal function. Deteriorating renal function and accelerated proteinuria, 
glomerulosclerosis and mortality in nephrectomised rats fed fish oil was attributed to 
the suppression of PGE2  synthesis. Nevertheless, when the anti-proteinuric effects of 
fish or safflower oil diets were compared to those of a low protein diet (LPD), fish oil 
was seen to reduce albuminuria more effectively - but not as the result of fall in blood 
pressure (Clark et al, 1990). The study was repeated using a higher dose of fish oil 
and although both FO and LPD preserved renal function and lowered proteinuria, the 
low protein diet was more effective (Clark et al, 1993a). Albeit plasma lipid levels 
and glomerulosclerosis were reduced by both diets, the authors conceded that the 
lesser weight gain in the low protein diet group might explain fall in albumin 
excretion. In 1990, Logan et al claimed to have discredited the hypothetical link 
between hyperfiltration and hypertrophy in normal and uninephrectomised rats fed a 
PUFA diet. The increased kidney weights in normal rats fed fish oil were attributed to 
direct growth-stimulating effects of fish oil since renal function was not increased 
whereas in uninephrectomised rats fed fish oil, increased glomerular function was not 
accompanied by renal hypertrophy.
Many studies have shown that PUFA diets reduce cholesterol levels (Huang et al,
1986). The lipoprotein disorders common in patients with progressive renal disease 
are associated with lipid deposits and foam cells in the glomerulus (Diamond and 
Kamovsky, 1988) and hypercholesterolaemia has been implicated in the proteinuria 
and glomerulosclerosis of the obese Zucker rat model. The favourable effects of fish 
oil on histological damage, serum cholesterol and proteinuria in uninephrectomised 
Zucker rats were attributed to changes in plasma lipid and glomerular prostanoid
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levels since renal function was unchanged (Wheeler et al, 1991). However, the 
culpability of cholesterol was questioned when Kasiske at al (1991) showed that 
although both fish and sunflower oil diets lowered albuminuria, glomerulosclerosis 
and serum triglyceride levels in intact Zucker rats, cholesterol levels were reduced 
only in the fish oil group and that the preceding fall in albuminuria was the 
explanation for the favourable result. No definitive explanation was given by de 
Caterina et al (1993) for the sustained fall in proteinuria observed in patients with 
chronic glomerular disease, treated with high or low doses of co-3 fatty acids. Serum 
cholesterol, platelet and urine prostanoid levels were all reduced and the modest 
reduction in blood pressure did not correlate with the fall in proteinuria.
Immune-mediated glomerulopathies: Interest in the immunosuppressive effects of 
PUFA diets in relation to production of E series prostaglandins, derives from reports 
of improved survival and decreased proteinuria in models of immune-mediated 
glomerular injury such as lupus nephritis (Prickett et al, 1981: 1983, Kelley et al, 
1985, Robinson et al, 1986, Westberg et al, 1989) albeit Hurd et al (1981) showed that 
EFA deficiency improved survival and EFA-enriched and EFA-deficient diets had no 
effect on proteinuria or survival rate (Dubois et al, 1982). The anti-proteinuric effects 
of high linoleic acid and fish oil diets in murine apoferritin-induced ICGN were 
attributed to favourable effects on glomerular tissue lipids since despite differences in 
glomerular thromboxane levels between the diet groups, the resultant degree of 
protection was similar (Kher et al, 1985; 1986). In rats with mercuric chloride- 
induced ICGN, both herring and evening primrose oil diets reduced proteinuria, 
increased survival and suppressed immune complex deposition when compared with 
the thromboxane synthetase inhibitor (OKY-046) which improved survival but did not 
prevent glomerular IgG deposition (Papanikalou et al, 1987)
In contrast to a previous study, in which they had demonstrated that fish oil 
accelerated glomerular functional deterioration, Scharschmidt and colleagues (1990) 
postulated that in the NSN model of anti-GBM nephritis, fish oil preserved glomerular 
function and reduced proteinuria, glomerular dienoic prostanoid levels and 
histological damage by suppressing the immune response. Such diametrically 
opposite effects of fish oil diets have been attributed to suppression of lipoxygenase 
activity which appears to be stimulated in immune, but not non-immune mediated 
glomerular diseases.
A significant and sustainable reduction in proteinuria in normal rats, and lowering of 
established proteinuria by up to 50% by fish oil, demonstrated by Weise et al (1993), 
occurred independently of any change in blood pressure or renal function and so was 
attributed co-3 PUFA incorporation into membrane phospholipids and subsequent
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release of trienoic eicosanoids with attenuated inflammatory activity. However, 
Bennett et al (1989) and Cheng et al (1990) reported that fish oil diets did not retard 
the progression of IgA nephropathy despite other optimistic reports (Hamazaki et al, 
1984, Donadio et al, 1990) and the results of a one year double-blind, randomised, 
cross-over study of fish oil diet in a group of systemic lupus erythymatosis (SLE) 
patients were not encouraging (Clark et al, 1993). Neither was there any improvement 
in renal function nor reduction in disease activity and only a slight, non-significant 
reduction in proteinuria. Nevertheless, more recent results from the Mayo Nephrology 
Collaborative Group on the effects of two years of fish oil treatment in patients with 
IgA nephropathy are favourable (Donadio et al, 1994).
The role of PUFA diets in the treatment of diabetic complications has been reviewed 
extensively by Horrobin (1988; 1990; 1992). PUFA diets may be useful in the 
treatment of diabetic nephropathy, in relation to the high incidence of cardiovascular, 
and coronary heart disease and increased mortality within the first few years following 
the onset of proteinuria (Jensen 1987; 1989). co-3 fatty acids have been shown to 
suppress the development of diabetic cardiomyopathy in streptozotocin diabetic rats 
(Black et al, 1989). However, some of the early optimism surrounding the use of 
PUFA diets in the treatment of diabetic nephropathy may have been dampened by one 
particular study in which fasting glucose levels rose in patients with type II diabetes 
fed co-3 fatty acids, returning to baseline only when the diet was discontinued 
(Glauber et al, 1988). Nevertheless, a subsequent study in diabetic rats, showed 
lowered proteinuria and fewer histological abnormalities in co-6 diet groups in 
association with elevated PGI2  levels and unchanged plasma lipids - whereas co-3 
diets, associated with a fall in PGI2  and reduced plasma lipid levels, had no effect on 
renal disease (Barcelli et al, 1990). Only diets rich in co-6 fatty acids were protective 
in this model of diabetic nephropathy.
The transcapillary escape rate of albumin (TER), which is a marker of systemic 
vascular permeability, was reduced in IDDM patients with proteinuria fed cod liver oil 
although urinary albumin excretion was not reduced; despite an improved lipid profile 
effect was attributed to modified vascular permeability and not to a fall in blood 
pressure (Jensen et al, 1989). Glomerular filtration rate, insulin, glycosylated 
haemoglobin and blood glucose levels were unaffected by cod liver oil diet.
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Although at first, the indiscriminate use of PUFA diets may seem innocuous 
(Robinson et al, 1986, Scharshmidt et al, 1990), under certain circumstances PUFA 
diets can have undesirable effects (Scharshmidt et al, 1987, Glauber et al, 1988, 
Logan et al, 1990). While most PUFA diet studies show some improvements in one 
or more of the parameters which affect glomerular disease progression, this section 
has demonstrated the many inconsistencies which makes it difficult to pinpoint any 
single mode of action (see Table 1.4.3).
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Section 2
EXPERIMENTAL D E SIG N  
MATERIALS a n d  M ETHODS 
RESULTS 
D ISC U SSIO N
SECTION 2
This second section of the thesis comprises a record of the experimental work 
undertaken to elucidate the mechanism behind the apparent anti-proteinuric effects of 
PUFA diets. It is sub-divided into five sections, the first four of which attempt to 
relate the effects of PUFA diets to the principal factors which govern the filtration of 
a molecule across the glomerular capillary wall, namely:
•  glomerular blood flow and pressure
•  glomerular capillary wall charge
• electrostatic charge on the filtered molecule
Sections 2.1 and 2.2 explore the interrelationships of PUFA diets and glomerular and 
circulating prostaglandin, thromboxane and renin levels in Lewis and DA rats.
Section 2.3 examines the possibility that, as intrinsic components of cell membrane 
phospholipids, PUFAs alter the permeability properties of the glomerular capillary 
wall with particular reference to the magnitude of the glomerular polyanion.
Section 2.4 investigates the effects of PUFA diets on the intrinsic electronegative 
charge (pi) on the serum albumin molecule.
The final section - 2.5 - evaluates the ability of an evening primrose oil diet to either 
prevent escalation of, or lower albumin excretion rate in diabetic Lewis rats.
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PUFA DIETS a n d  GLOMERULAR PROSTANOID PRODUCTION Section 2.1
2.1.1 In tro d u c tio n
How the glomerulus responds to an antigenic or haemodynamic challenge may be 
determined by inherited differences in the intensity of the anionic charge on the 
glomerular capillary wall or the efficiency of mesangial clearance function. A 
diminished glomerular polyanion may facilitate deposition of macromolecules or 
immune complexes within the GCW and impaired mesangial function may retard the 
rate at which they can be cleared - such persistance can prove highly destructive. 
Prostanoids elicit a multitude of effects within the glomerulus (see sections 1.3 and
1.4) which might influence molecular traffic across the glomerular capillary wall and 
through the mesangium and thus limit the extent of proteinuria and 
glomerulosclerosis. Prostanoid biosynthesis can be manipulated by feeding diets rich 
in essential fatty acid (EFA) prostanoid precursors (see section 1.3.2).
This first study was undertaken with a view to identifying whether differences in 
glomerular properties between the Lewis and DA rat strains extended to differences 
in their prostanoid production in vitro and also, the feasibility of altering the 
glomerular prostanoid profile by feeding different PUFA diets. Diets such as evening 
primrose or safflower oil which contain co- 6  fatty acids are used to stimulate the 
synthesis of 1- and 2- series prostanoids whereas fish oil diets, rich in co-3 fatty acids, 
may increase the levels of 3- series prostanoids (see section 1.3.1). Olive oil is used 
widely as a 'placebo' or control UFA oil supplement because it contains 
predominantly monounsaturated oleic acid (80%) but also a small amount of linoleic 
acid (7%).
2.1 .2  M a te ria ls  a n d  m e th o d s
During the planning stages of this study, it became clear that because of the number 
of diet groups, it would be necessary to stagger the diet regimes in view of the 
lengthy and labour-intensive surgical and glomerular sieving techniques performed 
on each rat at the end of each six week diet period. Had all the diets been started 
simultaneously, the feeding period of some rats would have extended beyond six 
weeks since the glomeruli can be harvested from a maximum of only four rats on any 
one day. A outline of the experimental design, similar to that used in this study, is 
illustrated in section 2.2. (Table 2.2.2.1).
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Five groups of Lewis (n = 5) and DA (n = 5) rats weighing some 200 to 250 grams at 
the start of the experiment, were fed ad libitum either standard laboratory rat chow or 
a fat-deficient diet supplemented with either evening primrose oil (EPO), safflower 
oil (SO), fish oil (FO) or olive oil (OO) diet for six weeks. Body weight was 
recorded weekly and at two and four weeks, the rats were put into metabolic cages to 
monitor both food intake and urine output and collect urine. Within any diet group, 
the kidneys were removed and the glomeruli recovered by a differential sieving 
procedure from Lewis and DA rats, alternately. Levels of PGE2, PGI2  (prostacyclin) 
and thromboxane metabolites and renin in the glomerular supernatants were 
measured and expressed as a function of glomerular protein content.
2.1.2.1 C on tro l a n d  e x p e r im e n ta l  PUFA d ie ts
The control diet was a standard laboratory rat pellet diet (Rat and Mouse No 1 
Modified Maintenance diet: Special Diet Services Ltd, PO Box 705, Witham, Essex 
CM8  3AD). The pellets were ground up to mimic the granular consistency of the 
PUFA diets which prevented the rats retrieving and consuming pellets in the centre of 
the cage, a common behaviour pattern which can result in not only substantial 
amounts of food falling into the urine container below but rats in the control diet 
group consuming more food than those fed the powdered PUFA diets which has to be 
scooped up in the paws directly from the food hopper.
Experimental PUFA diets were prepared according to the method used by 
Chandrachud (1986). Evening primrose oil, safflower oil, fish oil and olive oil 
(gifted by Scotia Pharmaceuticals Ltd, Guildford, Surrey GUI 1BA) were stored 
under nitrogen at 4°C and added to a commercially prepared fat-deficient diet which 
is designed for comparative use with, and was purchased from the same source as the 
control diet. 43 mis of evening primrose, safflower, fish or olive oil was added to 
2.7g butylated hydroxytoluene (Sigma Chemical Company: B-1378) dissolved in 150 
mis of AnalaR grade diethyl ether and then stirred into 500 grams of the fat-deficient 
diet, giving a dietary oil content of 8 .6 % (v,w). Newly-prepared diets were left in a 
fume cupboard overnight or until the odour of ether was no longer detectable. 
Batches of diet were prepared as required and never stored for longer than three days 
because of the susceptibility of fatty acids to oxidation over time. Antioxidants such 
as butylated hydroxytoluene (BHT) or Vitamin E are added to PUFA diets to 
suppress fatty acid peroxidation and free radical generation. Constituents of both the 
standard and fat deficient diets are shown in Table 2.1.2.1 and Table 2.1.2.2 lists the 
constituent fatty acids of safflower, evening primrose, fish and olive oils.
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Table 2.1.2.1 Diet c o m p o n e n ts
Crude fibre 
Polysaccharides 
Digestible crude fat 
Digestible crude protein 
Sodium 
Chloride 
Magnesium 
Potassium
Gross energy 
Digestible energy 
Metabolisable energy
units C on tro l Fat ■ 'deficient
% 4.3 4.7
% 63 72
% 2.4 0.07
% 13.6 13.7
% 0.26 0.24
% 0.38 0.36
% 0.21 0.12
% 0.65 0.52
MJ/kg 14.8 14.2
MJ/kg 11.4 12.4
MJ/kg 11.2 11.2
Table 2.1.2.2 C onstituen t fatty  a c id s  of d ie ta ry  oils
Fatty a c id
Chain length 
a n d  
d o u b le  bonds
Evening
Primrose
% total weight 
Safflower Fish Olive
Myristic C14:0 - - 13.3 0.2
Palmitic C16:0 5 8 0.3 10
Palmitoleic 0 6 :1 - - 12.2 0.2
Hexadecadienoic 0 6 : 2 - - 13.3 -
Stearic 0 8 : 0 1.7 2.6 3.8 2.6
Oleic 0 8 :1 9.5 13 16 80
Linoleic 0 8 : 2 77 76 1.2 6.4
dihomo y  Linolenic C20:3 4 - 1 0.5
Arachidonic C20:4 - - 5.6 -
Eicosapentaenoic C20:5 - - 27 -
Docosapentaenoic C22:5 - - 2.2 -
Docosahexaenoic C22:6 • 3.7 •
2.1.2.2 Rats
Male Lewis or DA rats (Bantin and Kingman, Universal Ltd, The Field Station, 
Grimston, Aldbrough, Hull, U.K) were used in this and all subsequent studies. After 
arrival, the animals were allowed to rest for at least a week before being entered into 
any study and were housed in facilities with a controlled twelve hour day and night 
cycle and ambient temperature of 20 - 21°C. The animals remained healthy 
throughout the course of the studies and were inspected regularly by a vet from the 
Home Office. All experimental procedures were subject to the regulations of the 
Animals (Scientific Procedures) Act 1986.
2.1 .2 .3  M e ta b o lic  c a g e  p r o c e d u r e
At two and four weeks, rats were put into metabolic cages for two consecutive days 
to monitor daily food intake and urine output and collect urine. The first day was 
regarded as an acclimatisation period during which measurements were recorded but 
not used for biochemical or statistical analyses: all metabolic cage data relates 
exclusively to that collected during the second day. Neither food nor water was 
restricted while the animals were in metabolic cages.
Urine was collected under mineral oil to minimise evaporation, absorption of carbon 
dioxide and food contamination. After recording the volume collected, urine was 
centrifuged at lOOOg for 15 minutes at 4°C and kept at 4°C or frozen at -70°C.
2.1 .2 .4  S u rg ic a l p r o c e d u r e s  - n e p h re c to m y
At the end of six weeks, the rats were culled and the kidneys removed. Each rat was 
anaesthetised with an intraperitoneal injection of Sagatal (pentobarbitone sodium BP: 
60 mg in 1 ml: Rhone Merieux (Ireland), Tallaght, Dublin) at a dose of 0.1 ml per 
100 g body weight. After isolating the trachea by blunt dissection, an endotracheal 
tube was inserted: the jugular vein was located and cannulated with polyethylene 
tubing (PE 50: Clay-Adams, Becton-Dickinson UK Ltd, Cowley, Oxford OX4 3LY) 
attached to a syringe loaded with Sagatal. (A cannula may be inserted into the carotid 
artery for blood pressure recording and into the femoral artery for blood sampling.) 
A dorsal mid-line incision was made to expose the major blood vessels and kidneys. 
The abdominal aorta was isolated by ligating it proximally, above both renal arteries 
and distally, at the level of the bifurcation: the superior mesenteric artery was tied off. 
A length of wide bore cannula (PE 90 tubing: Clay-Adams as above) attached to a 
syringe containing warm (37°C) saline (or other appropriate perfusate) was 
introduced into the aorta via a small incision and then tied securely. Before starting 
the perfusion, the vena cava and renal veins were punctured to allow the perfusate to
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escape. Perfusion was continued until the kidneys turned white (blanched), at which 
stage they were removed and put into ice cold (0-4°C) phosphate buffered saline and 
kept at 4°C until they underwent the sieving procedure. There will always be an 
unavoidable delay of some two to three hours between removal of the kidneys and the 
start of the sieving procedure.
2.1 .2 .5  G lo m e ru la r  s ie v in g  p r o c e d u r e
The glomeruli were recovered by sieving, after removal of the renal capsule and any 
extraneous fatty tissue. Renal cortical tissue was dissected and pressed through three 
sieves stacked in descending order of pore diameter (250 pm, 106 pm and 63 pm) 
(Endecotts Ltd., Lombard Road, London SW19 3BR). Fifty mis of ice-cold (0-4°C) 
phosphate buffered saline (PBS) in a syringe fitted with a 23 guage (blue) needle was 
used to force the macerated tissue with firm but gentle pressure through each 
successive sieve: the base of the syringe plunger was used to smear the tissue across 
the surface of the sieve. Finally, the 63 pm sieve was inverted within a large plastic 
funnel and the glomeruli collected in 50 mis of PBS in a polyethylene tube (to 
minimise adhesion) then centrifuged at 1000 g for 10 minutes at 4°C. The 
supernatant was discarded and the glomeruli resuspended in 50 mis of ice-cold PBS: 
this washing step was repeated twice. Finally, the glomeruli were resuspended in 10 
mis of cold Hartmanns solution (Baxter Healthcare Ltd, Thetford, Norfolk) then 
brought to room temperature and left to stand for 30 minutes at 37°C before being 
rotated gently on a roller mixer for a further 30 minutes at 37°C. The tubes were 
plunged into ice immediately to slow down and arrest prostanoid activity and then 
centrifuged at 4°C for 15 minutes at 1500 g.
Aliquots of glomerular supernatants were stored at -70°C and the glomerular pellet 
was retained for protein estimation.
2.1 .2 .6  G lo m e ru la r  p ro te in  c o n te n t
Neither a Neubauer haemocytometer nor Coulter counter was found to be suitable for 
counting glomeruli because of their size and so the alternative method of determining 
the protein content of the glomerular pellet was used. After the supernatant had been 
removed, the pellets of glomeruli were hydrolysed overnight in 1 ml IN sodium 
hydroxide at 37°C and the protein content of the glomerular pellet measured by the 
Lowry protein assay (see section 2.1.2.7). Glomerular hydrolysates may be stored 
frozen at -20°C.
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2.1.2.7 Lowry p ro te in  a s s a y
The Lowry protein assay has the interesting distinction of being the most widely 
referenced in the biochemical literature and has become the gold standard protein 
quantitation assay. In principle, a protein is reacted with alkaline copper sulphate in 
the presence of tartrate: Folin Ciocalteu's (FC) phenol reagent is then added and the 
copper complexes transfer electrons to the FC reagent which is reduced to a blue 
colour at 750 nm. Although the Lowry protein assay is some ten times more sensitive 
than the Biuret method, its drawbacks include the instability of the alkaline copper 
sulphate solution, photosensitivity of the reaction, linearity of the response and 
interference by lipids.
Stock reagents
Biuret reagent
Folin Ciocalteu's reagent
Standards
Solution A: 2% Na2  C 0 3 in 0. IN NaOH
Solution B: 2% Na K Tartarate
Solution C: 1% Copper sulphate
Add 1 ml of solution B and 1 ml of solution C to 100 
mis solution A.
Folin Ciocalteu's phenol reagent (BDH Chemical Ltd, 
Poole, Dorset) diluted 1:1 with deionised water.
Prepared as tabulated below using rat serum albumin 
(Sigma Chemical Company: A-6414) at 1 mg per ml.
rat
seru m  a lb u m in  
(M^ ls)
w a ter
d e - io n is e d
Ods)
p r o te in  
c o n c e n tr a t io n  
( | ig s /4 0 0  m is )
0 4 0 0 0
2 5 3 7 5 2 5
5 0 3 5 0 5 0
7 5 3 2 5 7 5
10 0 3 0 0 1 0 0
Concentrated samples were diluted to a final volume of 400 pis with deionised water. 
Bovine serum albumin (Sigma Chemical Company: A-7906) at 0.6 mg per ml was 
used as a quality control (QC). 100 pis BSA was adjusted to a final volume of 400 
pis with water. Standards and samples were set up in duplicate. 2 mis of Biuret 
reagent was added to 400 pis of standards, QC and samples. The tubes were vortex 
mixed and left to stand for 10 minutes. 200 pis of Folin Ciocalteu reagent was added 
to each tube, vortex mixed again and allowed to stand for 30 minutes. Optical 
density (OD) was measured at 750 nm (or 500 nm) and the values read from a 
standard curve.
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2.1.2.8 P rostag land in  a n d  th ro m b o x a n e  a s sa y s
The primary prostanoids PGE2, PGI2  and TxA2, are highly potent with biological 
activity ranging between 10*13M - 10 9M and because they occur in such minute 
quantities and in so many structurally diverse but similar forms, assays to measure 
them must be highly sensitive and specific (many prostanoid assays cannot detect 
below 1 0 8M). A bioassay, for example, will measure prostanoids on the basis of 
their biological ability to contract vascular smooth muscle or aggregate platelets and 
has the advantage of detecting total biological activity, if at the expense of specificity. 
Radioimmunoassay, on the other hand, is highly specific with low detection limits 
and facilitates rapid processing of a large number of samples and although high 
performance liquid chromatography (HPLC) or gas chromatography - mass 
spectrometry (GC-MS) is highly specific and ideal for identifying metabolites of 
different prostanoid series (eg PGEX, PGE2, PGE3), detection limits may not be 
sufficiently low and the rapid assay of a large number of samples is not practicable.
Over the years, refinements in prostanoid assay methodology and recognition of the 
importance of minimising the effects of ex vivo prostanoid production have improved 
the credibility of prostanoid measurements, but care with sample collection and 
processing is still essential. Some of the early prostanoid data may, unwittingly, be 
unreliable because the effects of surgical procedures and anaesthetics, tissue 
homogenisation, addition of precursor metabolites and various cofactors such as 
semm to culture media were not appreciated fully (Horrobin, 1990). Coagulation, for 
example, can raise circulating thromboxane levels several orders of magnitude higher 
than normal.
Highly unstable primary prostanoids circulate in the bloodstream in the low picogram 
range and are inactivated rapidly to be replaced by secondary metabolites, which with 
longer half-lives, accumulate to higher levels (~ 20- 50 picograms per ml) and so are 
more easily detected. Being so short-lived, PGE2, PGI2  and TxA2  have to be 
quantified by measuring their more stable metabolites, bicyclic-PGE2, 6 -keto PGFla 
and TxB2, respectively. Commercial radioimmunoassay kits were chosen to measure 
prostanoid levels, in this study, because of their speed and simplicity.
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(a )  11 d e o x y  13, 14 d ih y d ro  15 k e to  11(3, 16e c y c lo  (bicyclic) PGE2 a s s a y
In tissue, PGE2  derived from PGH2  by endoperoxide E isomerase may be converted 
to:
•  13, 14 dihydro, 15 keto- (DHK)- PGE2  which is oxidised further to 15, 
ketodihydro- 2, 3,4,  5 tetranor PGE2, the main circulating and urinary metabolite 
in man.
• PGB2  via PGA2  and PGC2  
or
• PGF2a by 9 ketoreductase.
The pathways of PGE2  and PGF2a metabolism are very similar and there is 
considerable interconversion between the two. Like PGE2, PGF2a is converted to its 
DHK- derivative and oxidised further to various tetranor derivatives.
More than 90% of PGE2  is inactivated through its conversion to 13, 14- dihydro- 15- 
keto- (DHK)- PGE2  during a single passage through the lungs but DHK-PGE2  also 
dehydrates spontaneously to form DHK-PGA2, some of which binds to albumin 
(DHK-PGA2 -albumin) thus generating three metabolic pools of PGE2. However, 
incubating samples at high pH cleaves the covalent bond between PGA2  and albumin 
and converts all three (and related tetranor) metabolites to the stable bicyclic 
intermediate 11- deoxy- 13, 14- dihydro- 15- keto- l ip ,  16e- cyclo- 0bicyclic) PGE2  
which can be measured by a commercial RIA system (Amersham International PLC: 
TRK 800).
Glomerular supernatants were assayed undiluted and in duplicate, after incubation 
with 1M sodium carbonate for 24 hours, according to the protocol outlined in Tables
2.1.2.3 (a) and (b). The radioimmunoassay system utilises tritiated (3 H) 11- deoxy- 
13,14- dihydro-15- keto- l ip,  16e- cyclo- (bicyclic) PGE2  as tracer and an antiserum 
for bicyclic PGE2, the cross-reactivity of which is shown in Table 2.1.2.3 (c). A 
standard binding curve was prepared using the DHK-PGE2  standards provided (6.9, 
3.4, 1.7, 0.86, 0.43 ng per ml). The detection limits of the assay are between 43 and 
690 pg of bicyclic PGE2.
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P rostag land ins % Cross reactivity
(50% B/B0 rep lacem en t)
13, 14-Dihydro- 15- keto- prostaglandin E2 100.0
13, 14-Dihydro- 15- keto- prostaglandin Ex 100.0
13, 14-Dihydro- 6, 15- diketo- prostaglandin E! <0.40
13, 14-Dihydro- 6, 15- diketo- prostaglandin Fla <0.01
13, 14-Dihydro- 15- keto- prostaglandin F2a <0.001
13, 14-Dihydro- 15- keto- thromboxane B2 <0.001
15- keto- prostaglandin E2 0.30
15- keto- prostaglandin Ei 0.2
15- keto- prostaglandin F2a <0.001
15- keto- thromboxane B2 <0.001
6, 15- Diketo-prostaglandin E, <0.01
6, 15- Diketo-prostaglandin Fla <0.01
Prostaglandin E, <0.01
Prostaglandin Dj <0.001
Prostaglandin F1(X <0.0001
6- Keto prostaglandin Flct <0.0001
Prostaglandin F2p <0.0001
Prostaglandin E2 <0.001
Prostaglandin D2 <0.001
Prostaglandin F2(X <0.0001
Thromboxane B2 <0.0001
2,3,4,5- Tetranor- 13, 14- dihydro-15- keto- prostaglandin E2 0.30
2 ,3 ,4 ,5 -  T etran o r- 13 , 1 4 - d ih y d r o - 1 5 - k e to -  p r o sta g la n d in  E r  1 ,2 0 -  d ic a r b o x y lic  a c id < 0 .0 0 1
2 ,3 ,4 ,5 -  T etran o r- 1 3 ,1 4 -  d ih y d r o - 1 5 - k e to -  p r o sta g la n d in  A r  1 ,2 0 -  d ic a r b o x y lic  a c id < 0 .0 0 1
Table 2.1.2.3 (c) Specificity of prostaglandin  E2 antiserum
(b) 6 k e to  p ro s tag lan d in  Fla  a s s a y
Prostacyclin (PGI2) is an unstable vinyl ether derived from PGH2  by prostacyclin 
synthetase, with a half-life of 2 to 3 minutes which may be converted to either
• 6 -keto prostaglandin Fla by spontaneous hydrolysis and then undergo further P 
oxidation to 2, 3 dinor 6 -keto prostaglandin Fla (so 6 -keto PGFla may not be the 
most appropriate metabolite to measure)
or
• 6 , 15 diketo- 13, 14 dihydro PGFla (enzymatically) and oxidised further to 
various 2, 3 dinor 6 , 15 diketo- products (Moncada et al, 1976, Grygwelski et al> 
1976).
In this study, 6 -keto PGFla levels in glomerular supernatants were measured by a 
RIA system (Amersham International PLC: TRK 790). Glomerular supernatants 
were assayed undiluted and in duplicate, according to the assay system protocol 
outlined in Table 2.1.2.4. The RIA system utilises (3 H) tritiated 6 -keto PGFla as 
tracer and a specific antiserum to 6 -keto prostaglandin Fla, the cross-reactivity of 
which is displayed in Table 2.1.2.4 (a). A standard binding curve was prepared using 
the 6 -keto PGFla standards provided (5, 2, 0.75, 0.3 and 0.14 ng per ml). The 
detection limits of the assay are between 14 and 500 pg 6 -keto PGFla per assay tube.
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P ro s ta g la n d in s % Cross reactivity
(50% B/B0 replacement)
6 -keto prostaglandin Flct 1 0 0 . 0
Prostaglandin Aj <0.014
Prostaglandin A2 0.014
Prostaglandin D2 <0.014
Prostaglandin E2 5.1
Prostaglandin F2a 0.30
Thromboxane B 2 <0.014
Table 2.1.2.4 (a) Specificity of 6-keto  prostag land in  Fj a antiserum
(c )  T h ro m b o x a n e  B2 a s s a y
Thromboxane A2  is synthesised from PGH2  by thromboxane synthetase and with a 
half-life of 20 to 30 seconds at 37°C is converted rapidly to its stable oxane 
derivative, thromboxane B 2  (Hamberg et alt 1975). In essence, circulating TxA2  
levels should reach little more than a few picograms per millilitre but may be raised 
artificially by platelet activation in association with tissue processing and 
coagulation.
Thromboxane B2  can undergo either:
• oxidation to 2, 3 dinor- TxB2  (barely detectable in blood but is the major urinary 
metabolite)
• dehydrogenation and further oxidation to 2, 3, dinor, 11 dehydro TxB2  (probably 
the best metabolite to measure because it is not formed artefactually)
or
• enzymatic conversion to 15, keto, 13, 14 dihydro TxB2  followed by 
dehydrogenation and (3 and co oxidation steps to various minor metabolites.
A RIA system (Amersham International PLC: TRK 780) was used to measure TxB2  
levels. Glomerular supernatants were assayed undiluted and in duplicate according to 
the assay system protocol outlined in Table 2.1.2.5. The system utilises (3 H) tritiated 
TxB2  as tracer and a specific antiserum to TxB2, the cross-reactivity of which is 
displayed in Table 2.1.2.5 (a). A standard binding curve was prepared using the TxB2  
standards provided (3, 1.1, 0.4, 0.13 and 0.05 ng per ml). The detection limits of the 
assay are between 5 and 300 pg TxB2  per assay tube.
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P rostag land ins % Cross reactivity
(50% B/B0 rep la ce m e n t)
Thromboxane B2 100.0
Prostaglandin D2 1.2
Prostaglandin F2a 0.15
13, 14-Dihydro- 15- keto- thromboxane B2 0.13
6(3- Prostaglandin Ij 0.10
Prostaglandin 0.05
Prostaglandin E2 0.01
Prostaglandin Fla 0.01
11- epi- Prostaglandin E, 0.01
13, 14-Dihydro- 6, 15- diketo- PGFla 0.007
Prostaglandin F1(3 0.007
8- iso- Prostaglandin E2 0.006
13, 14-Dihydro- prostaglandin E2 0.005
13, 14-Dihydro- prostaglandin Ei 0.004
13, 14-Dihydro- prostaglandin F2a 0.004
Di- homo- 6- keto prostaglandin Fla 0.004
6- Keto- prostaglandin Ej 0.003
Prostaglandin F2p 0.003
1 3 ,14-Dihydro- 15- keto- prostaglandin E2 0.003
15- keto- prostaglandin E2 0.002
13, 14-Dihydro- prostaglandin Fla 0.002
6, 15- Diketo-prostaglandin Fla 0.001
Prostaglandin Bj 0.001
13, 14-Dihydro- 15- keto- prostaglandin F2a <0.001
15- keto- prostaglandin Fla <0.001
15- Epi- prostaglandin E2 <0.001
13, 14-Dihydro- 15- keto- prostaglandin F la <0.001
15- keto- prostaglandin F2ct <0.001
Table 2.1.2.5 (a) Specificity of th rom boxane  B2 antiserum
2.1 .2 .9  C o o m a s s ie  Blue p ro te in  a s s a y
Assays to measure urine protein may be based upon dye-binding, acid precipitation, 
turbidimetric or immunological principles but because urine contains varying 
amounts of different types of protein, it important to select the most appropriate 
assay. In relation to the heterogenity of the component proteins in as sample of urine, 
problems often arise with linearity of the response, choice of a suitable protein 
standard and precision and accuracy: amongst many other contaminants, high 
concentrations of urinary pigments interfere with many protein assays. Often, there 
are qualitative differences amongst assay methods in terms of detecting low 
molecular mass proteins and peptides as well as albumin and globulins.
The Coomassie Blue method is recommended for measuring urine total protein levels 
(McElderry et al, 1982). As the name implies, the method is based upon dye-binding 
and although less sensitive than the Lowry protein assay, it is more suited to 
measuring albumin which is usually the predominant urine protein. The shift in 
absorbance from 465 nm to 595 nm which occurs when Coomassie Brilliant Blue 
G250 binds to protein in acidic solution is reflected by a colour change from reddish- 
brown to blue. The sulphonic group of Coomassie Blue bind to arginine residues 
predominantly but also weakly with histidine, lysine, tyrosine, tryptophan and 
phenylalanine. Non-linearity of the colour response over a wide range of protein 
concentrations is a problem with this assay but can be overcome by running a 
standard curve each time. The number of CB reagent ligands bound to each protein 
molecule is thought to be proportional to the number of charges on the protein ie 
about 1.5 to 3 dye molecules per charge.
Preparation of CBB reagent
Commercial preparations of CBB are widely available but are expensive for large 
numbers of samples and so the CBB reagent was prepared in the laboratory.
200 mgs of Coomassie Brilliant Blue-G, CBB (Sigma Chemical Company: B-1131) 
were dissolved in 1 0 0  mis of absolute alcohol. 2 0 0  mis of concentrated phosphoric 
acid (H3 P 0 4) plus 1 litre of deionised water were added to the CBB solution and the 
volume made up to 2 litres with deionised water and mixed well. 16g Diatomaceous 
Earth: Grade II (Sigma Chemical Company: D-5509) was added to the solution which 
was then stirred for 6  hours and left at 4°C for 24 hours. When cold, the solution was 
filtered twice through Whatman No 1 filter paper. The absorbance of the CBB 
reagent should be 0.28 ± 0.01 when read at 595 nm against deionised water and the 
reagent remains stable for at least 4 months at room temperature.
4 3
A standard curve ranging from 4 to 160 mg per 100 ml was prepared by diluting 
mixed protein standard (Sigma Chemical Company: 540-10) to lOmls as in the table 
below.
S ig m a  stand ard  
(U ls)
P ro te in  co n c e n tr a t io n  
(m g s  p e r  lO O m ls)
5 4
1 0 8
2 0 16
5 0 4 0
10 0 8 0
125 1 0 0
15 0 1 2 0
2 0 0 1 6 0
Duplicate 30 jxls samples of standard or urine was added to 3 mis of CBB reagent and 
mixed three times during colour development. The tubes were left to stand for 15 
minutes before the reading the absorbance at 595 nm against CBB reagent. The 
standard curve of the Coomassie Blue assay is linear up to 160 mg per 100 mis with a 
detection limits of between 400 and 1600 p.gs per ml.
2.1 .2 .10  M e a s u re m e n t  of g lo m e ru la r  ren in
Renin levels in Lewis and DA rat glomerular supernatants were measured at the 
Blood Pressure Unit, Western Infirmary, Glasgow, by a radioimmunoassay, the 
method of which is described in detail in section 2.2.2.4.
2.1.2.11 S ta tis tica l a n a ly s e s
Statistical analyses were performed using Minitab version 7.2. The non-parametric 
Mann-Whitney U-test for unpaired data was used predominantly throughout because 
sample size was small and data distribution was unknown; the parametric two sample 
Mest was used for descriptive statistics of variables such as body weight or food 
consumption. Accordingly, median and range or mean and standard deviation are 
quoted in the text and 95% confidence intervals and levels of significance are 
tabulated in supplementary tables. A significance level (p value) less than or equal to 
0.05 was taken to denote statistical significance (Altman et al, 1983, Braitman, 1991). 
Statistical comparisons are made only between Lewis and DA rats within a particular 
diet group and between the control diet and an experimental PUFA diet group, within 
either strain: no comparisons were made between PUFA diet groups.
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2 .1 .3  R e s u lts
2.1.3.1 M e ta b o lic  d a t a
Growth rate curves of normal healthy Lewis and DA rats derived from data supplied 
by commercial breeders (Harlan UK Ltd, Oxon, England) show that at any given age, 
Lewis rats are heavier than DA rats (Figure 2.1.3.1).
Although there have been reports that rats often develop an aversion to the oily PUFA 
diets and thus may consume significantly less food than contol rats, body weight 
increased steadily over the six week diet period in both strains of rat, albeit after an 
initial fall in all the PUFA diet groups during the first two weeks (Figure 2.1.3.1a). In 
both strains of rat, the percentage increase in body weight in the control group was at 
least double that of any of the PUFA diet groups [Lewis: CD: 41% vs (i) EPO: 20%, 
(ii) SO: 17%, (iii) FO: 13%, (iv) 0 0 :  15%; DA: CD: 29% vs (i) EPO: 10%, (ii) SO: 
11%, (iii) FO: 7%, (iv) 0 0 :  11%]. The percentage weight gain was greater in Lewis 
rats than in all corresponding diets groups in DA rats. At six weeks, mean body 
weight was greater in Lewis rats than DA rats in all the diet groups and Lewis and 
DA rats fed PUFA diets had significantly lower body weight than their respective 
controls [Lewis vs DA: CD: mean 344 (SD 16.5) vs 262 (12.4) grams, EPO: 295 
(10.45) vs 226 (15.4), SO: 281 (36) vs 228 (10), FO 281 (18.4) vs 217 (7), 0 0 :  286 
(21) vs 228 (9.12)] (see Table 2.1.3.1a for corresponding confidence intervals and 
significance levels).
Mean daily food consumption during time in metabolic cages is shown in Table 
2.1.3.2. At both two and four weeks, Lewis and DA rats fed control diet ate more 
than those fed PUFA diets. However, despite differences in body weight between 
Lewis and DA rats, consumption of PUFA diets was remarkably similar in both 
strains. At four weeks, there was no significant difference in food consumption 
between the strains except in the control diet group [Lewis vs DA: mean 21 (SD 1.9) 
vs 17.4 (0.65) grams per day, p = 0.014]. Food consumption was significantly lower 
in the PUFA diet than control diet groups in all but DA rats fed olive oil diet [Lewis: 
CD: 21 (1.9) grams - vs (i) EPO: 11.2 (2.1), (ii) SO: 11.6 (2.3), (iii) FO: 10 (0.35), 
(iv) OO: 10.8 (1.8): DA: CD: 17.4 (0.65) grams - vs (i) EPO: 12.2 (4.01), (ii) SO:
11.2 (0.84), (iii) FO: 10.8 (1.92), (iv) OO: 13.9 (3.3)] (see Table 2.1.3.2a for 
corresponding confidence intervals and significance levels).
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Figure 2.1.3.1 Growth ra te  cu rves (m ean  a n d  SD) of norm al 
Lewis a n d  DA rats (D ata from Harlan UK Ltd, 
Oxon)
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Table 2.1.3.1 (a) Body weight at six weeks -  s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control 58 to 102 p < o .o o o r
Primrose 49 to 89 P< o .o o o r
Safflower 8 to 100 p= 0.03*
Fish 40 to 86 p= 0.0008*
Olive 32 to 85 p= 0.002*
Lewis rats
Control vs Primrose 27 to 71 p= 0.001*
Control vs Safflower 17 to 108 p= 0.016*
Control vs Fish 36 to 89 p= 0.0008*
Control vs Olive 29 to 85 p= 0.002*
DA rats
Control vs Primrose 17 to 59 p= 0.004*
Control vs Safflower 19 to 53 p= 0.0016*
Control vs Fish 31 to 62 p= 0.0003*
Control vs Olive 19 to 52 p= 0.0013*
Two Sample T Test
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Table 2.1.3.2(a) Food consumption a t four weeks - s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control 1.3 to 6.2 p= 0.014*
Primrose -6 to 4 p= 0.64
Safflower -2 to 3 p= 0.73
Fish -3 to 1.6 p= 0.41
Olive -7 to 1 p= 0.11
Lewis rats
Control vs Primrose 7 to 13 p< 0.001*
Control vs Safflower 6 to 13 p= 0.0001*
Control vs Fish 9 to 14 p= 0.0002*
Control vs Olive 8 to 13 p< 0.001*
DA rats
Control vs Primrose 0.15 to 10 p= 0.04*
Control vs Safflower 5 to 7 p< 0.001*
Control vs Fish 4 to 9 p= 0.002*
Control vs Olive -0.66 to 8 p= 0.08
Two Sample T Test
Urine volume tended to be higher in the PUFA diet groups relative to controls in DA 
rats. Although there was no difference in mean urine volume between control and 
PUFA diet groups in Lewis rats at four weeks (Table 2.1.3.3) urine volume was 
raised significantly in the safflower and olive oil diet groups in DA rats (Table 
2.1.3.3a). Water intake was not monitored in this study.
Measuring metabolic parameters on both days on which the animals are in metabolic 
cages is useful for identifying 'rogue' data. Urine volume data in Table 2.1.3.3 
illustrates clearly, that the first Lewis rat in the primrose oil diet group did pass more 
urine than others in the group.
2.1 .3 .2  G lo m e ru la r  re c o v e ry
Viewed by light microscopy, the glomerular suspension appeared to be remarkably 
free of tubular contamination: isolated glomeruli viewed at xlO and x40 
magnification are shown in Plate 2.1. Some glomeruli were visible with their capsule 
intact and others were decapsulated, with or without their associated afferent and 
efferent arterioles.
The protein content of the glomerular pellets from Lewis and DA rats fed control or 
PUFA diets are shown in Table 2.1.3.4.
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Table 2.1.3.3(a) Urine volume at four weeks - s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -1.5 to 3 p= 0.5
Primrose -6 to 8 p=67
Safflower -5 to -0.2 p= 0.04#
Fish -9.5 to 1.2 p= 0.099
Olive -8.5 to 0.1 p= 0.055
Lewis rats
Control vs Primrose -9 to 5 p= 0.47
Control vs Safflower -2.5 to 2.6 p= 0.85
Control vs Fish -1 to 3 p= 0.26
Control vs Olive -2 to 2 p= 0.82
DA rats
Control vs Primrose -5 to 2 p= 0.33
Control vs Safflower -5 to -1 p= 0.01*
Control vs Fish -8.5 to 1.3 p= 0.12
Control vs Olive -9 to -0.2 p= 0.043
Two Sample T Test
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2.1.3.3 P rostano id  levels
Prostanoid binding curves from the assay systems used to measure bicyclic PGE2  
metabolite, 6 -keto prostaglandin Fla and thromboxane B 2  are shown in Figures 
2.1.3.5, 2.1.3.6 and 2.1.3.7, respectively.
At six weeks, levels of bicyclic-PGE2  in glomerular supernatants were similar 
between Lewis and DA rats [Lewis vs DA: CD: median 0.233 (range 0.048 - 0.405) 
vs 0.244 (0.09 - 0.69) ng per mg glomerular protein, EPO: 0.394 (0.2 - 0.46) vs 0.311 
(0.2 - 0.54), SO: 0.320 (0.233 - 0.355) vs 0.455 (0.208 - 0.538), FO: 0.148 (0.007 - 
0.207) vs 0.148 (0.088 - 0.284), OO: 0.303 (0.098 - 0.606) vs 0.336 (0.255 - 0.791)] 
(see Figure 2.1.3.5a). Although PGE2  levels appeared to be lower in the fish oil 
group in both Lewis and DA rats, the results did not reach statistical significance (see 
Table 2.1.3.5 for corresponding confidence intervals and significance levels). None 
of the other PUFA diets had any effect on glomerular PGE2  levels in either rat strain. 
There were no marked differences in 6 -keto PGFla levels in the glomerular 
supernatants between Lewis and DA rats (Figure 2.1.3.6a) [Lewis vs DA: CD: 
median 0.419 (range 0.398 - 0.599) vs 0.507 (0.320 - 0.583) ng per mg glomerular 
protein, EPO: 0.486 (0.365 - 0.926) vs 0.407 (0.379 - 0.625); SO: 0.462 (0.294 - 
0.546) vs 0.439 (0.320 - 0.606), FO: 0.126 (0.088 - 0.210) vs 0.094 (0.051 - 0.209), 
OO: 0.459 (0.330 - 0.556) vs 0.370 (0.327 - 0.576)]. However, 6 -keto PGFla levels 
were lowered to a statistically significant degree relative to controls in both Lewis 
(0.419 (0.398 - 0.599) vs 0.126 (0.088 - 0.210) and DA (0.507 (0.320 - 0.583) vs 
0.094 (0.051 - 0.209) rats fed fish oil diet (see Table 2.1.3.6 for corresponding 
confidence intervals and significance levels).
Measurement of thromboxane levels in Lewis and DA rat glomerular supernatants 
showed that Lewis rat glomeruli generated significantly higher levels of TxB2  in vitro 
than DA rat glomeruli, irrespective of diet [Lewis vs DA: CD: median 1.552 (range 
1.023 - 1.646) vs 0.559 (0.333 - 0.700) ng per mg glomerular protein; EPO: 1.250 
(0.875 - 1.694) vs 0.483 (0.402 - 0.791); SO: 0.978 (0.268 - 1.366) vs 0.358 (0.321 - 
0.606); FO: 0.167 (0.146 - 0.241) vs 0.089 (0.075 - 0.096); OO: 1.06 (0.83 - 1.212) vs 
0.543 (0.303 - 0.788)] (Figure 2.1.3.7a). Thromboxane levels were lowered to a 
statistically significant degree in both strains of rat in the fish oil diet group - and the 
significant interstrain difference was maintained within this diet group (see Table 
2.1.3.7 for corresponding confidence intervals and significance levels). In Lewis rats, 
lowering of glomerular TxB2  levels in safflower and olive oil diet groups did not 
reach statistical significance.
Table 2.1.3.7(b) shows bicyclic-PGE2, 6 -keto PGFla and TxB2  levels before factoring 
for glomerular protein and gives some indication of the extent of ex vivo stimulation.
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Figure 2.1.3.5 Standard bicyclic-PGE2 binding curve
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Table 2.1.3.5 Glomerular PGE2 release -  s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -0.4 to 0.23 p= 0.68
Primrose -0.17 to 0.2 p= 0.6
Safflower -0.23 to 0.11 p= 0.53
Fish -0.14 to 0.07 p= 0.83
Olive -0.5 to 0.27 p=0.4
Lewis rats
Control vs Primrose -0.3 to 0.04 p= 0.21
Control vs Safflower -0.27 to 0.10 p= 0.46
Control vs Fish -0.1 to 0.26 p= 0.09
Control vs Olive -0.38 to 0.16 p= 0.4
DA rats
Control vs Primrose -0.3 to 0.4 p= 0.68
Control vs Safflower -0.36 to 0.24 p= 0.4
Control vs Fish -0.08 to 0.54 p= 0.21
Control vs Olive -0.57 to 0.36 p= 0.3
Mann Whitney Confidence Interval and Test
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Figure 2.1.3.6 Standard 6, keto- PGF i a binding curve
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Table 2.1.3.6 Glomerular 6-keto PGFla release -  s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -0.17 to 0.21 P= 1
Primrose -0.13 to 0.52 p= 0.4
Safflower -0.15 to 0.14 P= 1
Fish -0.08 to 0.12 p= 0.4
Olive -0.16 to 0.17 P= 1
Lewis rats
Control vs Primrose -0.5 to 0.12
C
O
oIIa
Control vs Safflower -0.12 to 0.2 p =  0.8
Control vs Fish 0.2 to 0.47 p =  0.012*
Control vs Olive -0.14 to 0.19 P= 1
DA rats
Control vs Primrose -0.14 to 0.20
OIIQ.
Control vs Safflower -0.12 to 0.21 p= 0.6
Control vs Fish 0.18 to 0.51 p= 0.02*
Control vs Olive -0.24 to 0.22
ooIIa
Mann Whitney Confidence Interval and Test
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Figure 2.1.3.7 Standard thromboxane B2 binding curve
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Table 2.1.3.7 Glomerular thromboxane B2 release - s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control 0.14 to 1.01 p= 0.037*
Primrose 0.39 to 1.2 p= 0.012*
Safflower 0.37 to 1.01 p= 0.012*
Fish 0.05 to 0.15 p= 0.012*
Olive 0.23 to 0.80 p= 0.012*
Lewis rats
Control vs Primrose -0.22 to 0.67 p= 0.53
Control vs Safflower -0.006 to 0.82 p= 0.06
Control vs Fish 0.85 to 1.48 p= 0.012*
Control vs Olive -0.03 to 0.74 p= 0.06
DA rats
Control vs Primrose 0.33 to 0.27 P= 1
Control vs Safflower 0.23 to 0.37 p= 0.33
Control vs Fish 0.24 to 0.62 p= 0.02*
Control vs Olive -0.33 to 0.36 p= 0.9
Mann Whitney Confidence Interval and Test
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2.1.3.4 Urine to ta l p ro tein
Only in the fish oil diet group was proteinuria significantly higher in Lewis than DA 
rats [Lewis vs DA: CD: median 13.30 (range 10.5 - 15.6) vs 11.1 (8.75 - 15.4) mgs 
per 24 hrs, EPO: 5.85 (4.3 - 6 .6 ) vs 6.5 (4.9 - 8.9 mgs per 24 hrs, SO: 7.3 (4.8 - 12.3) 
vs 6.05 (5.2 - 7.1) mgs per 24 hrs, FO: 8.4 (8.3 - 11) vs 6  (5.6 - 7.6 mgs per 24 hrs*, 
OO: 7.25 (6.65 - 8.05) vs 8.3 (5.4 -10) mgs per 24 hrs; see Figure 2.1.3.8).
Urine total protein levels were lowered in both Lewis and DA rats in all the PUFA 
diet groups (see Table 2.1.3.8 for corresponding confidence intervals and significance 
levels).
Total protein excretion at weeks 2 and 4 in all the PUFA diet groups is shown in 
Figure 2.1.3.8(a)
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Table 2.1.3.8 Total protein excretion - s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -2 to 4.8 p= 0.4
Primrose -3 to 0.95 p= 0.25
Safflower -1 to 6.26 p= 0.29
Fish 0.8 to 5 p= 0.01*
Olive -3 to 1.9 p= 0.67
Lewis rats
Control vs Primrose 4.55 to 10 p= 0.03*
Control vs Safflower 0.4 to 9.3 p= 0.03*
Control vs Fish 0.6 to 7.2 p= 0.03*
Control vs Olive 3.1 to 8.4 p= 0.012*
DA rats
Control vs Primrose 1.9 to 8.8 p= 0.02*
Control vs Safflower 2.7 to 9.4 p= 0.012*
Control vs Fish 2.7 to 9.4 p= 0.012*
Control vs Olive 0.45 to 7.1 p= 0.02*
Mann Whitney Confidence Interval and Test
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2.1.3.5 G lom eru lar renin levels
Glomerular renin data shown in Figure 2.1.3.9 was derived from the difference 
between the standard incubation (15 minute) time value and the zero-time value (see 
Tables 2.1.3.9a and 2.1.3.9b) and then factored for glomerular protein content (Table 
2.1.3.4).
Renin concentrations in glomerular supernatants were significantly higher in Lewis 
than DA rats in all diet groups [Lewis vs DA: CD: median 2903 (range 1311 - 
105622) vs 246 (44 - 794) pg AI per hour per mg glomerular protein, EPO: 1833 (598 
- 7600) vs 219 (134 - 518), SO: 3932 (1699 - 9320) vs 511 (160 - 1648), FO: 2619 
(1119 - 44970) vs 446 (415 - 1724), OO: 5227 (1925 - 17493) vs 502 (336 - 640)]. 
However, none of the experimental PUFA diets had any effect on glomerular renin 
release in vitro in either Lewis or DA rats (Table 2.1.3.9c).
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Table 2.1.3.9(c) Glomerular renin concentration -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control 983 to 105382 p= 0.02*
Primrose 378 to 7381 p= 0.012*
Safflower 1007 to 8809 p= 0.012*
Fish 351 to 44524 p= 0.02*
Olive 1422 to 16991 p= 0.012*
Lewis rats
Control vs Primrose -4696 to 103789 p= 0.67
Control vs Safflower -6417 to 101690 P= 1
Control vs Fish -42066 to 103003 P= 1
Control vs Olive -14590 to 100395 p= 0.5
DA rats
Control vs Primrose -437 to 584 p= 0.9
Control vs Safflower -1407 to 287 p= 0.27
Control vs Fish -1483 to 361 p= 0.18
Control vs Olive -546 to 382 p= 0.27
Mann Whitney Confidence Interval and Test
2.1.4 Discussion
The purpose of performimg this study was to determine whether the reported 
inherited differences in GCW charge, mesangial function and disease susceptibility 
between the Lewis and DA rat strains might relate to differences in their glomerular 
prostanoid profiles. The principal aims were, therefore, to establish differences in 
glomerular PGE2, PGI2  and thromboxane production in vitro between Lewis and DA 
rats and to explore the effects of PUFA diets on glomerular prostanoid levels in vitro.
The great bugbear of any study involving the measurement of prostanoids is that 
levels may be raised erroneously due to various forms of tissue stimulation outwith 
the body. In practice, it is impossible to avoid artefactual prostanoid production, 
especially with an aggressive tissue recovery technique such as the sieving procedure 
used in this study, but various actions can be taken to minimise the problem. Low 
temperatures suppress prostanoid production and so, as soon as the kidneys were 
removed from the rat and the glomeruli recovered, they were kept in ice-cold saline 
or on ice as appropriate, throughout all the stages of the procedure. Following the 
subsequent rest period during which the temperature of the glomerular suspensions 
was raised slowly to 37°C, prostanoid production was re-activated by gentle agitation 
on a roller mixer at 37°C and maintained thus for thirty minutes. The extent to which 
the glomeruli will have recovered from the various cycles of quiescence and re­
initiation is unclear but the sieving and incubation technique is a common one, used 
widely by many workers (Stahl et al, 1990, Rosenberg et al, 1991). Although 
cyclooxygenase inhibitors such as aspirin or indomethacin, are often added to limit ex 
vivo prostanoid production, their use in this study would have been inappropriate 
because the purpose was to assess prostanoid generation rather than measure 
endogenous levels.
It is notable that despite the crude nature of the sieving technique, the glomerular 
suspensions were not contaminated, to any great extent, with tubular tissue which 
could alter prostanoid levels.
The problems associated with tissue stimulation can be limited by measuring 
prostanoid levels in urine, which is relatively free of extraneous cellular material. 
The advantages of measuring urine prostanoids were considered during the planning 
stages of this study but rejected on the basis that (i) urine contains a multitude of 
highly degraded tetranor metabolites originating from various tissues with as many as 
twenty different TxB2  tetranor metabolites alone, (ii) the object of the study was to 
examine glomerular prostanoid production and the very low levels of any primary 
prostanoids are likely to be of tubular origin, (iii) urine collected in metabolic cages
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has been at room temperature for some 24 hours, may be contaminated with food and 
faecal material and should, ideally, undergo some form of chemical extraction 
procedure which is time-consuming in a large number of experimental animals and 
(iv) in male rats, urine may be contaminated with seminal fluid which is a rich source 
of prostanoid metabolites.
Glomerular prostanoids: Interpretation of the prostanoid assay results is complicated 
by many factors. Although there appeared to be no differences in the glomerular 
levels of vasodilatory bicyclic PGE2  or 6 -keto PGFla between Lewis and DA rats in 
any of the diet groups, glomerular TxB2  levels were significantly raised in Lewis 
compared to DA rats in all the diet groups and the difference was quite clear despite 
the small number of animals. There was no concomitant rise in glomerular PGE2  
levels in Lewis rats but rather a suggestion that PGE2  levels might be lower in Lewis 
than DA rats in all the PUFA groups: however, interpretation of such data is 
confounded by sample size and may be subject to a type II statistical error (false- 
negative). In realistic terms, to detect such a difference in PGE2  levels would require 
a larger number of experimental animals. A power calculation based upon the small 
amount of PGE2  data gathered in this experiment, suggests that 44 Lewis or DA rats 
would be required in each experimental diet group to show a 20% reduction in PGE2  
levels between the strains, with 80% power at a significance level of 0.05.
In view of having fed different PUFA diets to manipulate glomerular prostanoid 
production, RIA was not the most appropriate method for detecting changes in the 
different prostanoids series. HPLC or GC-MS are the only analytical methods which 
can determine the levels of 1-, 2- and 3- series prostanoid metabolites simultaneously. 
Radioimmunoassay, as used in this study, measured specific dienoic prostanoids and 
so changes in biosynthesis towards 1- or 3- series prostanoids could only be 
insinuated from a relative fall in dienoic prostanoid levels. The fall in 6 -keto PGFla 
and TxB2  and to a lesser degree, bicyclic-PGE2, in both strains in the fish oil diet 
groups, is likely to be related to preferential synthesis of 3- series prostanoids. The 
maintenance of a significant difference in TxB2  levels between Lewis and DA rats in 
the fish oil group may reflect preferential metabolism of co-3 fatty acids in DA rats, 
resulting in a higher TXA3 : TxB2  ratio.
That dienoic prostanoid levels were unchanged in the evening primrose oil and 
safflower oil diet groups in both strains was a little surprising, since the rationale 
behind the use of such diets is to stimulate the biosynthesis of monoenoic prostanoid 
derivatives. Evening primrose and safflower oils have a similar linoleic acid content 
but EPO also contains y-linolenic acid (GLA) which is the immediate precursor of 1- 
series prostanoids; safflower oil contains no GLA and so lower dienoic prostanoid
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levels might be expected in the EPO, than the SO group. It should have been possible 
to detect relative changes in dienoic 6 -keto PGFla or TxB2  levels had they occurred, 
since the antibodies to both metabolites do not cross react to any great extent with 
other prostanoid metabolites (see Tables 2.1.2.3c and 2.1.2.4a). However, it would 
have been impossible to distinguish between changes in PGEj and PGE2  levels since 
the bicyclic-PGE2  antibody cross-reacts (100%) with both PGEt and PGE2.
Selection of the most suitable metabolite to measure is yet another problem of 
working with prostanoids. The 15 keto, 13, 14 dihydro- (or DHK-) metabolites are a 
major and constant index of the metabolism of the parent prostanoid in v/vo, which 
are not formed by artefact and circulate at higher levels (20 to 50 pg per ml) and so 
are easier to detect and measure: however, the DHK- metabolites of PGE2  and PGI2  
are metabolised further to dinor and tetranor derivatives which are the major 
circulating compounds. In man, there are few thromboxane metabolites other than 
TxB2  in the blood, in comparison with urine which contains some twenty TxA2  
metabolites, the predominant one being 2, 3 dinor TxB2, which is barely detectable in 
blood. 11, dehydro- TxB2  is the major metabolite in both blood and urine and is not 
formed by artefact and so is probably the best metabolite to measure. Of the three 
prostanoids measured, only bicyclic PGE2  can perhaps be regarded as a true end- 
product. Both 6 -keto PGFla and TxB2  can be metabolised further to various dinors 
and tetranors which might, ultimately, display a different biosynthetic pattern. 
Prostanoids can also interconvert or shunt between classes: in humans, for example, 
PGE2  can be reduced irreversibly to a PGFa compound - a reaction which is 
reversible in rats.
The purpose of this study was, however, to compare prostanoid production between 
the diet groups. The actual levels of prostanoids per assay tube (Table 2.1.3.7b) show 
that glomerular TxB2  levels in Lewis rats are raised, relative to both DA rats and 
PGE2  and 6 -keto PGFlct levels in both strains in all except the fish oil diet groups. 
(Prostanoid levels in glomerular supernatants relate to cumulative production over 
thirty minutes). PGE2  and 6 -keto PGFla levels did not exceed markedly, the accepted 
range of 20-50 pg/ml for circulating prostanoid metabolites, but TxB2  levels were 
well outwith the range in Lewis compared with DA rats, in all the diet groups (see 
Table 2.1.3.7b).
Reasons for the raised glomerular TxB2  levels in Lewis relative to DA rats are 
unclear (see Table 2.1.3.7a). Were TxB2  levels raised due to the sieving procedure, a 
similar pattern would be evident in DA rats but prostanoid levels were measured in 
supernatants from glomeruli subjected to identical sieving and storage procedures.
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Alternative explanations are that Lewis rat glomeruli are more sensitive to the 
mechanical stimulation of the sieving procedure or that DA rat glomeruli became 
exhausted more quickly in vitro than Lewis rat glomeruli, rather than Lewis rat 
glomeruli having a greater capacity to synthesise TxA2  than DA rats. It is perhaps 
unusual for thromboxane levels to be raised in an apparently healthy strain of rat, 
since elevated thromboxane levels are associated predominantly with disease states or 
coagulation disorders (see section 1.3.4).
Prostaglandin and thromboxane biosynthesis is regulated enzymatically at the level of
(i) lipases and phospholipases which are involved in the release of free arachidonic 
acid from membrane phospholipids (Zusmann and Kaiser, 1977; Benabe et al, 1982; 
Folkert et al, 1984), (ii) A- desaturases and elongases within the EFA metabolic 
pathways (see Figure 1.3.1), (iii) cyclooxygenase activity and (iv) specific prostanoid 
synthetase enzymes (see Figure 1.3.2). It is difficult therefore, to pinpoint the origin 
of increased thromboxane production in Lewis rats. Infiltrating neutrophils, 
macrophages or platelets produce TxB2  (see section 1.3.3). Alternatively, in Lewis 
rats, platelets may adhere more readily to the GCW with its depleted polyanion, 
become activated and generate thromboxane (Pugliese et al, 1987). Raised 
glomerular thromboxane levels have also been explained as an adaptive response to 
an already dilated vasculature (Craven et al, 1987) but PGE2  and 6 -keto PGFla levels 
were not higher in Lewis compared to DA rats in this study. Agents including 
angiotensin II and vasopressin (Nasjletti et al, 1985; Ardaillou et al, 1987; Wilcox et 
al, 1990), complement (Couser et al, 1985; Stahl et al, 1987), endothelin (Zoja et al, 
1990), calcium (Stork et al, 1985), reactive oxygen species (Baud et al, 1983; Adler 
et al, 1986), cytokines (Lovett et al, 1987a; Baud et al, 1989) and growth or platelet 
activating factors (Levine and Hassid, 1977, Schlondorff et al, 1984, Habenicht et al, 
1985, Floege et al, 1990), hypoalbuminaemia (Schiepatti et al, 1984) and increased 
dietary protein intake (Collins et al 1989) can also contribute to raised thromboxane 
levels.
Proteinuria: Urine protein excretion appeared to be lowered in both Lewis and DA 
rats in all the PUFA diet groups compared with those fed standard laboratory rat 
chow but the finding must be viewed with caution because of the small number of 
rats in each diet group and the high degree of intraindividual variation inherent in 
urine protein measurements. However, the effect overall, was evident in a relatively 
large number of PUFA-fed rats and was therefore deemed worthy of further 
investigation (see section 2.2.1). Urine protein levels between two and four weeks 
are shown in Figure 2.1.3.8(a). In the control diet group, urine protein levels are 
rising in both Lewis and DA rats, as occurs also in the evening primrose oil group,
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albeit at a lower level. In the safflower, fish and olive oil diet groups, urine protein 
levels are, in the main, lowered or stabilised to varying degrees. Although urine 
protein levels do tend to be lower in the PUFA diet groups, it is inappropriate to make 
any generalisation because of the small sample size and infrequent measurements.
Six weeks is a common PUFA diet feeding period and indeed, it is said that effects 
are evident after four weeks. The percentage increase in body weight in rats fed 
control diet was double that of those fed PUFA diets and could be an alternative 
explanation for the fall in proteinuria in the PUFA diet groups. However, the lower 
body weight in the PUFA groups does not appear to be related to reduced food 
consumption. It must also be considered that data derived from the time the animals 
spend in metabolic cages is only representative.
Glomerular renin: Renin levels in the glomerular supernatants of Lewis and DA rats 
were measured to see whether they might correlate with the fall in proteinuria in the 
PUFA diet groups. Generally accepted as being synthesised exclusively within the 
glomerulus, renin is a proteolytic enzyme involved in regulating blood pressure and 
fluid balance and there is a close relationship between prostanoid biosynthesis and 
activation of the renin-angiotensin system (see section 1.3.4). The renin assay used in 
this study is complicated, requiring an array of reagents which are not always readily 
available and so samples of Lewis and DA rat glomerular supernatants were 
dispatched, to be assayed using an established radioimmunoassay method. It was 
interesting to see that the pattern of glomerular renin was very similar to that of 
glomerular TxB2, with renin levels in supernatants from Lewis rats being 
significantly higher than those from DA rats, irrespective of diet. However, renin 
levels neither correlated with urine protein levels nor the fall in protein excretion in 
the PUFA diet groups in either strain of rat and none of the PUFA diets had any effect 
on glomerular renin levels in either strain of rat.
As with the thromboxane results, it is difficult to interpret the significance of the 
increased glomerular renin levels in Lewis rats in vitro. However, unlike prostanoids, 
which are synthesised as required and inactivated at their site of action, renin is 
synthesised and stored within juxtaglomerular cells in the afferent arteriole. Raised 
glomerular renin levels may relate to increased synthesis and release of renin or 
accumulation and entrapment of renin within the glomerulus (Johnston, 1993; Lush et 
al, 1993). The release of renin from the afferent arteriole is regulated by (a) 
intrarenal vascular receptors and the macula densa which is sensitive to sodium 
and/or chloride load, (b) sympathetic nerve stimulation via (3 receptors and (c) 
humoral agents such as vasopressin, angiotensin II and prostaglandins (Stella and 
Zanchetti, 1987; Samani e ta ly 1989; Stahl e ta l, 1984a; Nath e ta l , 1986).
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Whether heightened glomerular thromboxane and renin levels in Lewis rats are (i) 
independent or related events and (ii) mirror systemic activation of both the renin- 
angiotensin and cyclooxygenase systems remains unclear.
Summary
Of the three glomerular prostanoid metabolites measured - bicyclic PGE2, 6 -keto 
PGFla and TxB2  - only thromboxane levels were raised in Lewis relative to DA rats 
and irrespective of diet Proteinuria was lower in both Lewis and DA rats in all the 
PUFA diet groups and glomerular renin levels in vitro were also raised in Lewis 
compared to DA rats. Despite the significant differences between the strains, changes 
in glomerular TxB2  and renin levels in vitro did not correlate with the fall in urine 
protein levels in the PUFA diet groups. One must remain sceptical, however, about 
the fall in protein excretion in the PUFA diet groups in light of the high degree of 
intraindividual variation in urine protein measurements, the small number of animals 
in each diet group and the relative infrequency of urine protein measurements.
Although the significance of raised glomerular thromboxane and renin levels in 
Lewis rats is unclear, such findings may relate to glomerular hypertension or 
heightened platelet activity which contribute to impaired glomerular permeability.
Differences in the glomerular thromboxane B 2  levels and renin activity in vitro 
between Lewis and DA rats have not been reported previously.
PUFA DIETS, THROMBOXANE, RENIN and PROTEINURIA Section 2.2
2.2.1 Introduction and experimental design
The previous study left many questions unanswered. Was the tendancy for protein 
excretion to be lower in both Lewis and DA rats fed PUFA diets a genuine anti- 
proteinuric effect of PUFA diets? Were the differences in glomerular thromboxane 
and renin levels between the two strains of rat authentic, and if they were, was the 
effect confined to the glomerulus or were circulating levels of these two potent 
vasoconstrictors also raised? Did the heightened levels of thromboxane and renin 
correlate with urine protein levels and were the levels of thromboxane and renin 
affected by the PUFA diets also? Notwithstanding the small number of rats in each 
diet group, it was decided that the potential protein-lowering effects of PUFA diets in 
the previous study could not be ignored and should be investigated further.
As discussed in section 1.1.2, a fall in urine protein levels is significant in view of the 
following facts:
• proteinuria is the clinical hallmark of impaired glomerular permselectivity
• very low levels of albumin excretion (microalbuminuria) is both an early 
predictor of the development of nephropathy in diabetic patients and an 
established cardiovascular risk factor reflecting a generalised increase in 
systemic vascular permeability (Deckert et al, 1989). Microalbuminuria has 
been associated with early age at onset and long duration of diabetes, poor 
metabolic control, arterial hypertension and a family history of hypertension, 
peripheral neuropathy, retinopathy, a high protein or fat intake and abnormal 
plasma lipoproteins or coagulation factor levels in IDDM patients (see section
2.5.1).
• proteinuria may reflect increased protein flux both across the glomerular 
capillary wall and through the mesangium which are critical factors in the 
initiation and persistence of sclerosis of the glomerular tuft.
In the previous study (2.1), total protein excretion was measured, but albumin 
excretion is a more appropriate index of glomerular permselectivity because unlike 
many other proteins, albumin is not secreted by the renal tubules and being negatively 
charged at physiological pH, it appears in the urine in increasing amounts when the 
glomerular polyanion is diminished. Both total protein and albumin excretion were 
measured in this study.
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Urine albumin levels are best measured by immunological methods such as 
immunoturbidimetry, radioimmunoassay or ELISA which are more sensitive and 
specific than dye-binding and protein precipitation methods. It is important also to 
define the type of urine sample used for albumin estimation, such as short daytime, 
timed overnight or twenty four hour collection, and levels should be expressed as 
either a concentration, albumin excretion rate (AER) or an albumin to creatinine ratio 
which takes account of renal function. Each type of urine sample has inherent 
advantages and disadvantages: daytime samples may give higher results than an 
overnight sample (due to the effects of exercise) but the more accurate 24 hour urine 
collection is less convenient and therefore often incomplete, particularly in clinical 
practice. Ideally, urine should be stored refrigerated at 4°C for up to two weeks 
without added preservative (sodium azide at 0.03 mol/1, if necessary) or frozen at - 
20°C and after thawing, brought to room temperature and mixed thoroughly before 
assay.
The upper limits of the reference range of albumin excretion in healthy adults is some 
20-30 mg per 24 hrs which is equivalent to 14-18 p,gs ug per min in overnight sample 
or 2-3 mg per mmol creatinine. Microalbuminuria has been defined as a urinary 
albumin excretion rate of 20-200 p.gs per minute in an overnight or 24 hour sample 
(equivalent to 30-300 mgs per 24 hours or 3-30 mgs per mmol creatinine) on at least 
two of three occasions within a period of six months (Mogensen, 1987). The 
predictive or threshold levels of urine albumin above which the risk of nephropathy 
increases can vary from 15 p,gs per minute (Mogensen et al, 1984) to 30 p,gs per 
minute (Viberti et al, 1982) to 70 |igs per minute (Mathieson et al, 1984) amongst 
different centres. Acute diuresis, sex, age and body mass can affect urine albumin 
excretion although the necessity for reference ranges related to such parameters 
remains controversial (Rowe et al, 1990). There are, however, substantial problems 
with intraindividual variation of perhaps some 40% even in normal urine albumin 
levels, which are related to exercise, posture and other diurnal variations (Hutchison 
and O'Reilly, 1985; Mogenesen, 1987; Johnston eta l, 1993).
Because of the observed similarities between glomerular thromboxane and renin 
patterns, it was decided to examine glomerular and circulating renin levels. Renin 
converts angiotensinogen to angiotensin I (Al) which is then converted by 
angiotensin converting enzyme (ACE) to angiotensin II (All) primarily in the lungs, 
but also in the circulation. Renin is secreted by specialised myoepithelial cells in the 
wall of the afferent arteriole in response to either a fall in arterial blood pressure, 
renal perfusion or salt-load presented to the distal tubule, the latter being detected by 
the macula densa (Laragh, 1981).
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2.2.2 M aterials a n d  m e th o d s
The objectives of this second study were to (i) clarify whether the previously 
observed fall in proteinuria in Lewis and DA rats fed PUFA diets was genuine and 
therefore reproducible and (ii) explore the possibility of differences in glomerular and 
circulating thromboxane B2  and renin levels between the two rat strains. Although 
the data from the previous study does suggest that PUFA diet-induced changes in 
TxB2  and renin levels are not related to the fall in proteinuria, the results were 
inconclusive due, in part, to the small number of rats in each experimental diet group. 
The only feasible way to repeat the study with more rats in each diet group, was to 
omit one of the PUFA diets and so double the number of animals in the remaining 
groups. Although the fatty acid content of safflower oil and evening primrose oil are 
similar, EPO contains both linoleic acid and ^linolenic acid (GLA) which are 
precursors of 2 - and 1 - series prostanoids, respectively, whereas safflower oil 
contains linoleic acid but no GLA. It was decided also, that since there had been no 
marked differences or changes in glomerular PGE2  and PGI2  levels in any of the 
PUFA diet groups (except the fish oil diet groups) that the levels of these two 
prostanoids would not be measured again in this study.
As outlined in Figure 2.2.2.1, the experimental design of this study is similar to that 
of the previous one, but with some minor refinements to address the issue of whether 
the heightened thromboxane and renin production is confined to the glomerulus.
Four groups of 10 Lewis rats (n = 40) and four groups of 10 DA rats (n = 40) ranging 
in weight between 150 and 190 grams were fed either control, evening primrose oil, 
fish or olive oil diet for six weeks (see section 2.1.2.1). As before, body weight was 
recorded weekly, but in this study, the rats were put into metabolic cages at three and 
six weeks to measure food consumption and collect urine. Urine total protein 
excretion was measured by the Coomassie Blue method (see section 2.1.2.9) and 
albumin excretion rate was measured in 24 hour urine volumes by 
immunoturbidimetry.
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2.2.2.1 Im m unoturb id im etry
Immunoturbidimetry is based upon the principle of light absorption by antigen- 
antibody complexes and is suited to rapid analysis of large numbers of samples. 
However, the method is susceptible to non-specific light absorption or scattering from 
the sample but this is corrected for by blank or "initial reaction" readings. 
Polyethylene glycol (PEG) in the reaction mixture accelerates immunoprecipitation 
and the antibody must be present in excess if Beers law - which states that the amount 
of light absorbed or the probability of absorption is proportional to the number of 
molecules in the light beam - is to be obeyed. (An excess of antigen can give 
erroneously low results due to inadequate cross-linkage and precipitation). Turbidity 
is measured photometrically at 405 nm. Antibody-antigen binding may be influenced 
by the sample matrix which can vary markedly in urine. Highly coloured salts in the 
urine of normal rat are reputed to interfere with turbidimetric methods and so all 
urines were centrifuged at 1 0 0 0  g for 1 0  minutes before being de-salted in a 
Sephadex G-25M (PD-10) ion-exchange column (Pharmacia Fine Chemicals). 
Samples were eluted from the column with 0.9% NaCl and thus subject to a dilution 
factor of 1.75. Checks were carried out to ensure that de-salting did not alter urine 
protein levels to any great extent.
Polyethylene glycol 5.5% polyethylene glycol 6000 (BDH Limited, Poole,
England) in PBS
Rat serum albumin Rat serum albumin (RSA) (Sigma Chemical Company:
A-6416) at 5 mg per ml in PBS.
Antiserum Goat anti-rat albumin antiserum (Cappel laboratories:
Cat no 0213-0341) diluted 1: 2 with PBS. (1 ml of 
diluted antiserum is sufficient for 2 0  cuvettes)
All reagents were brought to room temperature. Duplicate standards were prepared 
as in the following table.
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Concentration
(mg/lOOmls)
RSA (5mg/ml) 
pis
Final volume 
mis
15 75 2.5
10 50 2.5
8 40 2.5
5 25 2.5
3 15 2.5
2 20 5.0
1 1:1 diln above 5.0
0.5 1:1 diln above 5.0
0.25 1:1 diln above 5.0
Duplicate samples of 50 pis of either RS A standard or urine were pipetted into plastic 
microcuvettes (1.6 mis; Sarstedt). 500 jxls of PEG 6000 was added to each cuvette 
which was then sealed and vortex-mixed. A photometer (Clinical System 100; 
Beckman) fitted with a 405 nm filter was zeroed on air and an initial absorbance 
reading (I) was recorded. 50 pis of diluted antiserum was added to all the cuvettes 
which were re-sealed, vortex-mixed and incubated at 37°C for 30 minutes. After 
incubation, the cuvettes were vortex-mixed again and a second absorbance (II) 
reading was recorded. An absorbance curve was constructed by subtracting 
absorbance reading (I) from absorbance reading (II) and the adjusted absorbance 
values were read against albumin concentration.
2.2 .2 .2  Urine c re a t in in e  m e a s u r e m e n t
Urine creatinine was measured using a Beckman creatinine analyser.
2.2 .2 .3  B lood s a m p lin g  p r o c e d u r e
At the end of six weeks, plasma and serum samples were prepared from blood 
withdrawn from each rat by cardiac puncture using a 25 guage needle.
(i) To measure serum thromboxane (TxB2) levels, one ml of blood was transferred to 
an eppendorff tube and placed immediately in a water bath at 37 °C to clot for one 
hour, which is an established time that dampens the effects of an initial burst of 
thromboxane from platelets by allowing them to equilibrate (McLaren, 1986). After 
one hour exactly, samples were removed from the water bath, mixed gently and 
placed on ice.
(ii) Plasma was prepared by withdrawing two mis of blood directly into a syringe 
containing 0.5 mis of prostanoid anticoagulant comprising 1 ml of 1% indomethacin 
(in absolute alcohol) and 1  ml of 2.7 mg per ml adenosine (Sigma Chemical
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Company: A-925) added to 98 mis of 3.2% sodium citrate. Indomethacin inhibits 
cyclooxygenase activity and adenosine suppresses platelet activity.
Blood samples were centrifuged at lOOOg at 4°C for 15 minutes and stored at -70°C, 
which is the optimal storage temperature for biological samples awaiting prostanoid 
measurements.
2 .2 .2 .4  G lo m e ru la r  s iev in g
The kidneys were removed and cortical tissue sieved to recover the glomeruli as 
detailed in section 2.1.2.5.
2 .2 .2 .5  T h ro m b o x a n e  m e a s u r e m e n t
Glomerular supernatant and serum thromboxane levels were measured by 
radioimmunoassay as detailed in section 2.1.2.8. Serum samples were diluted 1: 4 
with 0.9% sodium chloride prior to assay.
2 .2 .2 .6  M e a s u re m e n t  o f ren in
Renin assays are classified according to whether they measure plasma renin activity 
(PRA) or plasma renin concentration (PRC) - two distinct parameters related to the 
levels of circulating angiotensinogen (renin substrate) which may be rate-limiting and 
thus prevent attainment of maximal velocity. Plasma renin concentration is related to 
the generation of Al from plasma renin incubated with exogenous (or added) 
substrate whereas plasma renin activity is a measure of Al generated from 
endogenous substrate. Renin exists in two forms: active and inactive (prorenin). The 
assay method used in this study, measured the concentration of active renin: to 
measure total renin concentration, inactive renin is converted to its active form by 
acid or trypsin activation (Leckie et al, 1977).
In the previous study (section 2.1.3.5), renin levels were measured by staff in the 
laboratory of Dr B Leckie at the Blood Pressure Unit, Western Infirmary, Glasgow 
but in this study, their role was solely that of providing patient supervision and the 
reagents and buffers required for the assay. Glomerular supernatant and plasma 
samples from Lewis and DA rats fed control or PUFA diets were assayed.
The principles behind this renin radioimmunoassay are complex. Renin levels are 
measured according to a modification of the radioimmunoassay method of Miller et 
al (1980) by measuring angiotensin I generated during incubation of either rat 
glomerular supernatant or rat plasma (as the source of renin) with nephrectomised rat 
plasma (as the source of angiotensinogen). An antibody to Al is used to protect it
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from hydrolysis by endogenous angiotensinases. The concentration of 
angiotensinogen (exogenous nephrectomised rat plasma) in the reaction mixture is 
sufficient to guarantee substrate excess or zero-order kinetics and thus ensures that 
the reaction velocity is proportional to renin concentration.
Buffers and reagents
Incubation buffer Tris buffer (pH 6.9): 3M Tris HCl / 0.005M EDTA
182g Tris HCl and 37g EDTA dissolved in distilled 
water plus 300 mis of 5N HCl. pH adjusted to 6.9 
using [90.8g Tris and 18.61g EDTA in 250 mis 
distilled water] to a final volume of 500 mis.
Radioimmunoassay buffer Tris buffer (pH 7.4): 50 mM Tris HCl / 5mM EDTA /
0.2% (w/v) neomycin sulphate / 0.5% (w/v) BSA
24.2g Tris HCl and 7.4g disodium EDTA dissolved 
in 3.5 litres of distilled water and 15 mis 5N HCl, 8 g 
neomycin sulphate and 2 0 g bovine serum albumin 
added. pH adjusted to 7.4 with 5N HCl and volume 
made up to 4 litres with distilled water.
Modified (RIA) buffer as above plus 1% human serum albumin
Charcoal suspension 1.25g Dextran T70 dissolved in 10 to 50 mis of Tris
buffer (pH 7.4) was added to 63 g charcoal and 
volume made up to 1 0 0 0  mis.
Dilution buffer Tris buffer (pH 7.5): 0.05M Tris HCl / HSA /
neomycin sulphate
To dilute Al: « 500 mis 0.05M HCl, 1.75 g HSA 
and 3.5 g neomycin dissolved in 1  litre of prepared 
Tris HCl (6.057 g/1) and pH adjusted to 7.5 with 
0.05M HCl.
Procedures for the preparation of (i) Ile5-angiotensin I as RIA standard and antigen 
for antibody production, (ii) radiolabelled 1 2 5 I-angiotensin I, (iii) renin standards (iv) 
renin substrate (angiotensinogen) derived from nephrectomised rat plasma and (v) Rat 
Tris-Ab-Substrate mixture are detailed in the paper of Miller et al (1980).
Method
All stages of the assay were performed on a refrigerated (4°C) tray. Standards, 
samples and pre-mixed Rat Tris-Ab-Substrate mix were brought to room temperature 
and placed on the cold tray as soon as thawed. Tubes (LP4: Luckham Ltd) were 
numbered in duplicate for both preparation of a standard curve and measurement of 
renin concentration in glomerular supernatant and plasma samples.
A standard curve was constructed as follows: 50 pis of modified RIA buffer (+7%  
HSA) was pipetted into the first tube and 35 pis into the remainder.
Tube no 1 2 3 4 5 6 7 8 9
pg Al 1000 500 250 125 64 32 16 8  0
20 pis of angiotensin I (Al) standard at 100 ng per ml was added to the first tube and 
the contents were mixed: 35 pis were then removed, added to the second tube and 
mixed. This procedure was repeated up to the second last tube then the 35 pis 
volume was discarded: the last tube containing 35 pis of buffer was used as a blank. 
35 pis of Rat Tris-Ab-Substrate mix was then added to the standards, the reagents 
were mixed and 0.5 mis of ice-cold RIA buffer pH 7.4 added immediately. The tubes 
were stored at 4°C.
The next stage of the assay was to process the zero-time samples which are used to 
measure endogenous renin activation and the results of which will be subtracted from 
the test sample results in the standard incubation (15 minutes) assay. 35 pis of Rat 
Tris-Ab-Substrate mix was added to 5 pis of all test samples, the contents mixed and 
0.5 mis of ice-cold RIA buffer, pH 7.4 added immediately to stop the reaction. The 
tubes were set aside at 4°C.
In the standard incubation assay, renin concentration in the test samples was 
measured by adding 35 pis of Rat Tris-Ab-Substrate mix to 5 pis of either glomerular 
supernatant or rat plasma. Glomerular supernatants from Lewis rats required dilution 
1: 9 with Tris buffer (pH 6.9) but those from DA rats did not. The tubes were vortex- 
mixed and incubated in a water bath at 37°C for 15 minutes. The reaction was 
stopped by placing the tubes in crushed ice and diluting with 0.5 mis ice-cold RIA 
buffer (pH 7.4).
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50 fxls of radiolabelled ( 1 2 5I) angiotensin I (Al) (5pg per 50 pis) was added to the 
standards, test sample and zero-time tubes which were then covered, shaken and 
stored at 4°C for 48 hours. Five empty tubes were included for normalising on 
counter.
The final stage of the assay is to separate the bound, from the free label ( 1 2 5I) 
angiotensin I (total activity = 15.2 pCi). 200 pis of charcoal suspension was added to 
all but the five empty tubes and vortex-mixed. The tubes were then centrifuged at 
2800 rpm at 4°C for 10 minutes, the supernatants siphoned off and the tubes counted 
in a gamma counter (Nuclear Enterprises NE 6162 Turbo) programmed to report the 
results in picograms of angiotensin I (amount bound). The final result is expressed as 
picograms of Al per ml of plasma per hour. Should the results fall within the lower 
part of the curve (ie below 25%) then the incubation time must be increased: 
alternatively, if they fall within the upper part (ie above 6 6 % F) then incubation time 
may be decreased but not to less than 15 minutes. If the results are very high then 
samples should be diluted with Tris buffer (pH 6.9).
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2.2.3 Results
2.2.3.1 M e ta b o lic  d a t a
The growth rate curves shown in Figure 2.2.3.1 do not display the same initial fall as 
was seen in the previous study (see Figure 2.1.3.1a). At the end of six weeks, Lewis 
rats were significantly heavier than DA rats in all but the fish oil diet group [Lewis vs 
DA: CD: mean 235 (SD 24) vs 205 (11.5) grams, EPO: 250 (25) vs 200 (16), FO: 230 
(23) vs 216 (10), OO: 274 (23) vs 206 (20): see table 2.2.3.1 for corresponding 
confidence intervals and significance levels]. The percentage increase in body weight 
in all diet groups over six weeks, was greater in this study than the previous one, 
presumably as a result of the lower starting body weights of the rats in this study 
[Lewis: CD: 56%, EPO: 35%, FO: 39%, OO: 58%; DA: CD: 37%, EPO: 20%, FO: 
41%, OO: 32%] but the differences in percentage weight gain between control and 
PUFA diets in both strains of rat was not so marked in this study. Concern about 
weight loss in PUFA diet groups due to starvation appears to be unfounded: in DA 
rats, the increase in body weight was comparable between the fish oil (41%) and 
control (37%) diet groups and similarly in Lewis rats in the olive oil (58%) and 
control (56%) diet groups. At the end of six weeks, Lewis rats fed olive oil and DA 
rats fed fish oil diet were significantly heavier than their dietary controls (see Table
2.2.3.1).
As in the previous study, there was no generalised reduction in the consumption of 
PUFA diets compared to the control diet in either strain. Only Lewis rats fed fish oil 
and DA rats fed fish or olive oil diets consumed significantly less food than their 
respective controls [Lewis: CD: mean 17 (SD 3.6) grams vs (i) EPO: 17 (2.3), (ii) 
FO: 13.5 (2.4), (iii) OO: 16 (3); DA: CD: 15.2 (1.5) grams vs (i) EPO: 14 (1.6), (ii) 
FO: 13 (1.1), (iii) OO: 11.3 (2.1): see table 2.2.3.2(a) for corresponding confidence 
intervals and significance levels]. Mean food consumption differed between the 
strains only in the evening primrose oil diet and olive oil diet groups (Table 2.2.3.2a).
At six weeks, urine volume was significantly higher in Lewis than in DA rats in all 
the diet groups [Lewis vs DA: CD: mean 8.5 (SD 1.8) vs 6.2 (0.88) mis per day, 
EPO: 10.2 (4.1) vs 6.9 (2.1), FO: 9.25 (4.3) vs 6  (1.1), OO: 7.7 (1.4) vs 5.6 (1.4): see 
table 2.2.3.3(a) for corresponding confidence intervals and significance levels] but 
PUFA diets had no effect on urine volume in either strain (Table 2.2.3.3).
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Table 2.2.3.1 Body weight a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control 11 to 48 p= 0.004*
Primrose 30 to 71 p= 0.0001*
Fish -3 to 31 p= 0.099
Olive 48 to 89 p< 0.0001*
Lewis rats
Control vs Primrose -38 to 8 p= 0.18
Control vs Fish -17 to 27 p= 0.64
Control vs Olive 8 to 50 p= 0.009*
DA rats
Control vs Primrose -7 to 19 p= 0.37
Control vs Fish -20 to -0.4 p= 0.042*
Control vs Olive -16 to 15 p= 0.94
Twosample t  test
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Table 2.2.3.2a Daily food consumption a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control -1 to 4.4 p= 0.19
Primrose 1 to 4.8 p= 0.005*
Fish -1 to 2.6 p= 0.42
Olive 2.3 to 7.3 p= 0.0008*
Lewis rats
Control vs Primrose -3 to 3 P= 1
Control vs Fish 0.4 to 6.2 p= 0.03*
Control vs Olive -2 to 4 p= 0.59
DA rats
Control vs Primrose -0.2 to 2.6 p= 0.096
Control vs Fish 1 to 3.5 p= 0.001*
Control vs Olive 2.2 to 5.6 p= 0.0002*
Twosample t  test
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Table 2.2.3.3(a) M ean daily urine volum e a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control 0.8 to 3.65 p= 0.004*
Primrose 0.2 to 6.45 p= 0.04*
Fish 0.1 to 6.4 p= 0.04*
Olive 0.8 to 3.5 p= 0.0035*
Lewis rats
Control vs Primrose -4.8 to 1.4 p= 0.25
Control vs Fish -4 to 2.4 p= 0.6
Control vs Olive -0.8 to 2.3 p= 0.32
DA rats
Control vs Primrose -2.2 to 0.9 p= 0.38
Control vs Fish -0.76 to 1.2 p= 0.67
Control vs Olive -0.5 to 1.8 p=0.25
Twosample t test
Urine creatinine excretion was significantly higher in Lewis than DA rats only in the 
control and evening primrose oil diet groups [Lewis vs DA: CD: median 67 (range 50 
- 73) vs 49.5 (41 - 59) mmols per 24 hrs, EPO: 59.5 (45 - 83) vs 47 (36 - 52) mmols 
per 24 hrs, FO: 50 (32 - 69) vs 48 (27 - 55) mmols per 24 hrs, OO: 65 (46 - 102) vs 
55 (44 - 6 8 ) mmols per 24 hrs] (Figure 2.2.3.4). Only in the Lewis rat group fed fish 
oil diet was urine creatinine significantly reduced relative to the control diet group 
[CD: 67 (50 - 73) vs FO: 50 (32 - 69) mmols per 24 hrs: see table 2.2.3.4 for 
corresponding confidence intervals and significance levels].
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Table 2.2.3.4 Urine creatinine levels -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control 9 to 22 p= 0.0007*
Primrose 6 to 23 p= 0.004*
Fish -5 to 19 p= 0.08
Olive -7 to 30 p= 0.15
Lewis rats
Control vs Primrose -3 to 13 p= 0.13
Control vs Fish 1 to 21 p= 0.016*
Control vs Olive -15 to 15 p= 0.6
DA rats
Control vs Primrose -2 to 10 p= 0.15
Control vs Fish -3 to 10 p= 0.45
Control vs Olive -14 to 5 p= 0.6
Mann Whitney Confidence Interval and Test
2.2.3.2 G lom eru lar re c o v e ry
The protein content of pellets of glomeruli recovered from Lewis and DA rat kidneys 
is shown in Table 2.2.3.5.
2.2 .3 .3  Urine to ta l  p ro te in  e x c re tio n
Proteinuria was significantly higher in Lewis than DA rats only in the control and 
evening primrose oil diet groups [CD: 10 (7.7 - 15.6) vs 5.95 (4.6 - 7.1) mgs per 24 
hours, EPO: 10.7 (6.9 - 15) vs 7.1 (5.6 - 10.9) mgs per 24 hours, FO: 6.08 (4.8 - 11.5) 
vs 6.245 (3.7 to 11.4), OO: 7.6 (5.6 - 8.4) vs 6.4 (3.5 vs 7.7); see table 2.2.3.6 for 
corresponding confidence intervals and significance levels].
In contrast to the previous study, urine protein excretion was not reduced by all the 
PUFA diets in both strains of rat. Proteinuria was lowered significantly only in Lewis 
rats fed fish or olive oil diets [CD: 10 (7.7 - 15.6) vs (i) FO: 6.08 (4.8 - 11.5) mgs per 
24 hours, (ii) OO: 7.6 (5.6 - 8.4) mgs per 24 hours; Figure 2.2.3.6). In the evening 
primrose oil diet group, proteinuria was not lowered in Lewis rats but there was a 
slight and statistically significant increase in proteinuria in DA rats [CD: 5.95 (4.6 -
7.1) vs EPO: 7.1 (5.6 - 10.9) mgs per 24 hours, p = 0.015]. Neither fish oil nor olive 
oil diets had any effect on protein excretion in DA rats [CD: 5.95 (4.6 - 7.1) mgs per 
24 hours vs (i) FO: 6.245 (3.7 - 11.4) mgs per 24 hours, (ii) OO: 6.4 (3.5 - 7.7) mgs 
per 24 hours; see table 2.2.3.6 for corresponding confidence intervals and 
significance levels].
6 7
C
on
tr
ol
 
Pr
im
ro
se
 
Fis
h 
O
li
ve
<Q
to
<D
<O
CO
<1>
<a
to
■ 5
<D
<Q
CO
£O
iq in in inin v q v q cs inv q v q
CO cs’ cs’ CO cs’ cs’ cs' CO cs* cs’
CO 1-H
CO
CO
incs inq incs inv q <3 v q
CO CO CO CO CO CO CO cs’ CO cs’
incs ocs incq v q v q cs v q intq
cs CO CO CO CO CO CO CO CO cs’
ON OS o inCO cs m T—H moo inin t-H
1-H CO CO CO cs’ CO cs’ cs’ CO
<3 v o c> incs inON in "O’ in in1-H
cs’ CO cs’ CO cs’ 1-H cs’ cs’ CS
CO o incs ON OS ON in1—H inin mv q
Tf CO CO CO cs’ cs’ cs' CS CO cs'
in
ON
in
1-H o inin inin inc q r q in inT— 1 ON
o cs cs’ l - H l—H r-H r-H CS r -H
in
c q in incs mv q inON int- H ON inH 1-H
cs’ cs' cs’ cs" cs’ cs' cs’ cs’
CM CO IO VO OO Oo
o
£rss
.3
Pi Ta
ble
 
2.
2.3
.5 
Pr
ot
ein
 
co
nt
en
t 
of 
Le
wi
s 
an
d 
DA 
rat
 g
lo
m
er
ul
ar
 p
el
le
ts
I T
o
cm
□ □ a □ □ □
•  •
□ □□ CD3 □
•  •  • •  • • §
□ □ mum
•  •  •  •
Q §J|JJ Q
•  •  •  ft (M
CD
>
o
V)
CDUiO
E
Q_
c
o
O
i i | i i i ™ i |—i" 1 ■ ■ ■ | i i i i
m  o  in  o
sjnog p z  6 u j
Fi
gu
re 
2.2
.3.
6 
To
ta
l 
pr
ote
in 
ex
cr
eti
on
 
in 
Le
wi
s 
and
 
DA
 
rat
s 
at 
six 
w
ee
ks
Table 2.2.3.6 Total protein excretion a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control 2.7 to 6.4 p= 0.0002*
Primrose 1.3 to 4.9 p= 0.006*
Fish -1.6 to 2.4 p= 0.96
Olive -0.1 to 2.8 p= 0.08
Lewis rats
Control vs Primrose -2.6 to 2.2 p= 0.87
Control vs Fish 1.2 to 6 p= 0.007*
Control vs Olive 1.6 to 5.5 p= 0.002*
DA rats
Control vs Primrose -2.6 to -0.3 p= 0.015*
Control vs Fish -1.8 to 0.6 p= 0.37
Control vs Olive -1.3 to 1.2 p= 0.6
Mann-Whitney Confidence Interval and Test
2.2.3A  Urine a lbum in  ex c re tio n
Urine albumin excretion data is displayed on a logarithmic scale in Figure 2.23.1  and 
shows that at six weeks, AER was higher in Lewis than DA rats in all the PUFA diet 
groups [Lewis vs DA: CD: median 5.8 (range 0.25 - 23) vs 0.22 (0.15 - 0.46) mgs per 
24 hours, EPO: 0.190 (0.160 - 4.34) vs 0.09 (0.07 - 0.13) mgs per 24 hours, FO: 0.25 
(0.22 - 0.3) vs 0.145 (0.08 - 0.39) mgs per 24 hours, OO: 0.160 (0.11 - 0.21) vs 0.125 
(0.09 - 0.16) mgs per 24 hours] and albumin excretion was significantly reduced in all 
the PUFA diet groups in both strains of rat; see table 2.23.1  for corresponding 
confidence intervals and significance levels.
Changes in AER between weeks three and six are shown only for Lewis and DA rats 
fed control or evening primrose oil diet (Figures 2.2.3.7a and 2.2.3.7b). In the control 
diet group, median AER in Lewis rats tended to rise [2.6 (0.25 - 3.62) vs 5.89 (0.25 - 
23) mgs per 24 hours, Cl = -4.4 to -0.02, p = 0.039] but to fall in DA rats [0.285 (0.18 
- 0.91) vs 0.22 (0.14 - 0.46), Cl = -0.11 to -0.03, p = 0.02] (Figure 2.2.3.7a). In the 
evening primrose oil diet group, median AER rose slightly but significantly in Lewis 
rats between weeks 3 and 6  [0.160 (0.130 - 2.4) vs 0.190 (0.160 - 4.34), Cl = 0.02 to 
0.23, p = 0.004] but fell in DA rats during the same period [0.160 (0.11 - 0.43) vs 
0.09 (0.07 - 0.130), Cl = -0.14 to -0.05, p = 0.02] (see Figure 2.2.3.7b). Statistical 
comparisons were made between paired samples using the Wilcoxon paired rank test.
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Table 2.2.3.7 Albumin excretion rate a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control 0.1 to 6.9 p= 0.0028*
Primrose 0.07 to 0.29 p= 0.0002*
Fish 0.07 to 0.15 p= 0.006*
Olive 0.00001 to 0.06 p= 0.056
Lewis rats
Control vs Primrose 0.09 to 6.9 p= 0.002*
Control vs Fish 0.029 to 6.8 p= 0.01*
Control vs Olive 0.12 to 6.9 p= 0.0002*
DA rats
Control vs Primrose 0.08 to 0.2 p= 0.0002*
Control vs Fish 0.01 to 0.16 p= 0.017*
Control vs Olive 0.04 to 0.19 p= 0.0016*
Mann Whitney Confidence Interval and Test
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2.2.3.5 G lom eru lar a n d  serum  th ro m b o x a n e  m e a su re m e n ts
The standard binding curves from which glomerular supernatant and serum 
thromboxane B2  levels were calculated are shown in Figures 2.2.3.8 and 2.2.3.8(a), 
respectively. In this study, glomerular TxB2  levels were raised significantly in Lewis 
relative to DA rats only in the control and olive oil diet groups [Lewis vs DA: CD: 
median 1.063 (range 0.571 - 1.508) vs 0.223 (0.145 - 0.373) ng per mg glomerular 
protein, OO: 0.913 (0.485 - 1.202) vs 0.169 (0.108 - 0.616) ng per mg glomerular 
protein; see table 2.2.3.9 for corresponding confidence intervals and significance 
levels). There was no significant difference in glomerular TxB2  levels betweenLewis 
and DA rats in the evening primrose oil and fish oil diet groups [Lewis vs DA: EPO: 
0.489 (0.287 - 1.208) vs 0.549 (0.444 - 0.755) ng per mg glomerular protein, FO: 0.14 
(0.108 - 0.231) vs 0.125 (0.08 - 0.200) ng per mg glomerular protein].
In the evening primrose oil diet group, glomerular TxB2  levels were lowered in Lewis 
rats [CD: 1.063 (0.571 - 1.508) vs 0.489 (0.287 - 1.208) ng per mg glomerular 
protein] but raised in DA rats [CD: 0.223 (0.145 - 0.373) vs 0.549 (0.444 - 0.755) ng 
per mg glomerular protein] relative to their repective controls but in the fish oil group 
glomerular TxB2  levels were significantly reduced in both Lewis [0.14 (0.108 - 
0.231) ng per mg glomerular protein] and DA [0.125 (0.08 to 0.200) ng per mg 
glomerular protein] rats. Olive oil diet had no effect on glomerular TxB2  levels in 
either Lewis or DA rats [Lew: 0.913 (0.485 - 1.202) vs DA: 0.169 (0.108 - 0.616) ng 
per mg glomerular protein (see Table 2.2.3.9 for corresponding confidence intervals 
and significance levels.
There were no marked differences in serum TxB2  levels between the strains except in 
the fish oil group (Figure 2.2.3.10) [Lewis vs DA: CD: median 5.7 (range 4.2 - 9.3) 
vs 5.5 (4.8 - 6.3) ng per ml, EPO: 6.3 ( 6  - 7.8) vs 6.2 (5 - 9.2), FO: 3.5 (2.6 - 4.3) vs 
4.1 (4 - 5), OO: 5 (4.5 - 7.7) vs 5.7 (4 - 7.3): see table 2.2.3.10 for corresponding 
confidence intervals and significance levels].
Serum TxB2  levels were reduced significantly only in the fish oil group in both Lewis 
[5.7 (range 4.2 - 9.3) vs 3.5 (2.6 - 4.3 ng per ml); p < 0.001] and DA rats [5.5 (4.8 - 
6.3) vs 4.1 (4 - 5) ng per ml; p < 0.001].
Table 2.2.3.10(a) shows actual levels of glomerular and serum TxB2. Low serum 
T xB 2 values were not plotted.
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Table 2.2.3.9 Glomerular TxB2 release -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control 0.47 to 1.05 p= 0.0002*
Primrose -0.17 to 0.3 p= 0.76
Fish -0.01 to 0.05 p= 0.20
Olive 0.43 to 0.9 p= 0.0003*
Lewis rats
Control vs Primrose 0.11 to 0.78 p= 0.009*
Control vs Fish 0.57 to 1.18 p= 0.0002*
Control vs Olive -0.2 to 0.40 p= 0.38
DA rats
Control vs Primrose -0.41 to -0.24 p= 0.0002*
Control vs Fish 0.03 to 0.17 p= 0.0028*
Control vs Olive -0.14 to 0.11 p= 0.62
Mann Whitney Confidence Interval and Test
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Table 2.2.3.10 Serum TxB2 levels -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control -0.6 to 1.4 p= 0.45
Primrose -0.9 to 1.6 p= 0.6
Fish -1.3 to -0.2 p= 0.008*
Olive -1.3 to 0.9 p= 0.66
Lewis rats
Control vs Primrose -2 to 0.22 p= 0.15
Control vs Fish 1.2 to 3.4 p= 0.0006*
Control vs Olive -0.9 to 1.5 p= 0.66
DA rats
Control vs Primrose -2.1 to 0.3 p= 0.053
Control vs Fish 0.75 to 1.6 p= 0.00002
Control vs Olive -1.1 to 0.5 p= 0.37
Twosample t  test
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2.2.3.6 Renin a s s a y
Over the course of the study, six separate renin assays were performed: standard 
curve data is shown in Table 2.2.3.11 and illustrated in Figure 2.2.3.11. Renin levels 
in glomerular supernatants of Lewis and DA rats were derived from the difference 
between standard incubation (15 minutes) and zero-time values tabulated in Tables 
2.2.3.11(a) and 2.2.3.11(b).
Figure 2.2.3.11(a) shows that, as in the previous study (section 2.1.3.5), glomerular 
renin levels in Lewis rats were significantly higher than those of DA rats in the 
control and all the PUFA diet groups [Lewis vs DA: CD: median 469 (range 145 - 
911) vs 44 (12 - 80) pg AI per hour per mg glomerular protein, EPO: 1740 (327 - 
3126) vs 155 (74 - 485), FO: 844 (427 - 9880) vs 265 (190 - 450), OO: 1056 (736 - 
2424) vs 230 (118 - 556); see Table 2.2.3.11c for corresponding confidence intervals 
and significance levels]. However, in contrast to the previous study, glomerular renin 
levels were significantly higher in all the PUFA diet groups relative to controls (see 
Table 2.2.3.11c).
Plasma renin levels were derived from the difference between standard incubation 
(15 minutes) and zero-time values (Tables 2.2.3.11d and 2.2.3.lie ) . There were no 
statistically significant interstrain differences in plasma renin levels in any of the diet 
groups (Figure 2.2.3.11b) [Lewis vs DA: CD: median 149 (range 55 - 213) vs 230 
(25 - 589) pg AI per hour, EPO: 102 (36 - 152) vs 125.5 (29 - 207), FO: 89.5 (62 - 
252) vs 123.5 (30 - 220), OO: 134.5 (48 - 232) vs 135.5 (94 - 233); see Table 
2.2.3.I l f  for corresponding confidence intervals and significance levels].
None of the PUFA diets had any marked effect on plasma renin levels in Lewis rats 
but in DA rats, plasma renin levels were lowered significantly in the evening 
primrose and fish oil diet groups (see Table 2.2.3.1 If).
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Table 2.2.3.11c Glomerular renin concentration -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control 163 to 558 p= 0.0004*
Primrose 919 to 2074 p= 0.0002*
Fish 237 to 1094 p= 0.0008*
Olive 618 to 1099 p= 0.0003*
Lewis rats
Control vs Primrose -1973 to -629 p= 0.0017*
Control vs Fish -1066 to -88 p= 0.02*
Control vs Olive -1073 to -455 p= 0.0005*
DA rats
Control vs Primrose -191 to -56 p= 0.0004*
Control vs Fish -376 to -151 p= 0.0003*
Control vs Olive -401 t o -150 p= 0.0004*
Mann-Whitney Confidence Interval and Test
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Table 2.2.3.1 If Plasma renin concentration -  s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -154 to 10 p= 0.10
Primrose -69 to 23 p= 0.19
Fish -57 to 47 p= 0.79
Olive -71 to 37 p= 0.85
Lewis rats
Control vs Primrose -18 to 97 p= 0.16
Control vs Fish -17 to 107 p= 0.21
Control vs Olive -60 to 63 P= 1
DA rats
Control vs Primrose 16 to 168 p= 0.026*
Control vs Fish 16 to 193 p= 0.02*
Control vs Olive -18 to 130 p= 0.14
Mann-Whitney Confidence Interval and Test
2.2.4 Discussion
It was disappointing - but not surprising - that the fall in proteinuria in the PUFA diet 
groups was not so marked and did not attain the same degree of statistical 
significance in this, as in the previous study, being lowered significantly only in the 
fish and olive oil diet groups in Lewis rats and in the evening primrose oil group in 
DA rats. Single urine protein measurements are notoriously unreliable because of a 
high degree of intra-individual variability (Feldt-Rasmussen and Mathiesen, 1984, 
Hutchison and O'Reilly, 1985; Johnston et al, 1993). Ideally, urine protein levels 
would have been monitored more frequently to establish both a normal range and the 
extent of intraindividual variation but this was neither practicable nor possible due to 
number of experimental animals, utilisation of metabolic cages and manpower 
limitations.
Figures 2.2.3.7(a) and 2.2.3.7(b) show the pattern of albumin excretion in Lewis and 
DA rats between weeks three and six in the control and evening primrose oil diet 
groups. In Lewis rats, urine albumin levels were higher and a larger proportion were 
rising more steeply in the control than evening primrose oil diet group; in DA rats, 
the levels of albumin excretion were lower than in Lewis rats and the fall was more 
pronounced in the evening primrose oil diet group than control diet group. Despite 
the initial intention, it became difficult to accommodate measurement of both urine 
protein and albumin levels at three and six weeks, within the study protocol because 
the urine samples had to be de-salted - a procedure which could take up to thirty 
minutes per sample - prior to immunoturbidimetry: time constraints prevented 
measurement of the three week fish and olive oil samples. Because of the staggered 
diet regimes, each experimental group of twenty rats (10 Lewis and 10 DA) is a at 
different stage and in any one week, one group may have to be put into metabolic 
cages and monitored while another has to be culled, their kidneys removed and 
glomeruli harvested by sieving (see Table 2.2.2.1). In addition, blood and tissue 
samples must be collected, labelled, stored and/or processed and control and PUFA 
diets prepared as required. For a solitary worker, the practical problems associated 
with studies of this kind are substantial.
Despite the inability to reproduce the fall in total protein excretion in all the PUFA 
diet groups, albumin excretion rates were lowered in both Lewis and DA rats in all 
the PUFA diet groups and while it is acknowledged as unwise to measure urine 
albumin following strenuous exercise or an acute fluid overload, all the rats were of 
the same sex (male), of comparable body weight and relatively inactive within the 
confines of the metabolic cages when urine was collected.
7 1
Again, as was seen in the preceding study, glomerular TxB2  levels were raised in 
Lewis compared to DA rats - but this time, only to a statistically significant extent in 
the control and olive oil diet groups. Glomerular TxB2  levels were reduced 
significantly in both rat strains in the fish oil diet group and were lowered in Lewis, 
but raised in DA rats in the evening primrose oil group. Olive oil had no effect on 
glomerular TxB2  levels in either strain of rat, as before. These findings raise the 
question of whether the slightly larger sample size makes these thromboxane results 
more accurate than those from the previous study.
A major reason for, in effect, repeating the previous study was to establish whether 
circulating, as well as glomerular levels of thromboxane (and renin) were raised. 
Although measurement of circulating thromboxane levels is not advocated because of 
artefactual synthesis related to blood sampling and coagulation, it has been customary 
to estimate serum thromboxane levels by measuring the capacity of platelets to 
generate TxB2  in blood allowed to clot for an hour at 37°C (McLaren, 1986). There 
appeared to be no difference in serum TxB2  levels between Lewis and DA rats in any 
of the diet groups and levels were lowered only in the fish oil diet group relative to 
controls: fish oil was the only diet to have any effect on both glomerular and serum 
thromboxane levels in both strains of rat. It is very likely, however, that the inability 
to detect any difference in serum TxB2  levels between the groups is because the 
levels are close to the upper detection limit of the assay: serum samples could perhaps 
have been diluted a further ten, or even hundred fold. It had been anticipated that 
thromboxane levels would be high after the 30 minute incubation period but one 
drawback of using commercial assay kits is that they do not afford the luxury of 
protracted testing to establish the optimal dilution factor. Measurement of alternative 
TxB2  metabolites such as 11 dehydro- TxB2  found in both blood and urine, or 2, 3 
dinor TxB2  which predominates in urine and is highly reflective of platelet TxB2  
might have been more appropriate but the facilities to measure these metabolites were 
not readily available. Although blood was withdrawn into prostaglandin anti­
coagulant (section 2.2.2.3), plasma prostanoid levels were never measured. Few 
problems were encountered with the cardiac puncture procedure but any samples in 
which clotting was suspected, were discarded.
Renin levels too, were again raised in glomerular supernatants of Lewis rats 
compared to DA rats, but in contrast to the previous results, in which PUFA diets had 
no effect on renin levels in either rat strain, glomerular renin levels were raised in all 
the PUFA diet groups in both strains of rat It was notable that Lewis rat glomerular 
supernatants required dilution prior to assay whereas those from DA rats did not.
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Raised glomerular renin levels in association with apparently lowered rates of 
albumin excretion in the PUFA diet groups was unexpected.
Renin levels were measured in plasma containing prostaglandin anticoagulant and 
while median plasma renin levels are higher in DA than Lewis rats, the differences do 
not reach statistical significance. The suggestion that plasma renin levels are raised 
in DA rats compared to Lewis rats with raised glomerular renin levels, may indicate 
that renin is trapped within the Lewis rat glomerulus. Renin zero-time values too, 
which relate to endogenous activation, appear to be higher in the glomerular 
supernatants of Lewis rats compared to DA rats (Table 2.2.3.11b), particularly in the 
evening primrose oil diet group (Table 2.2.3.11a) but the amount and distribution of 
the data makes it difficult to analyse and interpret. There were no obvious 
differences in plasma renin zero-time values between Lewis (Table 2.2.3.l id )  and 
DA (Table 2.2.3.l i e )  rats. That no significant differences in plasma renin activity 
were observed either between Lewis and DA rats within any diet group or within 
either strain in any of the PUFA diets groups suggests that the increased glomerular 
renin activity in Lewis rats is indeed localised.
Renin results are most meaningful when related to sodium balance and blood pressure 
but neither parameter was measured in this or the previous study. Renin production 
is inversely proportional to sodium intake and affected by dietary protein (Paller and 
Hostetter, 1986; Rosenberg et al, 1987). Although dietary protein and sodium intake 
were not measured directly, overall, there was no difference in food consumption 
between Lewis and DA rats (see Table 2.2.3.2).
Even within the normal human kidney, there is a large degree of nephron 
heterogeneity with respect to renin synthesis and storage. Histological studies have 
shown that not all nephrons produce renin and that superficial nephrons may store 
more than deeper nephrons (Taugner et al, 1981; Gomez et al, 1988). Although renin 
is synthesised and stored in the JGA, the raised glomerular renin levels in Lewis rat 
glomerular supernatants may be explained by (i) an increased number of renin- 
secreting glomeruli, (ii) increased rates of renin synthesis and secretion or (iii) the 
glomerulus itself becoming an alternative site of renin synthesis either in relation to 
renin-containing cells migrating from the afferent arteriole into glomerular tuft or 
native glomerular cells such as mesangial cells starting to produce renin. Using the 
same glomerular sieving procedure as in this study, Rosenberg et al (1991) showed 
that compared to adriamycin nephrosis (ADR) rats, in which neither glomerular nor 
circulating renin levels were raised, in rats with reduced renal mass, glomerular renin 
levels were raised while circulating levels were unchanged. Evidence of increased 
glomerular renin was reinforced by immunofluorescence staining and increased
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transcription of messenger RNA although neither parameter was heightened in ADR 
rats (Rosenberg et al, 1993). The explanation for the increased renin levels in Lewis 
rat glomeruli might be that they store more renin which is released by the sieving 
procedure. It should be noted that there was no difference between Lewis and DA 
rats, in the number of glomeruli with attached or detached afferent arterioles (section 
2 . 1 .3.2).
Other issues to consider are that renin levels are not a good marker of the biological 
effects of AD since angiotensinogen can be cleaved by other means. Also, there is a 
storage pool of both active and inactive renin in the kidney and as much as 50% may 
be inactive. Not all procedures to measure renin necessarily reflect true amounts of 
active renin - although the method used in this study measured active renin: to have 
measured total renin would have involved trypsin activation of the samples.
It is unclear whether the heightened levels of both glomerular TxB2  and renin in 
Lewis rats are independent or related events but concomitant rises in thromboxane 
and renin levels are common (Shibouta et al, 1979; Podjamy et al, 1986; Lefkowith 
et al, 1987). The two kidney-one clip rat model of renovascular hypertension (Stahl 
et al, 1984a) and the hydronephrotic, ureter-obstructed kidney (Purkerson et al, 1986; 
Yanagasawa et al, 1990) are characterised by increased glomerular levels and urinary 
excretion of TxB2  and renin. It has been shown that A ll releases thromboxane within 
the kidney and that thromboxane may mediate the vascular effects of A ll within the 
normal rat glomerulus (Welch and Wilcox, 1990, Wilcox et al, 1991).
The nature of the link between elevated thromboxane and renin levels in the 
glomeruli of Lewis rats remains unclear. A possible explanation is that either a fall in 
glomerular blood flow, or platelet aggregation and a subsequent increase in plasma 
viscosity induced by thromboxane, may be detected by cells in the JGA and renin 
released in response. Alternatively, renin may elevate thromboxane levels through 
angiotensin II-mediated hydrolysis of membrane phospholipids (Luft et al, 1989; 
Welch et al, 1990; Mistry et al, 1990). Other explanations for raised thromboxane 
levels are discussed in section 2.1.4.
Studies centred around dietary manipulations are often difficult to interpret because 
of problems in regulating and standardising food intake. Glomerular filtration can be 
influenced by both protein and calorie intake (Klahr and Alleyne, 1973; Ichikawa et 
al, 1980; 1985, Tapp et al, 1989; Woods, 1993) and so a reduction in either dietary 
parameter could contribute to the fall in AER in experimental PUFA-fed rats. 
However, it has been reported that changes in dietary protein intake have no effect on 
urine albumin levels (Soiling et al, 1986). The fall in albumin excretion in this and
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the previous study, is unlikely to be linked to a reduced dietary protein or calorie 
intake or a resultant fall in body weight since the protein content of the control and 
PUFA diets was similar (see Table 2.1.2.1) and rats fed PUFA diets did not consume 
less than rats fed control diet. Although the initial calorie content of both the 
standard pellet and fat-deficient diets were similar, it is inevitable that the addition of 
the oils to the fat-deficient diet would raise the calorie content of the PUFA diets 
relative to the control diet; a reduced calorie intake is therefore unlikely to explain the 
fall in albumin excretion in PUFA-fed rats. Even had the PUFA-fed rats consumed 
significantly less food, the higher calorie content of the PUFA diets should 
compensate for any calorie deficit. Furthermore, if there is a link between increased 
calorie intake and proteinuria it might have been evident in the experimental PUFA 
diet groups. Dietary components other than the oils themselves are unlikely to have 
accounted for the fall in AER. Neither does the fall in AER correlate with changes in 
body weight: the absence of a fall in body weight, similar to that observed at two 
weeks in all the diet groups in previous study, and the greater increase in body weight 
may be related to the rats in this study having a lower body weight at the outset. 
Urine creatinine levels in Lewis rats reflected their greater body weight relative to 
DA rats but PUFA diets had no effect on urine creatinine levels in either strain of rat.
It is interesting that olive oil, as a UFA control with attenuated prostanoid activity, 
was as effective as the other oils in lowering urine albumin levels despite no change 
in glomerular prostanoids and renin levels.
Summary
It is impossible to state with conviction, at the end of this study, that PUFA diets 
lower albumin excretion rate although there is certainly little evidence of urine 
albumin levels being raised in the PUFA diet groups. There is some suggestion that 
the anti-proteinuric effects of PUFA diets are more pronounced in Lewis rats than DA 
rats.
Despite some discrepancies between this and the previous study, glomerular TxB2  
and renin levels in vitro appear to be raised in Lewis compared to DA rats. 
Notwithstanding some doubts about the accuracy of the serum thromboxane results, 
elevated TxB2  and renin levels seem to be confined to the glomerulus since their 
circulating levels were not raised. The functional significance of raised glomerular 
TxB2  and renin levels in Lewis rats is unclear but may be linked to their reportedly 
higher levels of proteinuria and heightened susceptibility to various forms of 
glomerular injury.
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PUFA diet-induced changes in glomerular or systemic thromboxane or renin levels 
did not correlate with the fall in albumin excretion rate in Lewis and DA rats. That a 
PUFA diet-induced fall in intraglomerular pressure (Pgc) was responsible for the fall 
in AER is not compatible with the pattern of glomerular thromboxane or renin 
production.
It is unlikely that factors such as restricted calorie or protein intake or differences in 
body weight account for the fall in albumin excretion rate in both rat strains.
The possibility that glomerular thromboxane and renin levels are depressed in DA 
rats, rather than raised in Lewis rats, should not be overlooked .
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PUFA DIETS and GLOMERULAR CAPILLARY WALL CHARGE Section 2.3
2.3.1 In tro d u c tio n  a n d  e x p e r im e n ta l  d e s ig n
Experimental data from the two previous studies suggests that changes in glomerular 
or circulating prostanoid or renin levels do not contribute to the apparent fall in the 
albumin excretion in healthy Lewis and DA rats fed PUFA diets. It was decided 
therefore, that other aspects of PUFA function such as their incorporation into the 
lipid bilayer of glomerular cell membranes should be explored (see section 1.3.6). 
Manipulation of the fatty acid content of glomerular membrane phospholipids by 
PUFA diets might alter the magnitude of the intrinsic negative charge on the 
glomerular capillary wall by altering the linkage to, and expression of glycoproteins 
on the cell surface.
The glomerular capillary wall controls the passage of albumin from the plasma into 
the glomerular ultrafiltrate in relation to its ability to discriminate amongst molecules 
on the basis of their size, electrostatic charge and shape (see section 1.2). Within the 
three-layered sandwich structure of the GCW, the endothelial and epithelial cell 
layers are separated by the non-cellular glycoprotein gel matrix of the glomerular 
basement membrane (GBM). The effective negative charge (or polyanion) on the 
GCW which repels anionic circulating proteins such as albumin, is derived from 
charged moieties in all three layers of the glomerular capillary wall.
Experimental design
The hypothesis underlying this study was that the trend towards lowered rates of 
urinary albumin excretion observed in Lewis and DA rats fed PUFA diets in the 
previous studies was the result of heightened glomerular capillary wall charge in rats 
fed PUFA diets. Quantifying the charge on the glomerular capillary wall is made 
difficult by the heterogeneous nature of the charged molecules which comprise the 
polyanion and their ubiquity in all three layers of the GCW. Using the same dietary 
regime and experimental design as in the two preceding studies, the effects of PUFA 
diets on the glomerular polyanion were assessed by measuring the uptake of 
radiolabelled cationic (+) human IgG by the glomeruli of Lewis and DA rats. Uptake 
of cationic IgG by whole spleen was also measured.
2.3.2 A nim als, m a te ria ls  a n d  m e th o d s
It is important to establish a dose of labelled cationic protein ( 1 2 5 I-IgG+) that is high 
enough to detect a difference in GCW charge but not so high as to overwhelm the 
glomerulus. Before beginning the study proper, therefore, a small preliminary study 
was performed to determine the dose of 1 2 5 I-IgG+ necessary for optimal detection of 
glomerular uptake.
Two groups of 5 Lewis and 5 DA rats fed evening primrose oil diet were given either 
1 or 5 mg of 1 2 5 I-IgG+ and similarly, one group of 5 Lewis and 5 DA rats fed control 
diet were given 5 mg of 1 2 5I-IgG+. The methods used to cationise and radiolabel IgG 
are described in sections 2.3.2.1 and 2.3.2.2.
Incorporation of the results from this pilot study explains the larger number of Lewis 
and DA rats in the control diet groups in the main study.
Main study
Four groups of 10 Lewis rats and four groups of 10 DA rats (n = 80) ranging between 
200 and 225 grams in weight at the start of the study, were fed either standard 
laboratory diet, evening primrose oil diet, fish oil diet or olive oil diet for six weeks 
(see section 2.1.2.1). At three and six weeks, the rats were put into metabolic cages 
and at the end of six weeks, seven or eight rats in each diet group were given an 
intravenous bolus injection of 5 mgs of 1 2 5 I-IgG+ and the remainder were given an 
equivalent dose of radiolabelled native IgG (^-IgG N ) to assess the extent of non­
specific binding to the glomerular capillary wall. Each animal was killed fifteen 
minutes after injection of label, the kidneys were removed (without saline perfusion 
because of the high levels of radioactivity) and the glomeruli were recovered by 
sequential sieving as described in section 2.1.2.5. The protein content of the 
glomerular pellets was measured by the Lowry protein assay (see section 2.1.2.7) and 
the amount of radioactivity accumulated by isolated glomeruli and whole spleen was 
measured in a gamma counter. A small sample of renal cortex was removed for 
immunofluorescence.
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2.3.2.1 P rep ara tio n  of n a tiv e  a n d  c a tio n ic  IgG
Native IgG Human immunoglobulin G (Sigma Chemical Company: I-
4506) reconstituted to 50 mg per ml in PBS.
Cationic IgG
IgG was cationised by activation of the carboxyl groups with carbodiimide (EDC) 
followed by nucleophilic attack with the base 3-dimethylaminopropylamine (DMPA). 
Cationisation takes place in a protein modification buffer (Buffer A, pH 5.5) prepared 
by dissolving 3.28 g ^/-sodium hydrogen phosphate and 8.77 g sodium chloride in 
just under 1 litre distilled deionised water then lowering the pH to 5.5 with HC1. The 
same buffer was used to prepare the following solutions.
Human IgG 50 mgs of human IgG (as above) were dissolved in 0.5 mis of
Buffer A and heated in a warm oven (» 37°C) to dissolve, if 
necessary.
EDC 30 mgs l-ethyl-3-(3-dimethyl-amino-propryl)-carbodiimide
hydrochloride (EDC: Sigma Chemical Company: E-7750) in 
500 Jills of Buffer A.
IgG and EDC solution were mixed together in a small tube and then 20 pis of the free 
base, DMPA added. DMPA must be removed from the preparation by five one hour 
dialyses against two litres of cold (4°C) PBS (pH 7.2-7.4). [Ten litres of PBS were 
prepared using sodium chloride ( 8  g/1), potassium dihydrogen phosphate (0.34 g/1) 
and ^/-potassium hydrogen phosphate ( 1 . 2  g/1)].
The initial pH of the IgG+ solution when tested using a pH strip (Sigma Chemical 
Company: P-4536) was greater than 10 but had fallen to 7 (in PBS) by the end of 
dialysis.
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2.3.2.2 R adio iod ina tion  of na tiv e  a n d  c a tio n ic  IgG
The following stock solutions were prepared for iodination of IgG (native and 
cationic):
IgG (native or cationic) 50 mgs per ml in PBS
Iodine monochloride IC1 at 25 nmols per pi in IN NaCl. Molar ratio of
iodine monochloride to protein = 2.5 : 1
Glycine buffer 250 pis of 1M Glycine buffer, pH 10, per ml of protein.
(7.51 g glycine in 100 mis deionised water: adjust pH to 
10.
Iodine-125 125-Iodine - 10 pis = 37 MBq s  1  mCi (Amersham
International pic: IMS 30)
250 pis of glycine buffer was added to 1 ml of cationic or native IgG in a 5 ml tube 
with snap-on cap (Sarstedt) and 31.25 pis of IC1 pipetted into the cap. 10 pis of 125- 
Iodine was added to the contents of the tube before replacing the cap (containing the 
iodine monochloride) carefully and mixing the contents by inversion. Free 125-Iodine 
was removed from the preparation by dialysis for 1  hour, five times, against two litres 
of cold (4°C) PBS (prepared as in the previous section).
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2.3.2.3 Iso e lec tric  focusing
Isoelectric focusing (IEF) was used to confirm the cationisation of IgG. 15 jxls of 
native and cationic human IgG and 20 jxls of IEF reference markers (Isoelectric 
focusing calibration kit from Pharmacia Biotech: Code no 17-0471-01) were run in an 
AmpholineR PAGplate, pH 3.5 - 9.5 polyacrylamide gel plate (Pharmacia Biotech: 
Code no 80-1124-80) on an Multiphor 2117 (LKB) electrophoresis unit. 1M H3 P 0 4  
was used as the anolyte and 0.1 M sodium hydroxide as the catholyte solution. 
Samples were placed 6.67 cm from the cathode and power was supplied at 750V and 
current at 25mA for 1 hour from a power pack (LKB 2301 Macrodrive 1).
The gel was stained using the following solutions for the stated times:
Fixing solution 29 g trichloroacetic acid and 8.5 g sulphosalicylic acid
in 250 mis distilled water - 30 minutes.
Destaining solution 500 mis ethanol and 160 mis acetic acid made up to 2 
litres with distilled water - 30 minutes.
Staining solution 0.1% Coomassie Blue G-250 in aqueous solution of 
25% methanol, 5% acetic acid (w,v,v,v) - 1 0 -2 0  
minutes.
Preserving solution 25 mis glycerol made up to 250 mis with destaining
solution. Change solution as required and leave until 
gel is clear.
The gel was dried overnight at room temperature.
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2.3.2.4 S urg ical p ro c e d u re : adm in istra tion  of IgG
Three syringes (1 ml) were labelled and primed with anaesthetic, saline or cationic or 
native 1 2 5 I-IgG at 5 mgs per 100 pis. Each rat was anaesthetised by an intraperitoneal 
injection of Sagatal and an endotracheal tube inserted. The jugular vein was exposed 
by blunt dissection and cannulated first, with the anaesthetic line and then the saline 
line. Each cannula was constructed from syringes fitted with a 23 guage needle 
attached to a length of PE 50 polyethylene tubing (see section 2.1.2.4).
To introduce 1 2 5 I-IgG+, the saline line was clamped and the syringe removed and 
exchanged for one containing radiolabelled native or cationic IgG. After the contents 
of the syringe had been expelled, the saline syringe was re-attached and 1 0 0  |ils of 
saline flushed through slowly to wash out the line. After fifteen minutes, the animal 
was killed by an overdose of Sagatal via the anaesthetic line. The kidneys and spleen 
were removed and placed in ice cold PBS; the weight of both kidneys and the spleen 
were recorded and a sample of cortical tissue was snap-frozen immediately for 
immunofluorescence (see following section).
The glomeruli were recovered from both kidneys of each rat by sieving as described 
in section 2.1.2.5 and resuspended in a final volume of 2 mis of Hartmanns solution 
(Baxter Healthcare). The quantity of radioactivity in the glomerular suspension and 
intact spleens was measured in a gamma counter (Packard). A 1 2 5I-IgG reference 
standard equivalent to 500 pgs of IgG was prepared by adding 10 pis of radiolabelled 
native IgG (50 mg per ml) to 990 pis of saline and counted with glomeruli and spleen 
each day to compensate for radioactive decay. The amount of 1 2 5I-IgG taken up by 
the glomeruli and spleen was expressed per mg of glomerular protein or wet spleen 
weight, respectively. The protein content of the glomerular pellet was measured by 
the Lowry method (see section 2.1.2.7).
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2.3.2.5 Im m u n o flu o re scen ce  stain ing  a n d  m ic ro sco p y
To prepare the antiserum, fluorescein isothiocyanate (FITC) conjugated sheep anti­
human IgG (Scottish Antibody Production Unit, Law Hospital, Carluke, ML8  5ES) 
was reconstituted as directed. 200 mgs of mouse liver powder (Cappel Laboratories: 
Cat no 20311) was washed with 2 mis of PBS, centrifuged at 1000 g for 5 minutes 
and the supernatant discarded. To minimise non-specific tissue binding, the 
antiserum was mixed with the washed liver powder for 1  hour at room temperature 
and then centrifuged twice at lOOOg for 5 minutes and dispensed into 10 pis volumes 
and stored at -20°C.
Antiserum was titrated and checked for specificity and the optimal conjugate dilution 
was determined by the immunofluorescence chessboard titration method and diluted 
1:160, 1:320 and 1:640 with saline. Serial dilutions of a positive control serum with 
an identified pattern and end-point were tested with a series of conjugate dilutions. A 
negative serum and buffer control were tested simultaneously.
Tissue was prepared for immunofluorescence by immersing 3-5 mm pieces of fresh 
rat kidney cortex in gelatine capsules, filled with embedding medium for frozen 
tissue sections (Tissue-Tek; Miles Scientific). The capsules were snap frozen 
immediately by floating them in a mixture of methanol and dry ice (solid CO2) and 
then stored in a sealed container at -70°C.
Frozen sections ( 4 - 6  pm) were cut on a cryostat (Slee) and air-dried for 30 minutes 
at room temperature. The slides were washed twice in PBS for 10 minutes, on a 
shaker, prior to fixing in an ice-cold mixture of ether and alcohol (50: 50) for 10 
minutes, to precipitate proteins. With the apparatus on ice, the tissue was fixed in 
95% alcohol for 20 minutes and then washed three times in PBS, for 5 minutes each 
time. After drying, the sections were kept in a moist chamber. Antiserum diluted 1: 
320 was dropped on to the sections which were then incubated for 30 minutes at room 
temperature. Sections from control kidneys were stained at the same time. The slides 
were washed three times in PBS each time for 7 minutes, mounted in Citifluor and 
then stored in the dark at 4°C. The sections were examined under a fluorescence 
microscope (Leitz) and scored subjectively on a scale of + /  ++++.
2.3.3 Results
2.3.3.1 I so e le c tr ic  fo c u s in g
An isoelectric focusing gel illustrating the cationisation of IgG is shown in Plate 
2.3.1. Lanes 1, 6  and 11 represent the IEF marker proteins [trypsinogen (pi 9.3), 
lentil lectin - basic band (pi = 8.65), lentil lectin - middle band (pi = 8.45), lentil 
lectin - acidic band (pi = 8.15), myoglobin - basic band (pi = 7.35), myoglobin - 
acidic band (pi = 6.85), human carbonic anhydrase p, pi = 6.55), bovine carbonic 
anhydrase P (pi = 5.85), P lactoglobulin A (pi = 5.2), soybean trypsin inhibitor (pi - 
4.55) and amyloglucosidase (pi = 3.5). Lanes 2, 4, 8 , and 9 contain cationic (+) IgG 
and lanes 3, 5, 7 and 10 contain native IgG.
Cationic (+) IgG exhibited bands ranging between * 8.45 and 9 whereas native IgG 
displayed bands between « 6.85 and 8.55.
2.3 .3 .2  Im m u n o f lu o re s c e n c e  m ic ro s c o p y
Immunofluorescence was used to illustrate the distribution of 1 2 5I-IgG+ deposited 
within the glomerular capillary loops of Lewis and DA rats. There was a perceptible, 
but not remarkable difference in glomerular uptake of 1 2 5  I-IgG+ between the two 
strains in the control and PUFA diet groups but differences in glomerular uptake 
between the diet groups within either strain were not discernible. Differences in 
glomerular uptake of 1 2 5I-IgG+ between Lewis and DA rats fed control diet are shown 
in Plate 2.3.2.
2 .3 .3 .3  D o s e - d e p e n d a n c y  s tu d y
The results showed a difference in glomerular uptake of 1 2 5I-IgG+ between Lewis and 
DA rats with DA rats taking up more than Lewis rats, irrespective of diet or IgG dose 
[CD: Lewis (5 mg): median 22 (range 18 - 24) vs DA: 18 (14 - 21) p,gs 1 2 5I-IgG+ per 
mg glomerular protein, p = 0.056, EPO (5 mg): Lewis: 30 (28 - 33) vs DA: 20 (19 - 
22), p = 0.02, EPO (1 mg): Lewis: 13 (11 - 19) vs DA: 8.5 ( 8  - 11), p = 0.016: see 
Figure 2.2.3.1]. The lack of a statistically significant difference between the strains in 
the control diet group given 5 mg of l2 5 I-IgG+ may relate to sample size but the 
decision to use 1 2 5I-IgG+ at a dose of 5 mg the main study was based upon the more 
marked distinction between the strains in the evening primrose oil diet group. 
Measurement of the glomerular uptake of 1 mg IgG+ in the control diet group was 
omitted because of time and numbers.
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Plate 2.3.1 Isoelectric focusing of cationic and native human IgG 
(see section 2.3.3.1 for details)
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2.3.3.4 A lbum in ex c re tio n  ra te
Figure 2.3.3.2 shows that albumin excretion rate was significantly higher in Lewis 
than DA rats only in the evening primrose oil diet group [Lewis vs DA: CD: 3.54 
(range 0.13 - 11.34) vs 0.392 (0.103 - 1.7) mg per 24 hrs, EPO: 0.156 (0.102 - 0.752) 
vs 0.1 (0.057 - 0.15), FO: 0.206 (0.13 - 0.32) vs 0.232 (0.18 - 0.64), OO: 0.165 (0.058 
- 1.26) vs 0.102 (0.05 - 0.238); see Table 2.3.3.2 for corresponding confidence 
intervals and significance levels]
In both strains of rat, AER was lowered significantly in both the primrose and olive 
oil diet groups [Lewis: CD: 3.54 vs (i) EPO: 0.155 mg per 24 hrs, (ii) OO: 0.165 mg 
per 24 hrs; DA: CD 0.392 vs (i) EPO: 0.098 mg per 24 hours, (ii) OO: 0.102 mg per 
24 hours; see Table 2.3.3.2 for corresponding confidence intervals and significance 
levels]. AER was unchanged in both Lewis and DA rats in the fish oil diet group.
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Table 2.3.3.2 Albumin excretion rate a t six w eeks -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Lewis vs DA rats
Control -0.07 to 7.2 p= 0.09
Primrose 0.02 to 0.11 p= 0.0028*
Fish -0.1 to 0.07 p= 0.51
Olive -0.01 to 0.3 p= 0.29
Lewis rats
Control vs Primrose 0.004 to 7.5 p= 0.025*
Control vs Fish -0.05 to 7.8 p= 0.13
Control vs Olive 0.017 to 7.5 p= 0.03*
DA rats
Control vs Primrose 0.02 to 0.5 p= 0.0025*
Control vs Fish -0.11 to 0.39 p= 0.67
Control vs Olive 0.03 to 0.55 p= 0.013*
Mann Whitney Confidence Interval and Test
2.3 .3 .5  G lo m e ru la r  u p ta k e  o f 125l-lg G +
The protein content of the glomerular pellets are shown in Table 2.2.3.1. (The group 
mean was used to replace any missing data points).
Significantly more 1 2 5I-IgG+ was taken up by the glomeruli of DA rats than Lewis 
rats in the control and all the experimental PUFA diet groups (Figure 2.3.3.3); [Lewis 
vs DA: CD: median 18.5 (14 - 27) vs 22 (range 17 - 30) pgs 1 2 5 I-IgG+ per mg of 
glomerular protein, EPO: 18.5 (15 - 22) vs 28 (19 - 33), FO: 16 (14 - 17) vs 18.5 (16 - 
21), OO: 16 (13 - 19) vs 20 (19 - 23); see Table 2.2.3.2 for corresponding confidence 
intervals and significance levels].
In Lewis rats, glomerular uptake of 1 2 5 I-IgG+ was unaffected in the evening primrose 
oil group but was significantly reduced in the fish and olive oil diet groups [Lewis 
CD: 18.5 (14 - 27) vs (i) FO: 16 (14 - 17) pgs 1 2 5 I-IgG+ per mg of glomerular protein,
(ii) OO: 16 ( 13 - 19 )  pgs 1 2 5 I-IgG+ per mg of glomerular protein]. In DA rats, neither 
evening primrose oil nor olive oil diet had any effect on glomerular 1 2 5I-IgG+ uptake 
but glomerular uptake was reduced significantly in the fish oil group [DA: CD: 22 
(range 17 - 30) vs FO: 18.5 (16 - 21) pgs 1 2 5I-IgG+ per mg of glomerular protein; see 
Table 2.2.3.2 for corresponding confidence intervals and significance levels].
Uptake of native human IgG was regarded as being low enough to be discounted.
2.3 .3 .6  S p le n ic  u p ta k e  o f 125l-lg G +
Splenic uptake of 1 2 5I-IgG+ was also significantly greater in DA rats than Lewis rats 
in all the diet groups [Lewis vs DA: CD: median 190 (132 - 260) vs 304.5 (18. - 494) 
pgs per gram of spleen, EPO: 260 (246 - 295) vs 409 (311 - 456), FO: 299 (263 - 
330) vs 408 (269 - 503), OO: 205 (151 - 277) vs 360 (178 - 456); see Figure 2.3.3.4 
and Table 2.3.3.4 for corresponding confidence intervals and significance levels].
In Lewis rats, splenic uptake of 1 2 5I-IgG+ was significantly higher in the evening 
primrose and fish oil diet groups than control diet group [Lewis: CD: 190 (132 - 260) 
vs (i) EPO: 260 (246 - 295) pgs per gram of spleen, (ii) FO: 299 (263 - 330) pgs per 
gram of spleen]. There is a suggestion that splenic uptake of 1 2 5I-IgG+ may be raised 
in the evening primrose and fish oil diet groups which did not reach statistical 
significance; see Table 2.3.3.4 for corresponding confidence intervals and 
significance levels.
Splenic uptake of native IgG also was low enough to be discounted.
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Table 2.3.3.3 Glomerular up take of 125l-lgG+ -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Lewis vs DA rats
Control -6 to -2 p= 0.0035*
Primrose -11 to -3 p= 0.0037*
Fish -5 to -1 p= 0.01*
Olive -7 to -2 p= 0.003*
Lewis rats
Control vs Primrose -2 to 3 P= 1
Control vs Fish 0.9 to 5 p= 0.009*
Control vs Olive 1 to 5 p= 0.02*
DA rats
Control vs Primrose -8 to 1 p= 0.13
Control vs Fish 2 to 6 p= 0.004*
Control vs Olive -1 to 4 p= 0.19
Mann Whitney Confidence Interval and Test
009
0) O
2 V)
_D>
W as <D>
$ < Ctf
— I O Z
• □ •
□ □ □ □
• • • •
m  □
M l*
OOoin
oo o oo
CM
OO
CO
0_>
b
</>
Ll
0
0O
E
CL
C
o
O
(ueajds 6 jed 6n) 961 gg |.-|
Fi
gu
re 
2.3
.3.
4 
Sp
le
ni
c 
up
ta
ke
 
of 
lg
G
(+
) 
in 
Le
wi
s 
an
d 
DA 
rat
s 
at 
six 
w
ee
ks
Table 2.3.3.4 Splenic uptake of 125l-lgG+ -  s t a t i s t i c a l  a n a l y s e s
95%
confidence significance
interval level
Lewis vs DA rats
Control -186 to  -51 p= 0.003*
Primrose -196 to  -51 p= 0.012*
Fish -173 to -32 p= 0.016*
Olive -224 to -2 p= 0.04*
Lewis rats
Control vs Primrose -109 to -31 p= 0.005*
Control vs Fish -140 to -70 p= 0.0013*
Control vs Olive -68 to 24 p= 0.35
DA rats
Control vs Primrose -163 to  31 p= 0.09
Control vs Fish -173 to  11 p= 0.08
Control vs Olive -130 to 107
coOIIQ.
Mann Whitney Confidence Interval and Test
2.3.4 Discussion
There are countless reports of diminished GCW charge in various glomerulopathies 
(see sections 1 .2 . 1  and 1 .2 .6 ) and it has been suggested that the inheritance of a 
diminished glomerular polyanion heightens susceptibility of animals and humans to 
progressive forms of renal disease (Boulton-Jones et al, 1986, Deckert et al, 1989). 
The extent to which the filtration of an anionic protein like albumin is retarded while 
the clearance of cationic molecules is facilitated, is regarded as being proportional to 
the intensity of the negative charge on the glomerular capillary wall. The glomerular 
polyanion comprises negatively charged groups located in all three layers of the 
glomerular capillary wall (Szarfman et al, 1982, Timpl, 1986, Smith et al, 1989, 
Kobayashi et al, 1989, Wada et al, 1990). Through their incorporation into the 
membrane lipid bilayer, PUFAs may affect membrane fluidity and thus alter the 
topography of endogenous lipid domains and micro-domains and so influence the 
orientation and expression of anionic glycoproteins within glomerular cell 
membranes (see section 1.3.6). At the most fundamental level, PUFAs may intensify 
GCW charge through the introduction of additional carboxylate (COO-) groups on to 
the cell surface.
To date, there is no ideal technique to evaluate the magnitude of the negative charge 
on the glomerular capillary wall, principally, because the inherent heterogeneity of 
the component sialoglycoproteins and glycosaminoglycans makes it difficult to 
develop sensitive and specific immunological methods. Measuring the glomerular 
uptake of a radiolabelled cationic (+) protein such as IgG is the best method available 
currently, to reflect the intensity of the glomerular polyanion and should therefore 
correlate inversely with the rate of albumin excretion (Border et al, 1981, Oite et al, 
1982; 1985). It is imperative, when employing this sequestration method, to measure 
the uptake of an equivalent amount of the same radiolabelled protein in its native, 
unmodified form to establish the extent of its non-specific binding to the glomerular 
capillary wall (and to give some indication of glomerular blood flow). That the 
uptake of native 1 2 5I-IgGN was negligible in both strains of rat in this study, 
strengthens the hypothesis that the differences in uptake are due to differences in 
GCW charge.
The cationisation procedure resulted in not one, but several IEF bands ranging 
between * 8.45 and 9 which was higher than those of native IgG (« 6.85 - 8.55). 
Whether it is possible to attain electrophoretic homogeneity is unclear.
A sample of renal cortex was taken from each rat, for IF microscopy but it would 
have been impossible to cut sections from all eighty rats and so only three or four 
frozen sections from each strain within each diet group were processed. The
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differences in glomerular uptake of 1 2 5 I-IgG+ between the strains as assessed by 
immunofluorescence, were neither outstanding nor very enlightening and so did not 
warrant displaying photographs of all the data. Immunofluorescence could have been 
utilised to greater effect had time allowed.
Although the fall in albumin excretion in the PUFA diet groups did not reach the 
same degree of statistical significance as in the previous study (section 2.2), AER 
tended to be lower in both strains of rat in all the experimental PUFA diet groups. 
Figure 2.3.3.3 shows that DA rat glomeruli take up significantly more 1 2 5I-IgG+ than 
Lewis rat glomeruli in the control and all the experimental PUFA diet groups, but 
there is little evidence of a correlation between a PUFA diet-induced increase in 
GCW charge and fall in albumin excretion rate. The link between GCW charge and 
albumin excretion in this study may be tenuous when one considers that the 
significantly diminished glomerular uptake of 1 2 6 I-IgG+ in the fish oil diet groups in 
both Lewis and DA rats was not accompanied by any rise in albumin excretion. In 
general, PUFA diets tended to reduce glomerular uptake of cationic IgG (ie lower 
GCW charge) which one would expect to accompany a rise in the excretion rate of 
albumin.
It was interesting that the differences in glomerular uptake of 1 2 5 I-IgG+ between 
Lewis and DA rats were mirrored in the spleen. Both evening primrose and fish oil 
diets increased splenic uptake of 1 2 5 I-IgG+ to a statistically significant extent in Lewis 
rats and there is a suggestion that splenic uptake also, was raised in the same two diet 
groups in DA rats although but the results did not reach statistical significance. That 
the increased splenic uptake of 1 2 5 I-IgG+ occurred in the EPO and FO diet groups 
suggests that the effect might be prostanoid-related and could be linked to changes in 
blood flow.
It would be encouraging if the differences in glomerular uptake of 1 2 5 I-IgG+ between 
Lewis and DA rats were related to GCW charge, but if the lower splenic uptake of 
1 2 5 I-IgG+ in Lewis rats is also charge-mediated, it suggests a diminished charge on all 
tissue surfaces in Lewis rats relative to DA rats (Deckert et al, 1989). Such a global 
diminution of cell surface charge would surely have significant implications for a 
variety of intercellular interactions including those between platelets and the 
endothelium (Rogers et al, 1992).
Alternative explanations for the differences in uptake of 1 2 5 I-IgG+ between the strains 
include:
(i) Differences in reticuloendothelial uptake. Increased glomerular and splenic 
uptake in DA, compared to Lewis rats suggests diminished mesangial or splenic
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function in Lewis rats although the perfusion of native IgG (and IF) does preclude 
this to some extent. The effects of PUFA diets on glomerular or splenic blood flow 
are unknown. If the differences in glomerular uptake are related to mesangial 
function, DA rats may have an increased rate of mesangial uptake, but a slower rate 
of egress. Mesangial function can be assessed by measuring the uptake of chemical 
or heat aggregated IgG.
(ii) The delivery of 1 2 5 I-IgG+ to the glomerulus and spleen. The reduced glomerular 
uptake of 1 2 5 I-IgG+ in Lewis rats could be linked to vasoconstriction, coagulation and 
increased plasma viscosity and impaired mesangial function as a result of raised 
glomerular thromboxane and renin levels.
(iii) Differences in glomerular uptake of IgG (+) between Lewis and DA rats might 
be related to differences in the magnitude of the non-selective shunt pathway through 
which IgG can filter unimpeded (Tomlanovich et al, 1987). Were the GCW of Lewis 
rats to have a greater proportion of enlarged pores, more 1 2 5I-IgG+ might pass into the 
glomerular ultrafiltrate: DA rats, on the other hand, may have no such increase in 
pore size or number and so much of the 1 2 5 I-IgG+ remains trapped within the GCW. 
Withdrawal of urine directly from the bladder during surgery and subsequent 
measurement of 1 2 5 I-IgG+ levels might help to clarify this point. Such a hypothesis 
does not, however, help to explain differences in splenic uptake.
Further doubts about whether this technique measures the net charge on the 
glomerular capillary wall relate to:
(i) The size of the IgG molecule (Mr = 55A) in relation to the size of the GCW pores. 
IgG is of similar dimensions to the effective GCW pore diameter and so although IgG 
will pass through the endothelial fenestrae ( 1 0 0 A) with relative ease, it should be 
impeded increasingly by the GBM and epithelial slit diaphragms - although 
cationisation will facilitate its passage. Whether IgG is distributed evenly throughout 
all three layers of the GCW is unclear and only more sophisticated microscopy might 
elucidate this issue. Table 1 .2 . 1  shows that both cationic ferritin (61 A, pi > 8 ) and 
catalase (52A, pi 5.7) are impeded at the level of the GBM and slit diaphragm. 
Perhaps the use of a smaller cationic molecule such as lactoperoxidase (38A, pi 8 ) or 
cationised albumin, might pinpoint anionic charges within the GCW more accurately.
(ii) The use of a cationic molecule to locate anionic sites within the glomerular 
capillary wall may neutralise the glomerular polyanion to some extent and thus 
impair the normal permselective properties of the GCW (Purtell et al, 1979).
(iii) The effects of cationisation and radioiodination on the physico-chemical 
characteristics of the IgG molecule are not entirely clear.
It has been reported that four weeks of PUFA diet supplementation is sufficient to 
induce near-maximal fatty acid substitution of glomerular membrane phospholipids
8 9
(Marshall et al, 1983, Huang et al, 1986, Anderson et al, 1989) and so if the fall in 
albumin excretion rate was indeed mediated by the effects of PUFAs on the 
glomerular capillary wall, it should be apparent by this stage.
The importance of PUFA incorporation into membrane phospholipids has been 
acclaimed by many groups but none has attempted to assess GCW charge (Weise et 
al, 1993, Heifets et al, 1987, Kasiske et al, 1991, Clark et al, 1990, Clark et al, 1993: 
see section 2.3). The extent of PUFA incorporation and the effects of PUFAs on 
membrane fluidity (as defined by anisotropy) was not investigated in this study but 
can be studied using spin labelled probes (Dominiczak et al, 1991, Le Grimellec et al, 
1992).
Summary
Despite a reduced glomerular uptake of cationic IgG (representing a diminished 
glomerular polyanion) in Lewis relative to DA rats, a change in the intensity or 
magnitude of the negative charge on the glomerular capillary wall is unlikely to be 
the mechanism behind the anti-proteinuric effects of PUFA diets. No evidence of any 
parallel increase in the uptake of 1 2 5I-IgG+ which could be related to a fall in albumin 
excretion rate in the PUFA diet groups was observed in either strain of rat. In 
anything, PUFA diets tended to reduce capillary wall charge which would be 
associated with an increase, rather than a decrease in albumin filtration across the 
glomerular capillary wall.
The method of measuring GCW charge used in this study, may be criticised on the 
basis that it is neither sufficiently specific nor sensitive. The optimal dose of IgG to 
detect differences in GCW charge should be titrated more thoroughly in a large 
number of animals.
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PUFA DIETS and  the ISOELECTRIC POINT (pi) of ALBUMIN Section  2 .4
2.4.1 In tro d u c tio n  a n d  e x p e r im e n ta l  d e s ig n
Characteristics such as the size, shape and electrostatic charge of the albumin 
molecule contrain its passage across the GCW (Brenner et al, 1978, Rennke et al, 
1978; 1979, Purtell et al, 1979). The human serum albumin molecule is oval-shaped 
(« 38A x 150A) with a mass of * 69,000 kD, effective radius of 36A and isoelectric 
point of 4.7 - 4.9 (Kuntz et al, 1974). It is a single polypeptide chain comprising 585 
amino acids folded into three semi-autonomous but homologous domains and has a 
half-life (t1/2) of 19 days. Compared to other proteins, albumin contains very few 
tryptophan and methionine residues but an abundance of cysteine and other charged 
amino acids such as aspartic and glutamic acid, lysine and arginine which endow 
human and rat albumin with an net charge of -15 and -12 mEq/L, respectively, at 
physiological pH. Rat serum albumin has a molecular mass of 64, 000 kD and a half- 
life of 2.2 days (Peters and Peters, 1972).
Because of its inherent anionic charge, circulating serum albumin is repelled, to a 
large extent, by the complement of fixed negative charges on the glomerular capillary 
wall. The tubular reabsorption of albumin is also dependent upon its charge and the 
effects of tubular fluid pH (Christensen et al, 1983, Christensen and Bjerke, 1986). 
Cationic albumin is not only filtered more readily but is also reabsorbed preferentially 
by the proximal tubule and when perfused, increases the permeability of the rat 
glomerulus to both modified and endogenous albumin (Baldamus et al, 1975, Purtell 
et al, 1979). In contrast, less of the anionic forms of ferritin, albumin, lysozyme and 
cytochrome C were reabsorbed by the proximal tubules relative to their cationic 
isoforms, relative to their cationic isoforms (Christensen et al, 1983). In addition to 
maintaining serum oncotic pressure, albumin transports and distributes calcium, fatty 
acids, bilirubin, hormones and drugs and it is this capacity to bind ligands which gives 
albumin its structural diversity and heterogeneity and makes its troublesome to study 
(Spector, 1975, Folco et al, 1979, Naval et al, 1982). Changing pH conditions can 
also generate isomers of albumin with altered molecular characteristics, known as N-F 
transitions (Foster et al, 1977).
Glucose binds covalently to albumin at lysine-525 and it is estimated that 6-15% of 
serum albumin is glycosylated but the effects of glycosylation on the charge on the 
albumin molecule are unclear (Day et al, 1979, Dolhofer and Weiland, 1980, Shaklai 
et al, 1984). In theory, glycosylation should render albumin more anionic but more 
often, cationic isoforms are observed (Candiano et al, 1983 and Ghiggeri et al, 1984). 
Glycosylated albumin is also filtered more readily and reabsorbed more avidly by 
endothelial cells than native albumin (Williams et al, 1981, Sampietro etal,  1987).
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The binding of ligands can elicit both competitive and cooperative effects within the 
albumin molecule. For instance, aspirin inhibits glucose binding to albumin by 
acetylating lysine-199 (Walker et al, 1976, Garlick and Mazer, 1983) and fatty acid 
binding can induce conformational changes within the albumin molecule which 
heighten its affinity for calcium (Aguanno et al, 1982). Reduced calcium excretion in 
rats (Wortsman and Traycoff, 1980) and humans (Ladenson and Shyong, 1977, 
Whitsett and Tsang, 1977) has been attributed to sequestration of free calcium by 
circulating fatty acids. Physiological levels of fatty acids do not affect calcium-to- 
albumin binding but dietary manipulation can raise plasma fatty acid levels high 
enough to alter calcium levels. Evening primrose oil, rich in y-linolenic acid, reduced 
urine calcium excretion in both normal and hypercalciuric diabetic rats (Tulloch et al, 
1994)
The rate of, and strength with which ligands bind to albumin can vary greatly. Not 
only does the glycosylation of albumin in vivo occur some ten times more rapidly than 
that of haemoglobin but it reduces the affinity of albumin for bilirubin by 50% and 
that for long chain fatty acids some twenty-fold (Brown et al, 1982, Shaklai et al, 
1984, Kragh-Hansen et al, 1990). Calcium ions bind to albumin more weakly than 
organic anions like bilirubin, or the long chain fatty acids, oleate, stearate, linoleate 
and palmitate which, with binding affinities in the region of of pKa = 10 8  M, are 
amongst the most tightly bound ligands transported by albumin. Acylated albumin is 
the predominant form circulating in the bloodstream and is more stable and resistant to 
hydrolysis and heat denaturation than native de-fatted albumin (Klapper et al, 1964, 
Yu et al, 1984). In analbuminaemic subjects with a high fatty acid to albumin ratio 
exogenous albumin is catabolised more slowly than native albumin (Dammacco et al, 
1980, Mego et al, 1984).
Serum albumin has six high affinity, and several more (20 to 60) lower affinity 
binding sites for fatty acids (Brown and Shockley, 1982) and under normal 
physiological conditions, these fatty acid binding sites are not fully occupied. The 
strength of binding between albumin and fatty acids is derived principally from 
hydrophobic interactions between the acyl tail of the fatty acid and the hydrophobic 
interior of the binding site(s). The tail of the fatty acid inserts into the binding site, 
leaving carboxyl (COO-) groups in the head of molecule free to introduce additional 
anionic charges on the surface of the albumin molecule (Brown, 1977, Peters and 
Sjoholm, 1977, Peters, 1985, Kragh-Hansen, 1990). The carboxyl (COO') groups in 
the head of the fatty acid molecule do not play a major role in its binding to albumin 
(Peters, 1985).
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The binding of fatty acids induces conformational changes within the albumin 
molecule which affect its filtration (Soetewey et al, 1972). Not only is the charge on 
the albumin molecule modified, but it becomes more spherical, compact and rigid, all 
of which are characteristics that retard its passage through the glomerular capillary 
wall. Removal of the fatty acids bound to human serum albumin converted it to a 
electrophoretically heterogeneous material but their replacement restored its 
electrophoretic homogeneity (Evenson and Deutsch, 1978). In relation to the degree 
of unsaturation and double bond configuration (cis or trans), fatty acids may alter the 
conformation of albumin to liberate additional COO- groups to bind calcium. Low 
levels ( 2  moles) of cis unsaturated fatty acids can influence calcium - albumin binding 
markedly (Aguanno and Ladenson, 1982).
Experimental design
Although initial speculation that the anti-proteinuric effects of PUFA diets were 
related to changes in either glomerular vasoactive mediators or the magnitude of the 
glomerular polyanion in the preceding studies (2.1-2.3), seems to have been 
groundless, the effects of PUFA diets on the electrostatic charge on the albumin 
molecule remained to be explored. The purpose of this study was to establish whether 
feeding PUFA diets altered the charge or isoelectric point (pi) of the serum albumin 
molecule.
The isoelectric point of a molecule is often measured by isoelectric focusing (IEF) but 
in this study, was measured by chromatofocusing (CF). The isoelectric point (pi) of a 
molecule is that pH at which it is electrically neutral. Proteins with a low pi value are 
negatively charged (anionic) whereas those with a high pi value are positively charged 
(cationic). The principal behind chromatofocusing is that at a pH below its isoelectric 
point, a protein will become positively charged and pass straight through an anion (-) 
exchange column, emerging in the eluting buffer. However, if as it migrates down the 
column, it encounters buffer of increasing pH, the charge on the protein reverses and 
when the pH of the buffer is higher than the pi of the protein, it will bind to the anion 
exchanger and remain bound until the developing pH gradient again drops below the 
pi of the protein, when it is released - until the pH rises above the pi and it binds 
again. This process is repeated until the protein emerges from the column at its 
isoelectric point.
The pi of albumin was measured by chromatofocusing in a selection of serum samples 
collected in study 2.2. Only Lewis rats fed control diet (n = 7), evening primrose oil 
diet (n = 4), fish oil diet (n = 3) and olive oil diet (n = 2) were studied.
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2 .4 .2  M a ter ia ls  a n d  m e t h o d s
2.4.2.1 Chromatofocusing
All solutions used for chromatofocusing were prepared with deionised water and 
degassed using a water vacuum pump for 30 minutes before use.
Start buffer (pH 6.2) 0.025M Histidine buffer. 1.19 g 1-histidine (Sigma 
Chemical Company: H-8000) dissolved in 500 mis of 
deionised water and pH adjusted to 6.2 after further 
degassing.
Eluate buffer (pH 4) TM62.5 mis of Polybuffer 74 (Pharmacia Biotech) was 
reconstituted to a final volume of 500 mis with 
deionised water and the pH adjusted to 4 with HC1. The 
solution was degassed again and the pH adjusted if 
necessary.
Sephadex G25 5g of Coarse Sephadex G25 (Pharmacia Fine 
Chemicals) was swollen in 50 mis of start buffer in a 
boiling water bath for one hour and then allowed to 
cool.
To generate the anion exchange column, a slurry was prepared by mixing 40 mis of 
Polybuffer exchanger, PBE 94™ (Pharmacia Biotech) with 20 mis of start buffer. The 
slurry was degassed for 30 minutes and then poured into a C 10/40 glass 
chromatography column (Pharmacia Biotech). Sephadex G25 was layered on top to a 
depth of about 2 cm to facilitate even mixing of sample and buffer. With a top adapter 
in position, the column was equilibrated with at least four column volumes of start 
buffer.
Attempts were made to maintain the volumetric flow rate at around 28 -30 cm per hr 
for optimal resolution. The volumetric flow rate through the packing (in mis per hour) 
is equal to the cross sectional area (mm) of the column multiplied by the linear flow 
rate (in cm per hour). Column packing and flow were checked using cytochrome C 
which, with a pi of 10.5, should pass straight through the column.
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Control samples
One ml sample volumes of human serum albumin (Pentex® Fraction V, Miles 
Laboratories; 10 mg per m l1), human serum diluted tenfold and rat serum albumin 
(Sigma Chemical Company: A-6414) diluted to 2 mg per ml in start buffer (pH 6.2) 
were run as control samples.
Test samples
One ml of rat serum diluted 1 : 9 with start buffer (pH 6.2) was introduced on to the 
column with eluate buffer (pH 4) using a pump (LKB Varioperpex® II) at a flow rate 
of 0.35 mis per minute which was equivalent to an effective linear flow rate of 27 mis 
c m 1 h r 1 under these conditions. Eluate from the column was collected in 1 . 5 - 2  mis 
fractions by a fraction collector (LKB 2070 Ultrorac® II) and the tubes containing 
albumin were located using Labstix. In each consecutive fraction, pH was measured 
to two decimal places using a digital read-out pH meter (Horiba F.8 L) and albumin 
levels were measured by immunoturbidimetry (see section 2.2.2.1). At the end of 
each run, the column was regenerated using several column volumes of 1M NaCl 
before it was re-equilibrated with start buffer (pH 6.2).
9 5
2.4.3 Results
During the initial chromatofocusing runs, every fraction was collected and the pH of 
every fifth fraction measured to monitor the development of the pH gradient (see 
Figures 2.4.3.1 - 2.4.3.7). Each fraction volume was between 1.5 and 2 mis.
The precision of the IT standard curve is shown in the following table
Standard 
mg/ 1 0 0  mis
n OD (405 nm) 
mean
SD CV (%)
1 2 2 0.0645 0.005 7.65
2 2 2 0.0965 0.006 6.55
3 2 2 0.1280 0.006 4.60
5 2 2 0.1805 0.008 4.50
8 2 2 0.2520 0 . 0 1 2 4.80
1 0 2 2 0.2870 0 . 0 1 2 4.40
15 2 2 0.3705 0 . 0 1 2 3.40
The chromatofocusing profiles of various control and test serum samples are shown as 
follows:
Control samples
• human serum albumin - 10 mg (Figures 2.4.3.1a and 2.4.3.2a).
• human serum (tenfold dilution) (Figures 2.4.3.3a and 2.4.3.4a)
•  rat serum albumin - 2 mg (Figure 2.4.3.5a)
Test serum samples 
• Control diet Rat 7 Figure 2.4.3.6(a)
Rat 9 Figure 2.4.3.6(b)
Rat 9 Figure 2.4.3.6(c) rpt
Rat 10 Figure 2.4.3.6(d)
Rati Figure 2.4.3.6(e)
Rat 3 Figure 2.4.3.6(f)
Rat 6 Figure 2.4.3.6(g)
Rat 2 Figure 2.4.3.6(h)
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• Primrose oil diet Rat 7 Figure 2.4.3.7(a)
Rat 6 Figure 2.4.3.7(b)
Rat 9 Figure 2.4.3.7(c)
Rat 4 Figure 2.4.3.7(d)
• Fish oil diet Rat 6 Figure 2.4.3.8(a)
Rat 10 Figure 2.4.3.8(b)
Rat 4 Figure 2.4.3.8(c)
• Olive oil diet Rat 6 Figure 2.4.3.9(a)
Rat 9 Figure 2.4.3.9(b)
The total amount of albumin recovered was calculated and displayed in the box under 
the curve.
Chromatofocusing profiles illustrate that serum albumin eluted from the anion 
exchange column as an unresolved double peak or with a distinct shoulder. Only the 
first few control samples (human serum albumin (Figures 2.4.3.1a and 2.4.3.2a) and 
tenfold dilutions of human serum (Figures 2.4.3.3.a and 2.4.3.4a) were run in 
duplicate.
Because pH is measured on a logarithmic scale, data were log-transformed prior to 
calculating the mean value and a virtual mid-point value between the two peaks was 
recorded as the pi (see Table 2.4.3.1). For example, serum albumin from Lewis rat 
(Figure 2.4.3.6 g) fed control diet eluted with one peak at pH 4.98 and another at pH 
4.91 and so a pi value of 4.944 was assigned.
The pi of serum albumin from rats fed evening primrose oil, fish oil or olive oil diet 
was significantly lower than that from rats fed a standard laboratory rat diet. There 
was a significant difference in the median pi values of serum albumin between the 
control and collective PUFA (EPO, FO and 0 0 )  diet groups [Control vs PUFA: 
4.944 vs 4.835, Cl = 0.064 to 0.170, p = 0.001] (see Figure 2.4.3.10).
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Figure 2.4.3.10 Iso e lec tric  po in t (pi) of Lewis ra t se ru m  
album in in control or PUFA d ie t groups.
Median pi of control vs amalgamated PUFA diet groups = 
4.942 vs 4.826, p = 0.001.
2.4.4 Discussion
Although isoelectric focusing is a more traditional method of establishing the 
electrical charge on a molecule, it was decided that the novel chromatofocusing 
technique might discriminate more accurately between small differences in pH 
because of its superior resolving power and focussing effects. It soon became clear 
however, that chromatofocusing is heavily dependent upon the sensitivity, accuracy 
and precision of the pH meter. In this study, a digital pH meter was used and 
calibrated with pH 4 and pH 7 standards at 20°C before each run, but like all 
equipment, it is subject to minor fluctuations which may introduce a certain degree of 
inaccuracy at the level of 0.01 pH units. In general, no major problems were 
encountered with development of the pH gradient although often it did become a little 
more 'bumpy' when consecutive fractions were measured. Fractions were collected 
overnight, usually, and although the tubes were covered, it is conceivable that some 
degree of evaporation or adsorption of carbon dioxide might cause minute changes in 
either fraction volume or pH. Also, measuring pH in small fraction volumes with a 
standard pH probe is not ideal.
More often than not, albumin eluted from the column either as a double peak or with 
distinct shoulders and this made it difficult to collate and interpret the data. Peak 
shape could be due entirely to procedural artefacts such as an inaccurate pH reading 
but this is unlikely. Several isoforms of albumin exist; for example, that albumin 
expands and expresses some forty carboxyl groups at around pH 4 to 4.5 (N-F 
transitions: Foster, 1977, Peters, 1985) might also affect the chromatofocusing profile. 
As in any chromatographic procedure, peak resolution may be improved through 
various technical manipulations including (i) increasing the length of the column, (ii) 
lowering the buffer concentration to expand the pH gradient, (iii) slowing the flow 
rate through the column and (iv) ensuring the uniformity of the column packing. 
Ultimately, the limits of resolution may have been reached in this instance. It is 
unclear whether the elution of albumin as a double peak in the control and PUFA diet 
groups is genuine or artefactual. One of the peaks could be glycosylated albumin 
(Ghiggeri et al, 1985) or some other albumin-ligand moiety which elutes close by. A 
paper by Evenson and Deutsch (1978) shows similar profiles of native serum albumin 
eluting in two peaks which are attributed to the quantity of fatty acids bound: one 
albumin peak, at pH 5.6, was de-fatted and another at pH 4.8 had some 2-3 moles of 
bound fatty acids. The pH 5.6 isoform of serum albumin could be generated by 
removing fatty acids and re-converted to the pH 4.8 isomer by the addition of long 
chain fatty acids. The authors attributed the isoelectric heterogeneity of HSA to 
variable losses of fatty acids during isolation and storage. The chromatofocusing 
profile of HSA in Figure 2.4.3.2(a) shows two similarly distinct peaks.
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The recovery of albumin was poor and might be due, in part, to small amounts of 
albumin in both tails of the elution profile which were not measured: alternative 
explanations include loss of albumin through surface adsorption or the capacity of the 
anion exchanger. Recovery can be improved by lowering the pH, or increasing the 
ionic strength of the eluting buffer. The accuracy of the immunoturbidimetry method 
used is also unknown.
Ideally, a larger number of serum samples would have been processed in duplicate at 
least, but chromatofocusing is an expensive technique. The bias in sample type and 
number is related to over-enthusiastic assay of control and evening primrose oil 
samples in the early stages, which limited the availability of chromatofocusing 
reagents for processing fish and olive oil samples. Chromatofocusing is not only 
expensive but is also very slow, requiring no fewer than two days to process a single 
serum sample. The most efficient arrangement was to collect fractions overnight and 
measure albumin levels the following day while regenerating the column for the next 
run. Chromatofocusing is very much slower than IEF in which several samples can be 
analysed simultaneously.
Although sample number is small and only Lewis rats were studied, the results of this 
study provided a persuasive explanation for the tendancy for albumin excretion to fall 
in all the PUFA diet groups. A fall in the isoelectric point of serum albumin in the 
PUFA diet groups implies increased anionic charge which heightens the degree to 
which it is repelled by the glomerular polyanion. That carboxyl groups in the polar 
head of the fatty acid molecule augment the anionic charge on the surface of the 
albumin molecule is the most likely mode of action: under normal physiological 
conditions, many of the fatty acid binding sites within the albumin molecule are 
unfilled.
The median pi of Lewis rat serum albumin was calculated as being around 4.95 which 
might be a little higher than that normally quoted for rat serum albumin (» 4.7 - 4.9) 
but often proteins do not elute at their exact pi as measured by IEF, when measured by 
chromatofocusing. Polymorphisms within the albumin gene are said to uncommon 
and are unlikely, therefore, to explain the elution pattern of serum albumin in Lewis 
rats (Kragh-Hansen, 1990). However, Lewis rat serum albumin could be depleted of 
fatty acid binding sites and thus more cationic and filtered more readily than that of 
DA rats. PUFA diets may restore or increase the anionic charge on the albumin 
molecule.
Few studies have given much consideration to the effects of fatty acid binding on the 
physico-chemical properties of albumin but Jensen et al (1989) did suggest that the
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fall in the transcapillary escape rate (TER) of albumin in IDDM patients with 
albuminuria was due to conformational changes in the albumin molecule induced by 
its binding fatty acids derived from cod liver oil. On the other hand, it is suggested 
that, more menacingly, fatty acids bound to albumin may generate damaging toxic 
lipid hydrolysis products following their uptake by renal tubular cells (Thomas and 
Schriener, 1993).
The functional significance of physical modification of the serum albumin molecule in 
glomerulopathies such as diabetic and minimal change nephropathy has been 
explored. In diabetic patients, the pi of serum albumin ranged from 3.5 to 7 and there 
was a preponderance of heavily glycosylated, more anionic isomers of albumin in the 
urine, perhaps as a result of increased reabsorption of cationic albumin (Ghiggeri et al, 
1985). In diabetics with normal albumin excretion, the pi of urine albumin was more 
anionic (4.1 - 4.7) than those with microalbuminuria, in which albumin was present as 
a single band at pi 4.7 (Candiano et al, 1990). In children with minimal change 
nephropathy, regarded as being related to a fundamental defect GCW charge, greater 
quantities of the more cationic (pi 4.8 - 5.5) isoforms of albumin were found in the 
urine (Ghiggeri et al, 1987) and following steroid therapy, proteinuria fell in 
association with disappearance of the more cationic bands and appearance of 
numerous more anionic pi (< 4.7) isoforms. Ghiggeri et al (1987a) suggested that in 
MCN patients, the pi of albumin is a function of its fatty acid content and indeed, 
analysis of the fatty acids bound to albumin showed that, relative to its serum 
homologue, de-fatted albumin was not only more cationic, and thereby filtered in 
excess of native acylated albumin but was deficient in linoleic acid, in particular. It 
was speculated that in MCN, changes in the pi of albumin from 4 to 6.1 reflect the 
fatty acid content of the albumin molecule (ranging from 20-30 to 2-3 moles of fatty 
acid per mole of albumin for the most, and least anionic albumin isoforms, 
respectively). The amount of fatty acids bound to albumin fell further during the 
proteinuric phase of MCN. The heightened filtration of de-fatted (cationic) albumin in 
MCN suggests that some degree of glomerular charge selectivity was maintained and 
that the fall in albumin excretion was due to a fundamental change in the structure of 
the albumin molecule itself.
It would be intriguing if binding fatty acids, of whatever degree of double bond 
unsaturation or configuration or acyl chain length, reduced the clearance of albumin, 
but the results must be viewed with caution (Aguanno and Ladenson, 1982). Two 
major flaws associated with the hypothesis of increased acylation of albumin lowering 
its excretion rate are that (i) hyperlipidaemic individuals would be expected to have 
low levels of albumin excretion albeit the anti-proteinuric effects of PUFA binding
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may be dependent upon the type of fatty acid bound and (ii) the pi of serum albumin 
might fluctuate considerably in response to circulating fatty acid levels with marked 
effects on protein excretion. It must also be said that there can be a high degree of 
subjectivity in determining the pi from chromatofocusing profiles
Unfortunately, this study did not establish if the pi of DA rat serum albumin was also 
lowered in the PUFA diet groups. The issues of whether (i) the pi of DA rat serum 
albumin is lower than that of Lewis rats under normal conditions and (ii) if a 
simultaneous change in the size or conformation of the albumin molecule also 
occurred in the PUFA diet groups could be addressed in the future. It is unclear 
whether a difference of 0.12 pH units (4.95 - 4.83) in pi between control and PUFA 
diet groups would be sufficient to elicit a fall in the clearance rate of albumin and 
designing an experiment to answer this question could be a difficult. The binding of 
PUFAs to albumin can also increase its size and shape or configuration (see section 
2.4.1). That olive oil had the same anti-proteinuric effect as evening primrose and fish 
oil diets, tends to preclude the role of prostanoids while strengthening the hypothesis 
that some structural modification of the serum albumin molecule, induced by fatty 
acid binding, altered its pi and reduced its clearance.
Summary
A change in the charge on the serum albumin molecule induced by binding 
polyunsaturated fatty acids (PUFAs) may explain the reductions in albumin excretion 
rate observed in the studies reported in this thesis.
Chromatofocusing was a satisfactory, but perhaps not ideal, method of measuring the 
pi of serum albumin because contrary to reports, it is expensive for assaying a large 
number of samples and is both time- and labour-intensive. IEF might have 
distinguished these differences just as well and lessened the problems of inter-assay 
variation.
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EVENING PRIMROSE OIL DIET a n d  EXPERIMENTAL DIABETES S ection  2.5
2.5.1 Natural history of diabetic nephropathy
Renal disease is still the leading cause of death amongst patients with type I insulin- 
dependent diabetes (IDDM) who present before the age of twenty but clearly, there 
are differing susceptibilities to nephropathy since only around 35 to 40% develop this 
complication (Andersen et al, 1983). The prognosis of established diabetic 
nephropathy is poor but strategies for preventing or arresting the progression of renal 
damage in diabetes are being pursued with some success (Viberti et al, 1987, The 
Diabetes Control and Complications Trial (DCCT) Research Group, 1993).
Diabetic renal disease progresses through five well-defined stages (Viberti et al, 
1982, Mogensen, 1987).
Stage I: Glomerular hyperfiltration, defined as a GFR in excess of 150 mis per min 
per 1.73 m2, is common in diabetic patients at diagnosis although albumin excretion 
rate (AER) may be normal (Mogensen, 1986). Kidney size increases but no other 
symptoms can be attributed to changes in renal function (Mogensen and Andersen, 
1973).
Stage II: A silent period during which lesions develop mainly in the glomerulus but 
AER remains normal.
Stage III: The early, incipient phase starts some five years after presentation.
Symptoms include an albumin excretion rate of 20-200 p.gs per minute (30-300 mgs 
per day) termed microalbuminuria (Albustix-negative) and which, although 
potentially reversible, is associated with a high risk of developing nephropathy. AER 
remains stable except perhaps during periods of poor diabetic control, severe exercise 
or infection (Viberti et al, 1982a, Christensen, 1984, Feldt-Rasmussen et al, 1985, 
Jensen et al, 1988a). The duration of this phase is unpredictable but in most patients 
it progresses to stage IV.
Stage IV: The overt or clinical phase is much less amenable to treatment than the 
incipient phase and is characterised by a rise in AER to levels in excess of 200 pgs 
per minute (300 mgs per day: Albustix-positive). It may last for three to five years 
and is marked by a progressive decline in GFR of about 1 ml per minute per 1.73 m2  
per month and an increase in AER of some 20 to 40% per year. Hypertension 
becomes progressively more severe, the patient may become nephrotic and other 
complications of diabetes such as retinopathy are common.
Stage V: End-stage renal failure with uraemia.
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Research into the treatment of diabetic nephropathy has developed rapidly and may 
already have reduced the proportion of patients with IDDM who develop renal 
complications. During the incipient phase, the efficacy of treatments is often 
assessed by their ability to reduce albumin excretion and both strict glycaemic control 
(Viberti et al, 1979; 1983, Feldt-Rasmussen et al, 1986) and antihypertensive therapy 
(Christensen and Mogensen, 1985, Parving et al, 1987; 1988, Anderson et al, 1989) 
may help accomplish this objective. Compared to those with good glycaemic control, 
diabetic patients with inadequate glycaemic control are more likely to display a 
sustained rise in GFR associated with a rise in intraglomerular blood pressure and 
progressive glomerular sclerosis (Mogensen, 1976, Wiseman et al, 1985, Sabbatini et 
al, 1992). Those patients with the highest early increase in GFR and AER are more 
likely to develop progressive disease (Mogensen, 1987). For any given degree of 
glycaemic control, a predisposition to hypertension may aggravate the resultant 
glomerular injury. Throughout the clinical phase, a reduction in proteinuria and 
retarded disease progression has been achieved by controlling blood pressure 
(especially intraglomerular hypertension) with ACE inhibitors (Taguma et al, 1985, 
Bjorck et al, 1986, Hommel et al, 1986a, Parving et al, 1988, Valvo et al, 1988, 
Marre et al, 1987; 1988) or low protein diets (Wiseman et al, 1987, Zeller et al, 1987; 
1987a).
Various hypotheses to account for a predisposition to diabetic nephropathy have been 
advanced but it is still unclear whether diabetic renal disease is precipitated by 
haemodynamic or metabolic derangements (Zatz et al, 1985, The DCCT Research 
Group, 1988). Elevated rates of sodium-lithium countertransport (SLC) across the 
erythrocyte membrane are associated with an inherited predisposition to essential 
hypertension and have been observed in both patients with diabetic nephropathy and 
their relatives (Mangili et al, 1988; 1993, Krolewski et al, 1988, Carr et al, 1990a, 
Walker et al, 1990).
The primary cause of glomerular hyperfiltration in diabetic renal disease remains 
unresolved but has been linked to disturbances in the renin-angiotensin system 
(Christlieb et al, 1978, Dworkin et al, 1983, Ballerman et al, 1984, Fioretto et al, 
1991, Beretta-Piccoli and Weidmann, 1981, Christiansen et al, 1988), growth factors 
(Christiansen et al, 1982, Flyvbjerg et al, 1990), glucagon (Parving et al, 1980), 
insulinopenia (Harrison et al, 1980, Pfaffman et al, 1982, Kreisberg et al, 1983, 
Schambelan et al, 1985) and heightened prostaglandin levels (Johnson et al, 1979, 
Silberbauer et al, 1979, Gerrard et al, 1980, Axelrod 1982, Rogers et al, 1982, 
Funakawa et al, 1983, Kirschenbaum et al, 1981; 1985, Craven et al, 1987, Jensen et 
al, 1986, Gambardella eta l, 1988, Green et al, 1988).
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Prostanoid levels are altered in diabetes and the vasodilatory actions of 
prostaglandins may contribute to glomerular hyperfiltration (Zatz et al, 1985, Quilley 
et aly 1985, Schambelan et aly 1985; Wilson et aly 1985, Benigni et aly 1986, Bunke et 
al, 1986). It has been suggested that prostaglandins sustain only the early stages of 
glomerular hyperfiltration and that the fall in GFR observed in the latter stages of 
diabetes is due to increased thromboxane synthesis (Craven et aly 1987). The 
protective effects of aspirin and indomethacin in diabetic renal disease may be related 
to their ability to reduce or prevent glomerular hyperfiltration (Jensen et aly 1986, 
Craven and DeRubertis, 1989). Aspirin prevented hyperfiltration, GBM thickening 
and a fall in GFR in STZ diabetic rats (Moel et aly 1987) and indomethacin lowered 
both glomerular filtration and albumin excretion rate in patients with type I diabetes 
(Hommel et al, 1987). However, experimental evidence implicating prostaglandins 
in diabetic hyperfiltration is weak. Despite raised glomerular PGE2  levels in STZ 
rats, compared to genetically diabetic (BB) and non-diabetic control rats, the response 
of isolated glomeruli to A ll and mesangial contractility were similar in all the groups 
(Barnett et aly 1987). Christiansen et al (1985) and Stirati et al (1986) showed that 
cyclooxygenase inhibitors did not reduction hyperfiltration in diabetic patients.
2.5.2 Experimental design, animals, materials and methods
This study was undertaken to establish whether feeding an evening primrose oil diet 
could attenuate or prevent increased rates of albumin excretion in rats made diabetic 
by an injection of streptozotocin (Carney et aly 1979, Jensen et aly 1987). Proteinuria 
had been shown to be higher in diabetic Lewis rats than diabetic DA rats and the 
difference became more marked over time. Mesangial expansion too, was greater in 
Lewis rats than DA rats after six months of diabetes (Payton and Boulton-Jones, 
1989). For practical and procedural reasons only one strain of rat and one PUFA diet 
could be studied. Lewis rats were selected because of their propensity to raised levels 
of proteinuria and heightened susceptibility to diabetic nephropathy compared to DA 
rats. It was more difficult to decide upon which diet to test, but evening primrose oil 
diet was chosen because of some adverse reports on the use of fish oil in diabetes 
(Glauber et aly 1988) and a strong endorsement of the use of linoleic acid diets in 
experimental diabetic nephropathy (Barcelli et aly 1989).
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2.5.2.1 STZ ran g in g  study
Compared to most other studies, the dose of streptozotocin to be used in this study 
(80 mg per kg) is rather high but Payton (personal communication) had found that a 
lower dose often did not induce diabetes. A small ranging study was performed in a 
group of ten Lewis rats to check the optimal dose of STZ required to induce diabetes. 
Rats were anaesthetised by ether inhalation and injected via the tail vein with 
streptozotocin prepared in citrate buffer, pH 4.5 at doses of 40, 50, 60, or 70 mg per 
kg (see method in section 2.5.2.3); two rats were given citrate buffer only and the 
progress of the animals was followed for three to four days. Body weight was 
recorded and urine glucose and protein levels were monitored using Labstix (Miles 
Laboratories, Slough SL2 4LY). Blood was withdrawn from the tail vein under ether 
anaesthesia for measurement of plasma glucose levels (see Table 2.5.3.1).
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2.5.2.2 A nim als
The main study was started after the dose of streptozotocin (80 mg per kg) had been 
confirmed by the ranging study. Two groups of 10 Lewis rats (total n = 20), of mean 
body weight around 1 0 0  grams at the start of the study, were fed either standard 
laboratory rat diet or evening primrose oil diet (section 2 . 1 .2 .2 ) for three weeks 
before STZ and throughout a subsequent six week period of diabetes. A six week 
diet period was selected because (i) the protein lowering effects of PUFA diets had 
been observed within this time period in the preceding studies and (ii) the Home 
Office stipulated that the study should be kept as brief as possible.
Both groups of rats were made diabetic by receiving an injection of the cytotoxic 
drug, streptozotocin (STZ) which destroys insulin-producing p cells in the pancreas. 
As there was to be no non-diabetic control group, data from normal Lewis rats fed 
standard laboratory rat chow in earlier studies was used for comparison, as required. 
Rats were put into metabolic cages one and three weeks before, and one, three and six 
weeks after STZ injection and food and water intake and urine output was measured. 
Urine urea levels were measured by a Hitachi 704 discrete autoanalyser in urine 
diluted 1:49 as an assessment of dietary protein intake.
2.5.2.3 Induction of diabetes
After anaesthesia, induced by ether inhalation, a single injection (80 mg per kg body 
weight) of streptozotocin (Zanosar, The Upjohn Company, Kalamazoo, Michigan 
49001, USA) reconstituted to 100 mg per ml in 0.1 M citrate buffer, pH 4.5 [ 8  mis of 
0.1M citric acid (21.1 g/1) and 12 mis of trisodium citrate (29.4 g/1)] was administered 
to each rat. 200-500 pis of blood were withdrawn from the tail vein using a 25 guage 
needle into a fluoride tube (Teklab) for measurement of baseline blood glucose 
levels. After recovering from the anaesthetic, the animals were returned to communal 
cages but as soon as diabetes was confirmed (within two to three days) by the 
development of polyuria and glycosuria, the rats were placed in individual gridded 
cages. Each morning throughout the six week diabetic period, body weight was 
recorded and urine was tested by Labstix (Ames) for glucose, ketones, protein and 
pH. Food and water intake were not restricted during the study.
Another pre-condition of performing the study, set down by the Home Office, was 
that insulin be given to control the severity of diabetes. The criteria for insulin 
administration were either or both a urine glucose concentration of 3+ to 4+ (by 
Labstix) or any decrease in body weight to less than 80% of the body weight of a
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non-diabetic control rat. In the early stages, a daily subcutaneous injection of 1 unit 
of insulin (Human Ultratard insulin: Novo) was given to each rat but this dose proved 
insufficient to control and the dose was increased gradually to 4 units per day. 
Although urine glucose levels may not accurately reflect plasma levels, measuring 
blood glucose involves tail venepuncture under anaesthesia and so was measured 
only at week three in the pre-STZ phase and at one, three and six weeks during the 
diabetic phase, using a Beckman glucose analyser.
2.5.2.4 Blood pressure measurement
The equipment for non-invasive blood pressure monitoring became available for this 
study. Arterial blood pressure was measured using a Buffington Cuff (Small Animal 
Indirect Blood Pressure Plethysmograph. Buffington Clinical Systems: PO Box 
24241 /  Cleveland, Ohio 44124 /  Area 216/442-3850) at one week before, and five 
weeks after injection of STZ.
The Cuff records blood pressure in the tail of the rat by differential pulse volume 
plethysmography (Pfeffer et al, 1971). Arterial blood flow to the tail is blocked by 
inflating an occluding cuff placed proximally to a detecting transducer cuff. Each rat 
was placed in an incubator at 37°C for 15 minutes to dilate the tail veins and subdue 
the animal and then restrained gently in a cloth and kept as still and calm as possible. 
The occluding cuff placed high on the tail with the transducing cuff about 1 cm 
below, was inflated until the trace from the pulse transducer was steady and noise- 
free and then released gradually until the first low amplitude pulsation - which 
represents systolic pressure - appeared on the trace. Each blood pressure 
measurement was the mean of five separate readings (see Plate 2.5.1).
2.5.2.5 Urine protein measurement
Urine total protein was measured by the Coomassie Blue method (see section 
2.1.2.9). In all the previous studies and during the pre-diabetic phase of this one, 
urine albumin was measured by immunoturbidimetry (see section 2 .2 .2 . 1 ) but it had 
not been anticipated that, with detection limits of 2.5-150 p.gs per ml, the method 
would not be sensitive enough to measure the low levels of albumin in the dilute 
urine of diabetic rats, even after further dilution. The options were to measure urine 
albumin either by radioimmunoassay (RIA) or ELISA (Enzyme-Linked 
ImmunoSorbent Assay): because a specific RIA method was not readily available, 
would be difficult to develop and with detection limits of * 0.5-20 pgs per ml was 
perhaps not much more sensitive than immunoturbidimetry, it was decided to use an 
ELISA to detect albumin within the nanogram range (7.5-150 ng per ml).
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Procedures from published rat serum albumin ELISA methods were followed 
(Mohamed et al, 1984, Torffvit and Weislander, 1986) and antibodies were titrated to 
establish optimal working dilutions. Sheep anti-rat albumin (The Binding Site, PO 
Box 4073, Birmingham B29 6 AT: PC341) was used as the coating (or capture) 
antibody and peroxidase-labelled sheep anti-rat albumin (The Binding Site, as above: 
PP341) was used as the secondary (or conjugate) antibody. Immediately, problems 
were encountered with both a lack of sensitivity at the lower end of the standard 
binding curve and a poor absorbance range from the bottom to top of the binding 
curve (see Figure 2.5.3.12).
The sensitivity of an ELISA may be improved by manipulating various procedural 
parameters - but only one at a time - since changing several at once can have 
devastating consequences: such parameters include
• the source and dilutions of the primary and secondary antibodies
• quality of the microtitre plates
• ambient temperature and duration of the different reaction steps
• number of washes
• use of agents such as gelatin, casein or serum which block non-specific binding 
sites.
After several months of attempting to improve the sensitivity of the method, the best 
results could only be obtained by using the coating and conjugate at unacceptably low 
dilutions of between 1:50 to 1:80 and 1:75 to 1:125, respectively. Microtitre plates 
were coated for 1 hour at room temperature (or overnight at 4°C) and blocked for 2 
hours at room temperature with a 1% casein solution. Rat serum albumin standards 
ranged from 500 to 4 ng per ml by doubling dilutions (Figure 2.5.3.12).
Ultimately, it was acknowledged that an alternative method would have to be found 
and two fundamental changes were implemented: a double antibody labelling 
procedure using the highly sensitive and specific biotin-streptavidin system was 
introduced and both the commercial and biological source of the antibodies were 
changed. The two-step streptavidin-biotin labelling procedure amplifies the detection 
stage of the assay and the sensitivity of the ELISA improved immediately (see Figure 
2.5.3.12a). The principle behind double-labelling is that instead of the secondary 
antibody being labelled directly with peroxidase, it is instead conjugated with biotin 
which has a very high affinity for avidin. The final reagent layer of horseradish 
peroxidase (HRP)-labelled Avidin D binds with high avidity to the biotin moiety of 
second antibody and thus heightens the sensitivity of the ELISA.
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The new rat serum albumin ELISA method evolved through the use of:
• goat anti-rat albumin antiserum (Cappel Laboratories: 0213-0341) as coating 
antibody
• a greater number of washing steps
• rat serum albumin standards ranging from 50 to 7.8 ng per ml
• 0 . 1 % gelatin as blocking solution
• biotin-conjugated goat anti-rat albumin (see method) and
• horseradish peroxidase (HRP)-labelled Avidin D (Vector laboratories,
Peterborough PE3 8 RF: Cat no A2004, 5mg).
The optimal dilutions of coating and conjugate antibodies and avidin-HRP were
determined by titration.
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2.5.2.6 Rat se ru m  a lbum in  ELISA
The first stage of the ELISA involves biotinylation of the antiserum. Goat anti-rat 
albumin serum was dialysed extensively against PBS and then diluted with PBS to an 
IgG concentration of 5 mg per ml. 2.13 mg of N-hydroxy-succimidobiotin (Sigma 
Chemical Company: H-1759) and 100 pis of dimethylformamide (DMF: Sigma 
Chemical Company: D-8654) were mixed and added immediately to 1 ml of 
antiserum (IgG = 5 mg per ml) and mixed again. (This gives a biotin to protein ratio 
of 200:1 which is equivalent to binding 5 to 150 molecules of biotin per molecule of 
protein.) The mixture was left at room temperature for two hours, dialysed against 
one litre of PBS five times and then stored at 4°C.
The following reagents and buffers were prepared:
Washing buffer 15M PBS-Txveen, pH 7.2: Sodium chloride (40 g/1);
potassium chloride ( 1  g/1); ^/-sodium hydrogen 
phosphate (5.75 g/1); potassium d/-hydrogen phosphate 
(1 g/1): Tween 20 (1 ml/1). Prepare 5 litres with 
distilled water - add Tween last.
Coating buffer 1.5 M carbonate-bicarbonate, pH 9.6: Sodium 
carbonate, pH 11 (3.8 g/1); sodium hydrogen carbonate, 
pH 8.3 (5.86 g/1). Mix equal volumes (approximately) 
of the two solutions until the correct pH is reached.
Blocking solution 
Substrate buffer
0.1% gelatine in phosphate buffered saline (PBS)
0.15M citrate-phosphate, pH 5: Citric acid (21 g/1); di­
sodium hydrogen phosphate (35.6 g/1). Mix equal 
volumes (approximately ) of the two solutions until 
correct pH is reached.
Albumin standards Stock rat serum albumin (RSA: Sigma Chemical
Company: A-6414) prepared at 5 mgs per ml diluted to 
1 mg per ml (10 pis + 40 pis) then according to the 
following table:
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Dilution RSA (ng/ml)
1:5T 200
1:10T 100
1:20T 50
1:40T 25
1:80T 12.5
1:160T 6.25
1:320T 3.13
1:640T 1.56
1:1280T 0.78
(T = x 103)
Method
Ninety four wells of a 96 well microtitre plate (Maxisorp; Nunc-Immuno Plate) were 
coated with 1 0 0  pis of goat anti-rat serum albumin diluted 1  in 2600 with coating 
buffer. The plate was covered and left overnight in a moist chamber at 4°C and then 
washed five times with washing buffer. 2 0 0  pis of 0 . 1 % gelatine solution as blocking 
agents was pipetted into each well. The plate was left covered for one hour at room 
temperature and then washed five times with washing buffer. 1 0 0  pis of either rat 
serum albumin standards (see table) or urine diluted 1:800 (see validation) was added 
to the wells. The plate was covered and left at room temperature for two hours then 
washed five times with washing buffer. 1 0 0  pis of biotin-labelled goat anti-rat serum 
albumin (see above) diluted 1:4000 (5 pis in 20 mis of PBS) was added to each well 
and the plate was left covered at room temperature for one hour and then washed five 
times with washing buffer. Finally, 100 pis of horseradish peroxidase (HRP)-labelled 
Avidin D diluted 1:5000 (2 pis in 10 mis of PBS) was added to each well. The plate 
was left covered at room temperature for one hour and then washed five times with 
washing buffer. Substrate buffer was prepared for immediate use. One tablet (15 
mg) of o-phenylenediamine dihydrochloride (OPD) (Sigma Chemical Company: P- 
8787) was dissolved in 44 mis of citrate buffer, pH 5 and then 18 pis of 30 % 
hydrogen peroxide was added: 1 0 0  pis of this substrate solution was added to each 
well. The plate was left in the dark, at room temperature, until sufficient colour had 
developed to read the lowest standard. The reaction was stopped by adding 50 pis of 
4N sulphuric acid to each well and the absorbance was read at 490 nm on a 
MicroplateR reader (Dynatech).
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The precision and accuracy of the ELISA were assessed. Precision is a measure of 
the reproducibility of an assay both within and between batches and is defined as the 
coefficient of variation CV(%) = SD/mean x 100. A urine sample (C2-5 diluted 1: 
3200) was used as quality control (QC) during optimisation of the standard curves. 
The accuracy of the assay relates to its ability to determine the true value of analyte 
present in the sample and can be calculated from recovery experiments. Recovery 
was assessed by "spiking" ultrafiltered rat urine (UFU) with rat serum albumin 
(Sigma Chemical Company: A-6414) at 6 , 4, 2, 1 and 0.5 ng per ml. Urine was 
ultrafiltered by centrifugation in a disposable Centriflo ultrafiltration membrane cone 
(Amicon Ltd. Gloucester GL10 2BJ) which, with a molecular weight cut-off of 
25,000 kD, claims to removes in excess of 95% of endogenous albumin. A stock 
preparation of UFU was spiked with 3.2 p,gs per ml (= 3200 ng per ml) of rat serum 
albumin which, following 800- fold dilution, results in a level of * 4 ng per ml which 
falls in the middle of the binding curve (previously determined). Ideally, ultrafiltered 
rat urine should be used as the diluent as PBS may alter the sample matrix.
Parallelism is another index of assay validation which determines whether albumin in 
urine behaves in an immunochemically similar manner to the albumin standard used. 
A urine sample (C2-5) diluted x200, x400, x800, xl600, x3200, x6400 was measured 
to establish the appropriate dilution factor and the parallelism of the response.
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2.5.3 Results
Results from the ranging study (Table 2.5.3.1) show that doses of 40 or 50 mg per kg 
of streptozotocin were insufficient to induce diabetes in Lewis rats. By day three, 
only rats given 60 or 70 mg per kg of STZ showed signs of glycosuria (+, ++ and +++ 
equivalent to 14, 28 and 55 mmol/1 glucose, respectively). Protein levels measured 
by Labstix were lower in the dilute urine of diabetic rats. Urine pH ranged between 8  
and 8.5 in most rats.
Many of the graphs in the following sections include both non-diabetic (pre-STZ) and 
diabetic (post-STZ) data. It should be noted that week zero represents a baseline 
period during which both groups of rats were fed standard laboratory rat diet albeit 
the legends on the graphs depicts evening primrose oil (EPO) diet. When it is 
necessary to make comparisons between pre- and post- STZ, they are made relative to 
the week 1 pre-STZ group since it was deemed that (i) comparisons made between, 
for example, 3 weeks pre- and 1 week post- STZ were too close and (ii) the effects of 
EPO diet are often apparent after one week (see urine pH results).
2.5.3.1 Body weight
Pre-STZ: Mean body weight increased by 80% in the control group and by 63% in 
the EPO diet group (Figure 2.5.3.1). Only at week three were control rats 
significantly heavier than EPO rats [CD vs EPO: 248 (24) vs 218 (22) grams, Cl = 9 
to 52, p = 0.009] (Table 2.5.3.1a).
Post-STZ: Growth rate slowed down during the diabetic period; only at week one 
were control rats significantly heavier than at week one in the non-diabetic phase 
[Table 2.5.3.1a]. Despite a fall in body weight following streptozotocin, the animals 
continued to gain weight, albeit at a slower rate than during the non-diabetic phase. 
Growth rate curves of rats in both the Control and EPO diets groups are shown in 
Figures 2.5.3.1a and 2.5.3.1b. There was no significant difference in mean body 
weight between diet groups during the diabetic phase of the study.
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Table 2.5.3.1 (a) Body weight before an d  after STZ -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Control vs Primrose
0 weeks - pre -6 to 14 p= 0.45
1 weeks - pre -1 to 35 p= 0.06
3 weeks - pre 9 to 52 p= 0.009*
1 week - post -8 to 75 p= 0.10
3 weeks - post -5 to 79 p= 0.10
6 weeks - post -35 to 71
ona
Control
1 week pre vs 1 week post 3 to 56 p= 0.03*
1 week pre vs 3 week post -33 to 55
ooIIa
1 week pre vs 6 week post -40 to 66 p= 0.5
Primrose
1 week pre vs 1 week post -7 to 73 p= 0.09
1 week pre vs 3 week post -9 to 39 p= 0.2
1 week pre vs 6 week post -23 to 23 p= 0.97
Two Sample t Test
4 0 0  -i
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Figure 2.5.3.1(a) Growth ra te  curves of d iab e tic  rats fed  control 
d ie t (* d e n o te s  n o n -d la b e tlc  ra t)
400 i
300 -
o
200 -
100
0 1 3 4 52 6
Weeks - post STZ
Figure 2.5.3.1 (b) Growth ra te  curves of d iab e tic  rats fed  prim rose 
oil d ie t (* d e n o te s  n o n -d ia b e tic  ra t)
2.5.3.2 Food co n su m p tio n
Pre-STZ: Mean food consumption was similar between the groups at baseline (week 
0) when both were fed control diet [19.5 (4.5) vs 21.6 (4.12) grams, p = 0.3] but was 
significantly lower in the evening primrose oil diet group at weeks one [CD vs EPO: 
20.8 (3.15 ) vs 15 (4.48), p = 0.0046] and three [CD vs EPO: 21 (2.36) vs 15.7 (2.36) 
grams, p < 0.001]. The fall in food consumption is likely to be related to the change 
from control to evening primrose oil diet (Figure 2.5.3.2).
Post-STZ phase: Mean food consumption increased in both diet groups during this 
period but there were no significant differences between the groups (Table 2.5.3.2).
2.5 .3 .3  W a te r  in ta k e
Pre-STZ: At week one, water intake was significantly lower in the evening primrose 
oil group [CD vs EPO: 19 mis (2.2) vs 14 mis (2.3), p = 0.0002] (Figure 2.5.3.3 and 
Table 2.5.3.3)
Post-STZ phase: Water intake increased markedly in both groups of rat after
streptozotocin (Figure 2.5.3.3). Only at week one was there a significant difference 
in mean water intake between the diet groups [CD vs EPO: 113 mis (50) vs 180 mis 
(43), p = 0.008].
2.5 .3 .4  Urine v o lu m e
Pre-STZ: Urine volume was not affected by diet during this period (Figure 2.5.3.4). 
Post-STZ phase: There was a significant increase in mean urine volume at week one 
in the evening primrose oil diet group [CD vs EPO: 104 mis (42) vs 169 mis (44) mis, 
p = 0.006] which reflected the significant increase in water intake in Figure 2.5.3.3 
(see Table 2.5.3.4).
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Table 2.5.3.2 Food consumption before a n d  after STZ -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Control vs Primrose
0 weeks - pre -6 to 2 p= 0.3
1 weeks - pre 2 to 9.5 p= 0.0046*
3 weeks - pre 3 to 7.5 p= 0.0001*
1 week - post -8 to 3 p= 0.37
3 weeks - post -4 to 9 p= 0.37
6 weeks - post -11 to 14 p= 0.71
Control
1 week pre vs 1 week post -9 to 1.5 p= 0.14
1 week pre vs 3 week post -14 to -1 p= 0.03*
1 week pre vs 6 week post -22 to 2 p= 0.075
Primrose
1 week pre vs 1 week post -15 to -8 p<0.0001*
1 week pre vs 3 week post -13 to -7 p<0.0001*
1 week pre vs 6 week post -18to-10 p<0.0001*
Two Sample t Test
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Table 2.5.3.3 Water intake before a n d  after STZ -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Control vs Primrose
0 weeks - pre -2 to 5 p= 0.36
1 weeks - pre 3 to 7 p= 0.0002*
3 weeks - pre -3 to 8.5 p= 0.31
1 week - post -114 to -21 p= 0.008*
3 weeks - post -41 to 38 p= 0.9
6 weeks - post -77 to 47 p= 0.56
Control
1 week pre vs 1 week post -133 to -56 p= 0.0004*
1 week pre vs 3 week post -145 to -85 p<0.0001*
1 week pre vs 6 week post -224 to -91 p= 0.005*
Primrose
1 week pre vs 1 week post -198 to -131 p<0.0001*
1 week pre vs 3 week post -151 to -88 p<0.0001*
1 week pre vs 6 week post -204 to -146 p<0.0001*
Two Sample t Test
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Table 2.5.3.4 Urine volum e before an d  after STZ -  s t a t i s t i c a l  a n a l y s e s
9 5 %
confidence significance
interval level
Control vs Primrose
0 weeks - pre -1 to 1.5 p= 0.67
1 weeks - pre -1.3 to 0.6 p= 0.4
3 weeks - pre -0.4 to 1.6 p= 0.24
1 week - post -107 to -21 p= 0.006*
3 weeks - post -58 to 17 p =0.26
6 weeks - post -87 to 50 p= 0.49
Control
1 week pre vs 1 week post -131 to -67 p=0.0001*
1 week pre vs 3 weeks post -123 to -67 p<0.0001*
1 week pre vs 6 weeks post -237 to -97 p= 0.005*
Primrose
1 week pre vs 1 week post -198 to -130 p<0.0001*
1 week pre vs 3 weeks post -146 to -86 p<0.0001*
1 week pre vs 6 weeks post -213 to -160 p<0.0001*
Two Sample t- Test
2.5.3.5 Urine pH
Pre-STZ: There was no difference in urine pH at baseline (week 0) when both groups 
were consuming control diet [CD vs EPO: 7.45 (0.685) vs 7.25 (0.589)] (Figure 
2.5.3.5). However, in the control diet group, urine pH rose significantly at weeks one 
and three [Week 0: 7.45 (0.685) vs (i) week 1: 8.2 (0.632), Cl = -1.4 to -0.1, p = 
0.002, (ii) week 3: 8.35 (0.530), Cl = -1.5 to -0.32, p = 0.005] and similarly, in the 
evening primrose oil group, urine pH fell significantly at weeks one and three [Week 
0: 7.25 (0.589) vs (i) week 1: 6.2 (0.258), Cl = 0.61 to 1.49, p = 0.0002, (ii) week 3:
6.1 (0.211), Cl = 0.71 to 1.59, p = 0.0001] (see Table 2.5.3.5).
Post-STZ phase: The difference in urine pH between the diet groups was maintained 
at weeks one [CD vs EPO: 6.5 (0.35) vs 6  (0)] and three [8.4 (0.2) vs 6.1 (0.5)] but at 
six weeks the difference did not reach statistical significance due perhaps to sample 
size [CD vs EPO: 7.3 (0.7) vs 6 . 6  (0.2): p = 0.07].
In the control diet group, despite a significant fall at week 1, pH remained raised at 
weeks 3 and fell to around the starting level at week 6  relative to week 1 in the pre- 
STZ phase [Pre-STZ - week 1: 8.2 (0.632) vs Post-STZ (i) week 1 : 6.5 (0.354), Cl =
1.2 to 2.2, p <0.0001, (ii) week 3: 8.4 (0.221), Cl = -0.66 to 0.280, p = 0.39, (iii) week 
6 : 7.3 (0.671), Cl = 0.05 to 1.75, p = 0.041]. In the evening primrose oil diet group, 
urine pH remained low at weeks 1, 3 and may be starting to rise again at week 6 . 
[Pre-STZ - week 1: 6.2 (0.258) vs Post-STZ (i) week 1: 6  (0), (ii) week 3: 6.1 (0.486), 
Cl = -0.31 to 0.49, p = 0.63, (iii) week 6 : 6 . 6  (0.177), Cl = -0.582 to -0.143, p = 
0.003].
2.5 .3 .6  S ysto lic  b lo o d  p re s s u re
There was no significant difference in systolic blood pressure between the control 
diet and evening primrose oil diet groups either in the pre-STZ [CD vs EPO: 138 (16) 
vs 144 (17) mm Hg, Cl = -24 to 11, p = 0.4] or diabetic [CD vs EPO: 136 (19) vs 139 
(10) mm Hg, Cl = -25 to 21, p = 0.8] periods (Figure 2.5.3.6).
Neither was there any difference in the control diet or evening primrose oil diet 
groups between non-diabetic and diabetic phases [Pre-STZ vs post-STZ: 138 (16) vs 
136 (19), Cl = -21 to 24, p = 0.9] or EPO [Pre-STZ vs post-STZ: 144 (17) vs 139 (10), 
Cl = -10 to 22, p = 0.5] diet groups.
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Table 2.5.3.5 Urine pH before an d  after STZ -  s t a t i s t i c a l  a n a l y s e s
95%
confidence
interval
significance
level
Control vs Primrose
0 weeks - pre -0.4 to 0.8 p= 0.5
1 weeks - pre 1.5 to  2.5 p<0.0001*
3 weeks - pre 2 to 2.7 p<0.0001*
1 week - post
3 weeks - post 1.8 to 2.7 P<o.ooor
6 weeks - post -0.1 to 1.6 p= 0.07
Control
1 week pre vs 1 week post 1.4 to 2.3 p<0.0001*
1 week pre vs 3 week post -0.4 to 0.36 p= 0.84
1 week pre vs 6 week post 0.2 to 1.9 p= 0.022*
Primrose
1 week pre vs 1 week post
1 week pre vs 3 week post -0.4 to -0.38 p= 0.95
1 week pre vs 6 week post -0.6 to -0.3 p= 0.0001*
Two Sample t  Test
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Figure 2.5.3.6 Systolic b lo o d  p re ssu re  o n e  w e e k  b e fo re  a n d  five 
w e e k s  after STZ injection. (Each point represents the 
mean of five readings)
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2.5.3.7 K idney w eigh t
At the end of six weeks kidneys from diabetic rats were significantly heavier than 
those of normal Lewis rats fed standard laboratory rat diet, irrespective of diet [Pre- 
STZ CD: median 0.67 (range 0.54 - 0.76) grams vs: (i) post-STZ CD: 1.425 (1.3 - 1.5) 
grams, Cl = -0.85 to -0.65, p = 0.0019, (ii) post-STZ EPOD: 1.59 (1.4 - 1.8) grams, Cl 
= -0.99 to -0.84, p < 0.0001] (Figure 2.5.3.7)]. The results suggest that kidneys from 
diabetic rats fed evening primrose oil diet may be heavier than those fed control diet 
[Post-STZ CD: 1.425 (1.3 - 1.5) vs EPO: 1.59 (1.4 - 1.8), 95% Cl = -0.3 to 0, p = 
0.055].
2.5.3.8 B lood g lu c o s e
Pre-STZ: At three weeks, plasma glucose levels were significantly higher in the EPO 
diet group [CD vs EPO: 4.9 (1.35) vs 6.5 (1.1) mmol/1, Cl = -2.8 to -0.4, p = 0.011] 
(Figure 2.5.3.8).
Post-STZ phase: Mean plasma glucose levels were higher than in the non-diabetic 
phase in both diet groups at weeks one but there were no statistically significant 
differences between the diet groups [CD vs EPO: week 1: 32.75 (2.7) vs 33 (3.9) 
mmol/1], week 3: 34 (2.8) vs 33 (3.0) mmol/1], week 6 : 47.5 (2.4) vs 41.6 (8.2) 
mmol/1].
2.5.3.9 U rine u r e a
Urea excretion was similar in both diet groups at weeks one and three during the non­
diabetic phase of the study (Figure 2.5.3.9) [CD vs EPO: week 1 : median 5.005 
(range 3.74 - 6 ) vs 4.3 (3.54 - 5.76) mmol/1, 95% Cl = -0.02 to 1.44, p = 0.038), week 
3: 5.4 (4.86 - 6.51) vs 5.63 (4.58 - 6.18) mmol/1: 95% Cl = -0.6 to 0.6, p = 0.94]. 
Urine urea was not measured in diabetic rats.
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d ia b e tic  (before  STZ) rats
2.5.3.10 Total p ro te in  a n d  a lbum in  ex c re tio n
Pre-STZ: Urine total protein excretion was significantly lower in the evening
primrose oil diet group after three weeks [CD vs EPO: median 12.05 (range 9 - 14.5) 
vs 5.6 mg per 24 hours (3.7 - 6.7), Cl = 5.4 to 8.4, p = 0.0002] (Figure 2.5.3.10).
Albumin excretion rate was significantly lower in the evening primrose oil diet group 
after three weeks [CD vs EPO: median 0.625 (range 0.221 - 0.875) vs 0.249 (0.137 - 
0.403) mg per 24 hours, Cl = 0.206 to 0.546, p < 0.0017] (Figure 2.5.3.11).
2.5.3.11 V a lid a tio n  o f EUSA m e th o d
The poor results obtained from the first sandwich ELISA method (Figure 2.5.3.12) 
may be compared to the immediate improvement in sensitivity using the streptavidin- 
biotin method (Figure 2.5.3.12a).
Optimal dilutions of coating and capture antibodies and avidin-HRP were derived by 
titration. Coating antibody was diluted 1: 2600, biotinylated antibody at 1:4000 and 
avidin-HRP at 1: 5000 dilution (Figure 2.5.3.12b) which are much higher dilutions 
than those used in the first method (see section 2.5.2.5). The standard curve now 
ranged over nearly two units of optical density.
Standard curve data of doubling dilutions from 25 to 0.2 ng per ml are shown in 
Figure 2.5.3.13. Not surprisingly, the precision of the assay (25%) was poor in the 
early stages of the assay (QC mean =1.169 and standard deviation = 0.288).
The results of diluting a urine sample x200, x400, x800, xl600, x3200 or x6400 is 
shown in Table 2.5.3.14. Actual levels at dilutions of 200- and 400- fold were too 
high but higher dilution factors gave more linear results and the intra-assay 
imprecision at all dilutions was less than 10%. Using this data, a dilution factor of 
800 was selected for assay of the test urine samples.
The results of spiking ultrafiltered urine (UFU) with rat serum albumin at 6 , 4, 2, 1, 
0.5 ng per ml are shown in Table 2.5.3.15. Recovery and precision (CV%) are shown 
in table 2.5.3.15(a).
Assay imprecision may be estimated from the measurements shown in Tables 
2.5.3.16, 2.5.3.16a and 2.5.3.16b but by omitting results of Assay E which tended to 
read high.
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ng/ml 6 4 2 1 0 .5 UFU
n 1 2 1 2 1 2 1 2 1 2 1 2
mean 5.652 3.414 1.580 0.742 0.452 0.250
SD 0.25 0.28 0.17 0.033 0.015 0.004
CV (%) 4.4 8 . 2 10.75 4.4 3.3 1 . 6
Recovery (%) 94.2 85.4 79 74.2 90.5
T a b le  2 .5 .3 .1 5 (a ) S ta tis tica l a n a ly s is  o f ELISA r e c o v e ry  d a t a
2.5.3.12 A lbum in e x c re tio n  - p o s t STZ
Tables 2.5.3.16, 2.5.3.16(a) and 2.5.3.16(b) depict mean albumin concentration in 
urine diluted 800- fold (2.5 pis to 2 mis). Urine samples were assayed several times 
in different assays from separate frozen aliquots and it is from this data that Figure 
2.5.3.17 is derived. There was little difference in albumin excretion rate between the 
diet groups at weeks one and three but at six weeks, albumin excretion started to rise 
in the EPO diet group [CD vs EPO: (i) week 1: median 311 (range 126 - 429) vs 299 
(185 - 793) pgs per 24 hours, Cl = -198 to 56, p = 0.8, (ii) week 3: 208 (152 - 341) vs 
229 (171 - 309) pgs per 24 hours, Cl = -78 to 46, p = 0.46, (iii) 230 (215 - 725) vs 
821 (522 - 937) pgs per 24 hours, Cl = -701 to -51, p = 0.034].
Within the control diet group, there was no change in AER at weeks three and six 
compared with week one [Week 1: 311 (126 - 429) pgs per 24 hours vs (i) week 3: 
208 (152 -  341), Cl = -30 to 134, p = 0.22, (ii) week 6 : 230 (215 - 725) pgs per 24 
hours, Cl = -413 to 104, p = 0.7].
In the evening primrose oil group, compared with week one, median AER may be 
slightly lower at week three but was raised significantly at six weeks [Week 1: 299 
(185 - 793) mgs per 24 hours vs (i) week 3: 229 (171 - 309), Cl = -9 to 236, p = 0.07, 
(ii) week 6 : 821 (522 - 937), Cl = -613 to -241, p = 0.003].
Statistical comparisons made using six week data must be viewed with caution since 
there are so few surviving rats in the control group.
Only one rat in each diet group did not become diabetic following injection of 
streptozotocin. At the end of six weeks, four rats remained in the control diet group 
and eight in the evening primrose oil diet group (Figure 2.5.3.18).
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Rat Urine
volum e
Assay A
(ng/ml)
Assay B
(ng/ml)
Assay C
(ng/ml)
Assay D
(ng/ml)
Assay E
(ng/ml)
Assay F
(ng/ml)
m ean
(jags/24 hrs)
C l 104 3.19
2.64
3.51
3.77
4.93 3.147 5.780 3.328 3.84
(319)
C2 6
C3 1 10 3.76
3.33
5.36
4.42
4.86 3.596 8.145 4.194 4.87
(429)
C4 104 3.05
2.95
3.72
3.1
3.54 2.873 6.145 3.425 3.73
(310)
C5 76 2 .1 0 0
2.003
2.94
1.45
2.08 1.282 2.290 2.514 2.07
(126)
C6 15 8 .8 8
9.62
10.92 10.869 17.946 6.769 11.15
(134)
C7 148 1.307
1.358
3.115 2.536 2.4 1.870 2.25
(266)
C8 98 2.654
2.955
4.078 4.159 6.059 2.734 3.97
(311)
C9 130 2 .2 2
1 .88
2.54 2.522 3.694 2.037 2.57
(267)
CIO 154 2.115
1.950
2.389 2.342
2.178
3.901 2.386 2.59
(320)
PI 208 2.52
2.39
3.45
3.65
3.02 2.948 4.916 2.088 3.16
(526)
P2 170 1.48
1.40
2.04
3.86
1.997 1.918 2.540 1.234 2 .0 1
(274)
P3 194 3.47
4.16
5.4
7.56
4.63 5.502 6.496 3.745 5.11
(793)
P4 167 0.99
1.055
1.93
2.75
2.29 1.744 2.536 1.422 1.89
(253)
P5 65 4.09
4.57
7.9
9.82
6.06 5.259 7.601 5.281 6.23
(324)
P6 190 1.299
1.195
2 .1 1 2 1.714 2.476 2.300 1.97
(299)
P7 192 1.516
1.422
1.64
1.79
1.962 2.497 2.116 1.95
(300)
P8 18
P9 193 1.019
0.99
1.357 0.822 1.658 1.143 1 .2 0
(185)
P10 140 1.793
1.642
2.77 2.454
2 .2 2 2
2.836 2.104 2.35
(264)
T a b le  2 .5 .3 .16  Urine album in excretion  in rats fed  control (C) or even ing  prim rose oil 
(P) d iet -1  w eek  post STZ
Rat Urine
volum e
Assay C
(ng/ml)
A ssay D
(ng/ml)
A ssay E
(ng/ml)
A ssay F
(ng/ml)
m ea n
(ngs/24 hrs)
C l 110 2.44 1.790 3.107 2.278 2 .40
(2 1 2 )
C2 7
C3 135 1.954 1.645
1.429
2.529
1.815
2.006 1.92
(207)
C4 135 1.817 1 .2 2 0 2.179 1.632 1.71
(185)
C5 72 4.683 4.324 6.684 3.682 4 .84
(279)
C6 85 2.026 2.019 2.647 2.397 2.27
(155)
C7 75 6.185 4.571 7.250 4.716 5.68
(341)
C8 130 2.311 1.918 2.628 2.385 2.31
(240)
C9 130 1.505 1.177
1.090
2.178
1.478
1.397 1.47
(152)
CIO 32 8.263 7.677 10.150 6.373 8 .1 2
(208)
PI 150 3.044 1.929 2.709 2.629 2.58
(309)
P2 90 4.432 2.730 3.466 2.322 3.24
(233)
P3 140 2.717 1.728 6.602 1.694 2.05
(229)
P4 110 2.091 1 .8 6 6 2.798 1.94
(171)
P5
P6 150
P7 12 0 4.256
4.090
3.056 2.498 2.362 3.02
(290)
P8 8
P9 155 1.986 1.381
1.330
2.086 1.943 1.84
(229)
P10 52 6.273 3.508 3.594 5.066 4.61
(192)
T ab le  2 .5 .3 .1 6 (a ) Urine album in excretion  in rats fed  control (C) or even ing  
prim rose oil (P) d iet - 3 w eeks post STZ
Rat Urine
volum e
Assay D
(ng/ml)
A ssay E
(ng/ml)
A ssay F
(ng/ml)
m ea n
(fig s /2 4  hrs)
C l
C2 8
C3
C4
C5 125 6.882 6.682 7.052 7.25
6.476 9.926 6.495 ( 7 2 5 )
C6
C7 190 1.323 1.477 1.393 1.44
1.324 1.905 1.355
1.290 1.483 (2 1 8 )
C8 150 1.599 1.966 1.774 1.80
1.598 2.124 1.752
1.700 ( 2 1 5 )
C9 225 1 .1 1 2 1.587 1.405 1.35
1.033 1.642 1.334 ( 2 4 3 )
CIO
PI 215 2.119 2.667 4.200 3.15
2.141 3.623 4.138 ( 5 4 1 )
P2 160 6.335 6.596 6.510 6.82
6.295 8.815 6.493
6.326 ( 8 7 3 )
P3 155 5.945 6.961 7.135 6.98
6.089 9.715 6.030 ( 8 6 5 )
P4 195 5.584 5.327 6.240 5.89
5.341 7.089 5.766 ( 9 1 9 )
P5
P6 225 3.347 3.664 4.476 3.85
3.094 3.928 4.599 ( 6 9 3 )
P7 2 2 0 5.222 5.424 5.691 5.32
4.607 5.703 5.577
5.138 ( 9 3 7 )
P8 7
P9 2 1 0 4.213 4.155 6.130 4.62
3.754 4.450 5.015 ( 7 7 6 )
P10 150 4.144 3.636 5.056 4.35
3.849 4.504 4.712
4.369 ( 5 2 2 )
T ab le  2 .5 .3 .16 (b )  Urine album in excretion  in rats fed  control (C) or even ing  
prim rose oil (P) d iet - 6 w eeks post STZ
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2.5.4 Discussion
The propensity of PUFA diets to reduce proteinuria and albuminuria in healthy Lewis 
and DA rats had raised hopes that an evening primrose oil diet might moderate or 
prevent an increase in albumin excretion rate in diabetic Lewis rats since Payton and 
Boulton-Jones (1989) had shown previously that proteinuria was raised in Lewis rats 
after four weeks of diabetes. In the non-diabetic period of this study, both total 
protein and albumin excretion were lowered relative to controls after three weeks of 
EPO diet; after STZ, there was little difference in albumin excretion between the two 
diet groups at weeks one and three until week six when AER rose in the EPO group. 
The results at six weeks may be misleading, however, since so few rats remain in the 
control group: AER might have been raised in the control diet group had the rats 
survived. That albuminuria levels was not raised during the first few weeks of 
diabetes compared with pre-STZ levels may be so, or might be related to differences 
in the methods used to measure albumin before and after STZ. Urine albumin levels 
were measured by immunoturbidimetry during the non-diabetic period of the study 
(Figure 2.5.3.11) and were comparable with those in the previous studies (see Figures 
2.23.1  and 2.3.3.2), if a little lower; urine albumin levels measured by ELISA during 
the diabetic phase were within a similar range to those in the pre-STZ period.
In relation to possible discrepancies in urine albumin levels before and after STZ, 
additional points to consider are that (i) turbidimetry has a greater degree of 
imprecision and tends to overestimate albumin concentration compared to 
radioimmunoassay (McElderry et al, 1982, Bakker, 1988, Ermann et al, 1988, Rowe 
et alt 1990), (ii) normal rat urine is highly coloured and concentrated whereas 
diabetic rat urine is very dilute and almost colourless and this leads to differences in 
the urine matrix which can influence immune complex formation, (iii) urine volume 
had increased some ten to twenty fold in diabetic, relative to non-diabetic rats which 
makes it more difficult to detect small changes in albumin levels, (iv) the ELISA had 
been newly developed for this study and may not have been entirely accurate or 
precise and (v) although albumin is stable in urine, the effects of pH, centrifugation 
and freezing on urine albumin levels are unclear. When it became clear that the 
ELISA would take some time to develop, diabetic urine samples were frozen (non­
diabetic urine samples were not) and some work suggests that defrosting causes 
protein precipitation and underestimation of real values. Albumin levels were 
underestimated by some 2 0 % in frozen urine and were significantly higher in fresh 
urine than the same urine frozen for seven days: the precipitation of exogenous 
radiolabelled albumin was greater in frozen urine than that kept at 4°C (Erman et al, 
1988, Elving etal> 1989).
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In this study, freshly defrosted aliquots of urine were assayed several times by ELISA 
as shown in Tables 2.5.3.16, 2.5.3.16(a) and 2.5.3.16(b).
The principal objective of the study was to establish whether there was any difference 
in the rate of increase in albumin excretion between the two diets groups during 
diabetes. However, albumin excretion remained stable until week six of diabetes, 
when it rose in the EPO group and there is some suggestion that AER was higher in 
rats fed EPO than those fed control diet at weeks one and six. The enigma is that 
there was no rise in AER but an increased number of deaths in diabetic rats fed 
control diet whereas albumin excretion started to rise but survival was much 
improved in diabetic rats fed evening primrose oil.
The issue of whether differences in body weight and food consumption relate to the 
anti-proteinuric effects of PUFA diets arose again in this study, when both parameters 
were found to be significantly lower at three weeks in non-diabetic rats fed EPO, in 
line with the fall in AER. At the end of six weeks of diabetes, although there was no 
difference in food consumption, rats in the EPO group still tended to be lighter than 
control rats (despite a raised albumin excretion rate) and this might also explain their 
improved survival.
This was the only study in which the means to measure the effects of a PUFA diet on 
arterial blood pressure became available and the results showed that evening primrose 
oil diet did not affect blood pressure in either normal or diabetic rats.
Irrespective of diet, kidneys removed from diabetic rats were heavier than those from 
normal control rats and the data also suggests that renal hypertrophy may be more 
pronounced in diabetic rats fed evening primrose oil than those fed a normal diet but 
the small number of animals in the control group at six weeks makes it difficult to 
discern whether this is a genuine difference. Dienoic prostanoids, in particular, have 
been attributed with direct and indirect growth-stimulating effects (Logan et al, 1990) 
and indomethacin prevented hypertrophy in association with reduced PGE2  and PGI2  
levels in uninephrectomised rats (Logan et al, 1986). Hypertrophy and 
hyperfiltration is an alternative explanation for the failure to detect a fall in albumin 
excretion in EPO-fed diabetic rats although glomerular levels of dienoic PGE2  and 
PGI2  were not changed markedly by evening primrose oil diet in non-diabetic Lewis 
or DA rats when measured in the first study (see section 2.1.3). Fish oil has been 
shown to induce renal hypertrophy in normal rats (though independently of increased 
filtration) and obese Zucker rats (Logan et al, 1990, Kasiske et al, 1991). The effects 
o f evening primrose oil diet on glomerular blood flow and pressure and filtration rate 
in this study, are unknown.
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The difference in survival between the two diet groups is intriguing: many studies 
have shown marked improvements in the survival of animals fed PUFA diets 
(Prickett et al, 1981; 1983, Robinson et al, 1986, Papanikalou et al, 1987) while 
others have reported increased mortality (Scharschmidt et al, 1987). Although one 
rat died early on in the EPO group, survival was similar between the two groups until 
week five when there was an sudden increase in the number of deaths in the control 
diet group, the causes of which were never identified; survival rate in the evening 
primrose oil diet group was double that in the control diet group. It can be argued 
that had the study continued, the number of rats in the evening primrose oil group 
might have started to decline; nevertheless, the increased mortality in the control 
group was untimely since the study had been designed to last for only six weeks and 
it would have been pointless to continue with a depleted control group. 
Hypoglycaemia is the most plausible explanation for the deaths since most occurred 
within hours of insulin administration. The rats had been given the same dose of 
insulin every day for some five weeks, in response to assessment of glycosuria, which 
is not always an accurate reflection of blood glucose levels, and so insulin could have 
given been given to normo- or even hypoglycaemic rats although this is unlikely. 
Hyperglycaemia has been cited as a side-effect of PUFA diets in diabetic patients 
(Glauber et al, 1988) and plasma glucose levels were significantly higher in non­
diabetic rats after three weeks of evening primrose oil diet (Figure 2.5.3.8 ) but blood 
glucose levels were comparable between the two diet groups during diabetes.
Differences in their response to insulin may explain the improved survival in EPO- 
fed rats, co- 6  fatty acids derived from EPO may have altered lipid domains within the 
membrane and thus the status of the insulin receptor in relation to changes in number 
and affinity (Ginsberg al, 1981). It has been reported that arachidonic acid stimulates 
insulin release from pancreatic cells (Metz, 1988) and that diabetic rats fed fish oil 
have a reduced requirement for insulin (Logan et al, 1988). There may also be a 
generalised deficiency of unsaturated fatty acids in diabetes (Dutta-Roy, 1990); for 
instance, PGElf derived from evening primrose oil, lowers the concentration of 
insulin required to produce a given effect (Ray et al, 1985). Insulin resistance, which 
occurs in non-insulin dependent diabetes, is associated with a failure of tissue to 
respond to insulin, rather than an inability to produce insulin. The number and 
affinity of insulin receptors may be reduced in some individuals, while in others, 
insulin binding is normal but post-receptor responses such as activation of glucose 
transport is abnormal. Rats in the EPO group may have become more tolerant of a 
larger dose of insulin than rats fed control diet. Alternatively, the feeding of evening 
primrose oil diet prior to receiving STZ, may have spared some pancreatic islet cell 
function.
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The marked differences in urine pH between the diet groups during both phases of the 
study was interesting. Urine pH fell after one week and remained lowered throughout 
the diabetic phase of the study in the evening primrose oil diet group whereas in the 
control diet group, urine pH rose during the non-diabetic period and varied during the 
diabetic phase. That control Lewis rats are unable to excrete acid offers an 
alternative explanation for the increased number of deaths in this group whereas the 
fall in urine pH in the EPO group could be related to higher levels of free fatty acids 
or changes in tubular permeability to H+ ions. Urine PH may not accurately 
represent the pH of tubular fluid which is modified extensively as it flows along the 
nephron. Filtered proteins are reabsorbed in the proximal tubules as a function of 
their charge which, as well as anionic binding sites within the tubular brush border, 
are susceptible to changes in the pH of the proximal tubular fluid. Cationic albumin 
is not only filtered more readily but is also reabsorbed more avidly than native 
albumin and Coimbra et al (1984) found that raising urine (or tubular fluid) pH with 
sodium bicarbonate, increased the excretion of exogenous cationic albumin and 
reduced its nephrotoxicity. Were the fall in urine pH to reflect a fall in proximal 
tubular fluid pH, albumin would become more cationic, a form in which its tubular 
reabsorption is enhanced and so urine levels reduced (Christensen and Bjerke, 1986). 
The possibility of a link between changes in urine pH and the fall in albumin 
excretion may be misleading since it is difficult to reconcile the fall in albumin 
excretion rate in non-diabetic rats fed EPO diet with the rise in albumin excretion rate 
in the later stages of diabetes when urine pH remained lowered. Urine pH was not 
measured in any of the previous studies although it is significant that the ranging 
study data shows that the pH of Lewis rat urine pH was around 8  - 8.5 (see Table 
2.5.3.1).
It had been hoped that this study would uncover (i) a difference in AER between the 
control and evening primrose oil diet groups in non-diabetic rats which was sustained 
during diabetes and (ii) a slower rate of increase in albumin excretion rate in diabetic 
rats fed EPO compared with those fed control diet. However, although both 
proteinuria and albuminuria were lowered in non-diabetic rats fed EPO, when the 
animals were made diabetic, there was no difference in AER between the diet groups 
until six weeks, when AER rose in the EPO group, at which point, the study was 
terminated. That EPO did not prevent a rise in AER in diabetic Lewis rats might 
otherwise be explained by the preferential binding of glucose to serum albumin in 
diabetic animals, thus blocking the binding of PUFAs which intensifies the anionic 
charge and so impedes the filtration of albumin.
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Summary
Albumin excretion rate in diabetic Lewis rats was not lower in the evening primrose 
oil than control diet group, despite a difference in the pre-diabetic phase of the study. 
There was little difference in albumin excretion rate between control and EPO diet 
rats until week six of diabetes, when levels started to rise in the EPO diet group. It is 
unclear whether this is a genuine difference because of differences in survival 
between the diet groups. Competitive binding between glucose and fatty acids on the 
surface of the albumin molecule might explain the inability to demonstrate a fall in 
AER in diabetic rats.
Blood pressure was not affected by evening primrose oil diet in normal or diabetic 
rats.
The contribution of a fall in urine pH to a fall in albumin excretion rate in normal rats 
fed evening primrose oil diet may be a red herring.
Whether differences in food consumption and body weight account for both the fall 
in AER during the non-diabetic period and increased survival in the diabetic period is 
also unclear.
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Section 3
CONCLUSIONS and FINAL DISCUSSION
FINAL DISCUSSION Section 3
3.1 C o n c lu s io n s
• Albumin excretion rate tended to be lower in groups of healthy Lewis and DA rats 
fed PUFA diets than those fed a standard laboratory rat diet. Although both 
glomerular thromboxane B2  and renin levels in vitro were higher in Lewis rats than 
DA rats, changes in the levels of these two vasoconstrictors did not correlate with the 
fall in albumin excretion rate in the PUFA diet groups.
• Compared to DA rats, Lewis rats had a diminished negative charge on the 
glomerular capillary wall when assessed by glomerular uptake of a cationic (+) 
marker protein. However, the fall in albumin excretion rate in the PUFA diet groups 
did not correlate with any increase in the magnitude of the glomerular polyanion. 
Splenic uptake of the same cationic protein was also lower in Lewis rats compared to 
DA rats.
• The isoelectric point (pi) of serum albumin from Lewis rats in the PUFA diet 
groups was lower than that from those in the control diet group.
• Despite having lowered proteinuria and albuminuria during the non-diabetic phase 
of the study, evening primrose oil diet did not prevent a rise in albumin excretion rate 
in Lewis rats after six weeks of diabetes although survival was improved in this 
group.
• The explanation for the anti-proteinuric effects of PUFA diets is more likely to be 
some physical modification of the serum albumin molecule such as a change in its 
isoelectric point - or even its size or shape - as a result of its binding PUFAs.
1 2 4
3.2 G e n e ra l d iscussion
In association with many other factors, a rising albumin exretion rate is a strong 
predictor of glomerular disease progression (see section 1.1) and so it is important to 
consider the pathogical range and prognostic significance of different levels of 
albuminuria, the degree to which it reflects the presence of established renal disease 
and its use both to monitor the progression and regression of renal disease and 
perhaps define a stage at which early intervention might reverse, retard or prevent 
nephropathy. The finding therefore, that albumin excretion tended to be lower in two 
strains of healthy rats with different disease susceptibilities, fed either evening 
primrose oil, fish oil or olive oil diets was exciting in view of the fact that any fall in 
proteinuria may indicate an improvement in, or reversal of glomerular injury. In 
diabetics patients, for example, a fall in albuminuria resulting from antihypertensive 
treatments, glycaemic control or low protein diets is taken as being indicative of just 
such an improvement (see section 2.5.1). Persistent proteinuria is also associated 
with structural damage within the glomerulus, tubulointerstitium and other vascular 
beds (Deckert et aly 1988, Remuzzi and Bertani, 1990).
However, the critical aspect of any fall in urine albumin excretion is whether it is 
genuine, in relation to the high degree of intra-individual variability of urine protein 
levels associated with exercise, posture and other diurnal variations. The extent of 
this variability and necessity for multiple measurements within any individual was 
highlighted in a study in which albumin levels were measured in twenty 24 hour, 
timed overnight and short, timed daytime collections from two individuals; although 
24 hour collections showed the least intraindividual variation there were even wider 
variations in overnight and daytime collections (Hutchison and O'Reilly, 1985). It is 
staggering when one considers that to be 95% confidence of detecting urine albumin 
levels to within 10% of the true value would require some 144 samples from the same 
individual and to be within 5% would require 576 samples (Johnston et aly 1993). 
One abnormal urine albumin result is not adequate to classify a patient as 
microalbuminuric and likewise, a single low urine protein result should not be 
regarded as conclusive or reliable proof of a genuine fall in albumin excretion and 
improved glomerular permselectivity. One has to acknowledge, however, that much 
published data on proteinuria relates to only a small number of animals or humans.
The purpose behind the experimental work carried out in this thesis was to establish 
the mechanism behind the apparent trend towards a significant lowering of AER in, 
ultimately, some two hundred male Lewis and DA rats fed PUFA diets. That the fall 
in albumin excretion occurred in normal healthy rats suggests that the diets may have 
affected some fundamental aspect of glomerular permselective control and while it is 
usually assumed that albumin leaks across damaged glomeruli mainly, Yoshioka et al
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(1988) demonstrated by serial micropuncture, albeit in rats with reduced renal mass, 
that the filtration of proteins across individual healthy non-sclerotic glomeruli often 
exceeded that across sclerosed glomeruli.
Dietary manipulation is a common method of modifying disease progression (Mitch, 
1984, Barcelli and Poliak, 1985, El Nahas and Coles, 1986). Protein restriction, low 
phosphate and reduced calorie diets have been shown to be beneficial in the treatment 
of experimental and human nephropathies (Ibels et al, 1978, Zeller, 1987, Harris et 
al, 1988, Ichikawa et al, 1985, Tapp et al, 1989: see section 1.1.3). Recognition too, 
of the role of lipids and cholesterol in the initiation and progression of glomerular 
injury prompted the use of lipid-lowering agents and PUFA diets, particularly those 
rich in co-3 EFAs with the capacity to reduce plasma lipid levels (see section 1.4). 
PUFA diets have been shown both to prevent the onset and lower established 
proteinuria in experimental and clinical studies - often without further impairing 
glomerular function, which is important if renal function is already compromised 
(van der Heide et al, 1990, Heifets et al, 1987, Weise et al, 1993: see section 1.4). 
PUFA diets can be used to regulate prostanoid metabolism less aggressively than 
non-steroidal anti-inflammatory drugs because they generate alternative series 
prostanoids with attenuated activity.
Ever mindful that the fall in albumin excretion may not be genuine, one can still 
speculate upon how PUFA diets might reduce albumin excretion rate. Potentially, the 
relationship between PUFA diets and a fall in albumin excretion rate is complex 
because PUFAs perform many functions (section 1.3) and albumin excretion is 
controlled by a variety of factors (section 1.2) and this makes most investigators 
unwilling or reluctant to endorse one single mode of action (section 1.4). It is most 
likely that the anti-proteinuric actions of PUFA diets are related to altered prostanoid 
levels, cell membrane physiology or plasma lipid levels.
In the first two studies (2.1 and 2.2), it was speculated, perhaps too hastily, that the 
anti-proteinuric effects of PUFA diets might be prostanoid-mediated in association 
with a fall in glomerular or systemic blood flow and pressure. However, the nature of 
the relationship between not only PUFA diets and blood pressure control but also 
between blood pressure and protein excretion remains unclear (Dusing et al, 1983, 
Axelrod, 1991). Not all antihypertensive therapies reduce protein excretion; in the 
main, it is ACE inhibitors which lower proteinuria through a selective reduction in 
glomerular hypertension. Although there have been several reports of a fall in blood 
pressure in animals and humans rats fed PUFA diets (Heifets et al, 1987, Izumi et al, 
1986, Clark et al, 1990; 1993; 1993a), often no antihypertensive effect is observed
1 2 6
(Barcelli et al, 1982; 1990, Wheeler et al, 1991, Weise et al, 1993) and indeed, PUFA 
diets effected only a modest fall in blood pressure in patients with lupus nephritis 
(Clarke et al, 1993), chronic glomerulonephritis (de Caterina et al, 1993) or diabetic 
nephropathy (Jensen et al, 1989). Indomethacin blocked both the antihypertensive 
effects of a high linoleic acid diet in rats with salt-induced hypertension and the more 
pronounced cardiac hypertrophy in rats fed a low linoleic acid diet (Hoffman et al, 
1982) which may be attributed to inhibitory effects of linoleic acid on renin 
production (Reddy et al, 1987). Vasodilatory prostaglandins can also increase blood 
pressure by either stimulating renin secretion or increasing cardiac output (Dunn and 
Grone, 1985) and fish oil raised renal blood flow and GFR in normal humans, 
independently of any change in systemic blood pressure (Dusing et al, 1990).
Whether PUFA diets had any effect on systemic or glomerular glomerular 
haemodynamics in Lewis and DA rats is not known although arterial blood pressure 
was shown to be unaffected by EPO diet in Lewis rats in the diabetic study (see 
section 2.5.3.6). Indices of intraglomerular blood flow and pressure, such as 
glomerular plasma flow rate, transcapillary hydraulic pressure (AP) and ultrafiltration 
coefficient (Kf) were not measured because they require micropuncture techniques, 
the facilities for which were not available. Glomerular filtration rate and renal 
plasma flow could have been assessed by measuring the clearance of inulin and para- 
amino hippuric acid (PAH), respectively and a femoral line introduced to measure 
systolic blood pressure, but the additional cannulation steps required for such 
procedures would have extended the surgical procedure substantially and so were not 
performed in this, or any subsequent study. Clearly, the non-invasive tail vein 
plethysmography method used to measure systolic blood pressure in the diabetic 
study, is more convenient but there may be problems associated with over-heating of 
the animals.
The finding that glomerular thromboxane and renin levels were raised in Lewis 
compared to DA rats was interesting. Although there is much evidence of the 
involvement of prostanoids in abnormal protein excretion, many studies have shown 
that prostaglandin and thromboxane production does not always correlate with the 
course of proteinuria (see section 1.3.5): changes in prostanoid levels may well be a 
consequence, rather than a cause of increased urine protein loss. Reciprocal changes 
in prostaglandin and thromboxane production modulate systemic and glomerular 
blood pressure. The proteinuric effects of thromboxane may be related to heightened 
arterial or intraglomerular blood pressure or a rise in filtration fraction as a result of a 
fall in glomerular plasma flow but the patterns of lowered proteinuria in sections 2.1 
and 2.2 were not reflected by a generalised fall in glomerular thromboxane levels.
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Baylis (1987) suggests that thromboxane impairs renal function predominantly 
through changes in renal vascular resistance and not through contractile actions on 
the mesangium. Attempts were made in section 2.2.4 to define the role of heightened 
glomerular renin and its potential relationship with raised glomerular thromboxane 
levels in Lewis rats but it is difficult to do so with the limited amount of data.
PUFA diets may have affected glomerular permeability in relation to regulation of 
intraglomerular thrombosis and coagulation by altering the balance between the 
generation of thromboxane by platelets and prostacyclin by vascular endothelium 
(Haines et al, 1986, Knapp et al, 1986, Rondeau et al, 1986, Sraer et al, 1987, Hansen 
et al, 1989, Vane et al, 1989, Clark et al, 1993). Suppression of platelet activity 
dampens not only the procoagulant effects of thromboxane but also the release of a 
variety of platelet-derived factors with both growth-promoting and hydrolytic 
properties which impair the permselectivity of the glomerular capillary wall 
(Habenicht et al, 1988, Mene et al, 1990, Lianos and Zanglis, 1990). The direct and 
indirect effects of PUFAs on cell proliferation and hypertrophy (Fox et al, 1988, 
Logan et al, 1990, Wight et al, 1990, Mene et al, 1990), inflammation (Meydani et al,
1990), sclerosis (Ross, 1986, Weiner et al, 1986) and the immune response (Endres et 
al, 1989) are alternative contributory factors to their anti-proteinuric actions.
Membrane function: Attempts were made in section 2.3, by the best means available, 
to examine the effects of PUFA diets on glomerular cell membrane phospholipids in 
relation to changes in the glomerular polyanion. One cannot dismiss the fact that 
Lewis and DA rats can be distinguished on the basis of glomerular (and splenic) 
uptake of a cationic protein but must retain some degree of scepticism as to whether 
the difference in uptake between the strains is entirely charge-dependent - although 
the uptake of native IgG suggests that it is. One also has to ask whether a single non­
specific molecule could accurately quantify the effective net charge on the GCW 
without more substantial validation of the method. An alternative explanation of the 
findings is that the GCW of Lewis rats is invested with a greater number of larger 
pores which allow IgG to escape into the glomerular ultrafiltrate whereas DA rats 
have no such enlarged pores and so IgG remains trapped within the glomerulus: the 
differences in glomerular uptake of cationic IgG could, in effect, reflect the 
magnitude of the shunt pathway. However, such a hypothesis does not help to 
explain the similarly increased splenic uptake of IgG(+) in DA rats which is more 
likely to relate to differences in tissue charge, blood flow or reticuloendothelial 
uptake.
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The lipid- and cholesterol- lowering effects of PUFA diets may improve glomerular 
permselectivity in relation to favourable effects on atherogenic lipid deposition and 
hypertension caused by changes in plasma viscosity (Mensink et al, 1989; 1990, 
Steinberg et al, 1989, Nestel, 1990; see section 1.4). Kasiske et al (1989) showed 
that the PUFA content of renal cortical phospholipids were reduced in Zucker rats 
relative to their lean littermates and that changes in the degree of saturation of fatty 
acids may correlate with the extent of renal histological damage. The relationship 
between altered lipid metabolism and glomerular permselectivity is unclear (Scanu, 
1991). Changes in plasma lipid levels may lower protein excretion either directly, by 
inhibiting hepatic lipoprotein synthesis through substrate diversion (Smit et al, 1991) 
or indirectly, through changes in plasma oncotic pressure (Kaysen, 1991).
That a lowering of the isoelectric point (pi) of serum albumin was the most likely 
explanation for the fall in albumin excretion rate in all the PUFA diet groups is 
intriguing but unlikely, therefore, to have any significant effect on glomerular disease 
progression. The hypothesis forwarded in section 2.4.4 is that albumin excretion was 
lowered in rats fed PUFA diets due to a heightened negative charge on the albumin 
molecule as a result of binding PUFAs. However, the important questions of whether
(i) the isoelectric point (pi) of DA rat serum albumin is lower than that of Lewis rat 
serum albumin under normal dietary conditions and (ii) if PUFA diets further reduce 
the pi of DA rat serum albumin remain unanswered. It would be of interest to 
compare the pi of both serum and urine albumin in both Lewis and DA rats in control 
and experimental PUFA diet groups and the relationship between changes in the pi of 
serum albumin and its clearance rate and the effects of fatty acid binding on the size 
and shape of the albumin molecule could be developed further - perhaps in humans. 
The problem with this hypothesis is that hyperlipidaemic subjects might be expected 
to have low levels of albumin excretion unless, of course, the effect is dependent 
upon specific fatty acids. It is less likely that the effect is related to the essential 
nature of the fatty acid, since it was seen in the olive oil group. The fat content of the 
PUFA diets, in all the studies, was derived exclusively from the PUFA oils whereas 
the control diet contained 2.4% fat, of which the ratio of saturated to unsaturated fatty 
acids is unknown.
That albumin excretion rate was reduced as effectively in the olive oil diet group as in 
the evening primrose oil and fish oil diet groups, may have been overlooked as an 
early clue that the anti-proteinuric effects of the PUFA diets were not prostanoid- 
dependent but related instead to some other aspect of fatty acid function. Clark et al 
(1993) drew attention to the markedly similar benefits of fish and olive oil diets in the 
treatment of patients with lupus nephritis. Although olive oil was, and is used widely
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as a 'control' PUFA, its effects on plasma viscosity, red blood cell flexibility and 
arachidonic acid, VLDL-cholesterol and complement levels were similar to those of 
fish oil. Pagnan et al (1989) demonstrated a substantial degree of incorporation of 
oleic acid into the red blood cell membrane in normotensive, normolipidaemic 
volunteers fed olive oil diet for three weeks and observed a significant increase in the 
flux rate of Na+/K+countertransport and a slight, if non-significant reduction in 
sodium lithium countertransport activity. In an earlier study, the same authors 
reported a significant reduction in blood pressure in eighty three normotensive 
subjects fed olive oil diet (Pagnan et ah 1986). In all of the studies reported in this 
thesis, the effects of the olive oil diet were often as potent as the other EFA diets.
Diabetes: In the diabetic study (section 2.5), throughout the diabetic period, there 
was no difference in AER between the diet groups until six weeks when AER rose in 
the EPO group. Whether this is a genuine rise compared to the control diet group is 
difficult to discern since so few rats remain in the control diet group. It is interesting 
that although at no time during diabetes was AER significantly lower in the EPO than 
control group, survival was improved. Competition between fatty acids and glucose 
for binding sites on the albumin molecule may explain the failure of evening 
primrose oil diet to lower albumin excretion in diabetic rats despite having done so in 
the non-diabetic phase of the study. That evening primrose oil diet had offered no 
protection from an increase in albumin excretion rate in diabetic Lewis rats, despite 
having lowered both proteinuria and albuminuria during the pre-STZ period, was 
taken as confirmation that the PUFA diet did not target the glomerulus directly. The 
observed differences in albumin excretion, survival, renal hypertrophy and tolerance 
of insulin between the diet groups is intriguing and might produce interesting results 
were the study to be repeated in a larger number of animals for a longer period of 
diabetes. The transition from IT to ELISA to measure urine albumin levels was 
unavoidable and might explain possible disrepancies in albumin levels before and 
after diabetes. To a large extent, the emphasis of the diabetic study shifted towards 
developing and validating a suitable ELISA method to measure albumin in dilute rat 
urine and although annoying, the problems encountered provided an excellent 
grounding in the theory and practice of ELISA s.
Species and strain differences in prostanoid metabolism and protein excretion (Alt et 
alt 1985) and differences in lipoprotein metabolism between nephrotic rats and 
humans (Gherardi et ah 1977, Marshall et ah 1990, Joven et ah 1990, Fine et ah
1991) prompt questions about the relevance of animal studies to humans. Even 
within the rat, PGF2a metabolism can vary with age, sex and strain (Pace-Asciak, 
1975). However, as prostanoid measurement techniques become more sophisticated,
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it may become apparent that many of the reported discrepancies are related to 
experimental artefacts and not to altered tissue differentiation or prostanoid enzyme 
activity. Yet another consideration is that although some glomerular structural 
changes can be induced in experimental animal models of diabetes, it is not possible 
to demonstrate in rats by diabetes alone, progressive renal dysfunction culminating in 
ESRF which represents the real problem of clinical diabetic nephropathy in humans 
(Carney et al, 1979, Hirose et al, 1982, Jensen et al, 1987). Often however, 
extrapolation of animal studies to humans is the only option: for obvious reasons, it 
would be impossible to measure glomerular prostanoid and renin production in vitro 
and assess GCW charge in humans, using the experimental methods applied in this 
thesis. On the other hand, apart from possible problems with dietary compliance, it 
would be relatively easy to study the effects of PUFA supplements on urine protein 
levels, urine pH and to measure the pi of urine and serum albumin in normal and 
diabetic humans. One can surely presume however, that the fundamental mechanism 
controlling protein excretion is unlikely to differ substantially between rats and 
humans.
Several points arising from the work carried out in this thesis may require further 
modification and clarification.
Studying two strains of rat in four or five different study groups serves only to cloud 
and complicate issues. It would have been more prudent to explore the anti- 
proteinuric effects of one, or even two PUFA diets in a larger group of either Lewis 
or DA rats; this would have facilitated more frequent monitoring and implementation 
of a variety of additional analytical parameters. The measurement of many 
parameters was omitted and others were not explored fully due, principally, to the 
constraints of time and working alone; these include (i) plasma lipid levels and 
incorporation of PUFAs into glomerular tissue lipids, (ii) glomerular histological 
changes, (iii) pair-feeding and establishing the calorie content of the experimental 
PUFA diets, (iv) serum and urine levels of albumin, sodium, creatinine and pH as 
appropriate.
Perhaps the most significant omission was the use of fat-deficient diet supplemented 
with beef tallow (as a source of saturated fatty acids) rather than standard laboratory 
rat chow, as the control diet. There are various permutations of procedures and 
methods for PUFA diet studies; for example, many groups merely supplement a 
standard laboratory diet with PUFA oils and so it can be difficult to compare PUFA 
diet studies because fatty acid content is not standardised.
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It must also be conceded that radioimmunoassay was not the best technique to use for 
identifying changes in different series prostanoid metabolites in relation to PUFA diet 
feeding and although HPLC or GC-MS would have been more appropriate, RIA does 
have the specificity for comparing dienoic prostanoid levels between the two rat 
strains within a particular diet group. Were the prostanoid studies to be repeated, it 
would be advisable to re-introduce measurement of PGE2 and PGI2 levels and 
measure serum thromboxane levels at a higher dilution.
Certain aspects of the studies could be developed further.
(i) The effects of dietary protein intake on protein excretion are unclear and there are 
questions as to whether a reduced dietary protein intake (or even a lower body 
weight) might account for the observed fall in albumin excretion in PUFA-fed rats
(ii) The duration of the PUFA diet and it's use as either a preventative or therapeutic 
intervention.
(iii) There is scope for further investigation of the interstrain differences in 
glomerular thromboxane and renin by cell culture or molecular biological techniques 
such as Northern blotting.
The problem of sample size underlies all the studies reported in this thesis. Not only 
is it tiresome, but it also disheartening, to invest time, effort and enthusiasm in studies 
which, ultimately, cannot be justified on the basis that statistical analyses are 
inappropriate. However, although the number of experimental rats used seems small 
in statistical terms, in practice, the problems associated with this number are 
extensive (see section 2.2.4). Comparisons amongst ten different groups, as in the 
first study, is ludicrous because (i) sample size must be sacrificed and so there is 
greater scope for possible type I (false positive; as in the case of urine albumin 
measurements) and type II (false negative; as in the case of PGE2results) statistical 
errors and (ii) it is well known that the greater the number of statistical comparisons 
performed, the more likely that a significant difference will occur by chance alone 
(although this problem can be corrected for by applying the Bonferroni formula). For 
example, a statistically significant correlation between glomerular TxB2 levels and 
AER, albeit only in DA rats fed control diet (r2 = 0.82: p = 0.003) was uncovered in 
section 2.2, which may be related simply to statistical chance. There are several 
instances, in many of the studies, in which results might have attained statistical 
significance had numbers been larger such as kidney weight and survival data 
(section 2.5), glomerular PGE2 levels (section 2.1) and splenic uptake of 125I-IgGN 
(section 2.3). It is prudent to apply a power calculation to provide some indication of 
the optimal number of subjects required to observe a desired effect.
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Experimental reproducibility is yet another issue arising from the work in this thesis. 
It is disconcerting that the results of the first two studies are so different despite the 
intended similarities between them and while it has been conceded ad nauseum 
throughout, that sample size is small, in many studies published currently, sample 
size is often not much greater.
A fall in albumin excretion does not necessarily indicate an improvement in 
glomerular permselectivity. The final amount of protein in the urine is governed by 
GFR, plasma protein concentration and tubular reabsorption and so although PUFA 
diets may have reduced urine albumin levels in healthy Lewis and DA rats, the 
amount of albumin filtered at the glomerulus may not have changed. PUFA diets 
could have increased tubular reabsorption of albumin, reduced GFR or effectively 
lowered serum albumin levels. There is some suggestion that the Lewis rat 
population might be bimodal in terms of albumin excretion (see Figures 2 2 3 .1  and 
2.3.3.2). However, despite the intraindividual variation in urine protein 
measurements, comparisons were made between control and PUFA diet groups, 
assuming the same degree of variability.
It is intriguing that few trials have shown that lowering or elimination of 
microalbuminuria does, in fact, influence patient mortality or the incidence of ESRF 
(Rowe et al, 1990). Indeed, demonstrating a fall in albumin excretion rate cannot, of 
itself, be regarded as a measure of improved glomerular function until the contentious 
issue of whether increased amounts of protein crossing the glomerular barrier actively 
exacerbates the progression of renal disease is resolved once and for all.
The concept that PUFA diets reduce albumin excretion rate in rats by changing the pi 
of serum albumin suggests that such diets are unlikely to have a beneficial effect on 
the course of a progressive glomerular disease such as diabetic nephropathy, although 
neither does it exclude such a possibility. In the final analysis, the success of PUFA 
diets may be related to the absence of saturated fats rather than the presence of 
unsaturated fats.
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